Micromet - vor Rebound ? - 500 Beiträge pro Seite

[MasaRatti]

Hallo zusammen,

wollte mal auf eine spekulative Aktie aus dem Bereich Pharma/Onkologie aufmerksam machen. Letzte Daten in der
Phase 1 vom Antikörper MT103 waren nicht schlecht, denke
mal der Kurs hat sicherlich noch Potential nach oben. Die
Forschungspipeline ist nicht zu verachten. Das vereinte
Unternehmen aus CancerVax/Micromet ist seit dem Börsengang
nur nach unten "geprügelt" worden, meiner Meinung nach zu
Unrecht - eine Empfehlung aus Börse online konnte daran nichts
ändern !
Was meint Ihr ?
Werde bei diesem Kurs mal zugreifen und ein paar abfischen

[MasaRatti]

Möglicher neuer Therapieansatz zur Behandlung von Arthritis durch Neutralisierung von GM-CSF
Dienstag 27. Juni 2006, 09:07 Uhr




Carlsbad, Kalifornien, USA - 27. Juni 2006 - Micromet Inc. (NASDAQ: MITI), ein transatlantisches, biopharmazeutisches Unternehmen, das antikörperbasierte Medikamente entwickelt, gibt die Ergebnisse einer Studie (1) bekannt, die kürzlich auf dem European Congress of Rheumatology in Amsterdam, Niederlande, vorgestellt wurde. Die Studie zeigt, dass GM-CSF ein möglicher neuer Ansatzpunkt für die Behandlung von rheumatoider Arthritis sein könnte, einer sehr häufigen degenerativen Gelenkerkrankung. Darüber hinaus lassen die Ergebnisse darauf schließen, dass die Neutralisierung von GM-CSF durch einen therapeutischen Antikörper nicht nur die Entzündung Anzeige
Anzeigen - Ihre Meinung
dämpft, sondern auch die Gelenkknorpel vor Zerstörung schützt.

In der Studie wurde bei Mäusen durch Injektion von bakteriellen Zellwandfragmenten in ein Kniegelenk eine Arthritis induziert. Gleichzeitig wurde ein Teil der Mäuse mit einem GM-CSF-neutralisierenden, monoklonalen Antikörper (mAk) oder mit dem TNF-alpha-Blocker Etanercept behandelt. Dabei wurde die Schwellung der betroffenen Gelenke durch den mAk gegen GM-CSF in höherem Maße reduziert als durch den TNF-alpha-Blocker. Sowohl der mAk als auch Etanercept verminderten die Anzahl der Entzündungszellen in den Gelenken, aber nur der mAk war in der Lage auch die Produktion des Zytokins IL1-beta und den Verlust von Proteoglykanen aus dem Kniegelenksknorpel zu reduzieren. IL1-beta induziert die Sekretion von Metalloproteinasen, die zu Knorpel- und Knochenabbau und einer verlangsamten Synthese von Proteoglykanen führen. Proteoglukane sind Grundbestandteile von Knorpel, der als elastische Polster Gelenke auskleidet und vor Verschleiß schützt.

"Die Ergebnisse unterstützen unserer Hypothese, dass die Neutralisierung von GM-CSF ein viel versprechender Ansatzpunkt für die Behandlung von Arthritis-Patienten sein könnte", sagte Patrick Baeuerle, Chief Scientific Officer von Micromet. "Es sieht so aus, als ob die Neutralisierung von GM-CSF nicht nur die Entzündungsprozesse verringern, sondern auch die Gelenkknorpel vor der Arthritis-typischen Zerstörung schützen könnte - und dies eventuell bei Erkrankungen, die unabhängig von TNF-alpha verlaufen."

Micromet entwickelt derzeit einen menschlichen Antikörper gegen GM-CSF. Präklinische Ergebnisse für den neuen Arzneimittelkandidaten MT203 wurden kürzlich in der Zeitschrift Molecular Immunology (2) veröffentlicht.

GM-CSF wurde erst vor kurzem als wichtiges entzündungsförderndes Zytokin erkannt, das für die Vermehrung, Aktivierung und das Überleben zahlreicher Zellen des Immunsystems verantwortlich ist, die ihrerseits eine Schlüsselrolle bei der Entstehung entzündlicher Erkrankungen spielen. Die Neutralisierung von GM-CSF hat bei Tiermodellen für rheumatoide Arthritis, Multipler Sklerose, chronisch-obstruktiver Lungenerkrankung, allergischem Asthma und Psoriasis eine deutliche Besserung und zum Teil sogar eine Verhinderung der Erkrankungen gezeigt. ###

Literaturhinweise 1) Plater-Zyberk C et al., GM-CSF Neutralization Suppresses Inflammation and Pro-tects Cartilage in Acute Streptococcal Cell Wall Arthritis of Mice, Poster presented at the European Congress of Rheumatology, Amsterdam, The Netherlands, June 2006 2) Krinner, EM et al., A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF, Molecular Immunology, May 2006, published elec-tronically ahead of print

Kontakt: Investoren: Ines-Regina Buth [phone] [e-mail] Medien: Evelyn Wolf [phone] [e-mail]

Über Micromet, Inc. Micromet, Inc. ist ein biopharmazeutisches Unternehmen, das neue antikörperbasier-te Medikamente gegen Krebs, Entzündungen und Autoimmunerkrankungen entwi-ckelt. Zwei Arzneimittelkandidaten befinden sich zur Zeit in klinischen Studien. Adecatumumab (MT201), ein rekombinanter humaner monoklonaler Antikörper wird in zwei Phase 2-Studien zur Behandlung von Prostata- bzw. Brustkrebs untersucht. MT103 wird in einer Phase 1-Studie zur Behandlung von Non-Hodgkin-Lymphomen geprüft. Auf Basis seiner BiTE®-Technologie hat das Unternehmen eine Plattform zur Entwicklung neuer Medikamente etabliert. BiTE®- Medikamente nutzen das zytotoxi-sche Potenzial von T-Zellen, den wirksamsten "Killer-Zellen" des menschlichen Im-munsystems. Das Unternehmen hat Partnerschaften mit MedImmune, Inc. und Serono abgeschlossen.

[MasaRatti]

So, hoffe mal der Boden ist bereitet - habe immer
mal ein paar Stücke gesammelt und denke, das
die Talfahrt beendet ist und wir neue Höhen sehen
werden. Die höheren Umsätze tun ihr übriges dazu !!!

Hopp oder topp

[MasaRatti]

Beinahe vergessen, hier paar wichtige Daten zum Unternehmen,
vielleicht gab es etwas positives in Baltimore !!!



July 16 - 19, 2006

14th SPORE Investigators' Workshop, Baltimore





August 9, 2006

Q2 2006 Micromet, Inc. Earnings Release





August 9, 2006

Q2 2006 Micromet, Inc. Earnings Conference Call





August 22 - 23, 2006

Cancer Immunotherapeutics and Vaccines, Boston





September 11 - 13, 2006

Monoclonal Antibodies in Therapeutics, London





September 18 - 19, 2006

Strategic Research Institute’s 4th Angiogenesis Drug Discovery and Development Summit, Boston





September 29 - October 3, 2006

31st Congress of the European Society of Medical Oncology (ESMO), Istanbul, Turkey





November 9, 2006

Q3 2006 Micromet, Inc. Earnings Release





November 9, 2006

Q3 2006 Micromet, Inc. Earnings Conference Call

[rudiratlos51]

Antwort auf Beitrag Nr.: 22.814.146 von MasaRatti am 20.07.06 20:05:16

Hallo MasaRatti....
hab mir mal die Firma grob angesehen.
Nicht gerade ein Highlight im Bio-Pharma-Bereich.
Trotzdem habe ich noch ein paar Euro locker gemacht und einige Shares gekauft.
Sollte sich die Story, die gestern erst nach Handelsschluss der Börse rauskam, realisieren...könnte das einen riesigen Wertzuwachs bedeuten.
Nur, die Wege über die klinischen Studien sind noch lang und es muss Geduld aufgebracht werden.
No risc, no fun...
Ich drück dir die Daumen für deinen Wert !

[MasaRatti]

Hallo Rudi....

ja, natürlich ist die ganze Geschichte spekulativ und man sollte
risikobewusst investieren, aber wer nicht wagt ....
und sooooo schlecht ist die Pipeline ja auch nicht !

http://www.micromet.de/en/pipe/overview.php

Ansonsten nächste Finanzierungsrunde erfolgreich platziert, könnte
sich noch etwas negativ auf den Kurs auswirken (genau wie die
allgemein schlechte Situation an den Finanzmärkten), aber etwas
Zeit sollte man bei solchen Investments einkalkulieren !

[rudiratlos51]

Antwort auf Beitrag Nr.: 23.005.085 von MasaRatti am 24.07.06 09:17:53

Was mich verwundert, dass in NY der Bid bei $1,00 steht und der Ask bei $6,44...
Hast du dafür eine Erklärung ?

[rudiratlos51]

Antwort auf Beitrag Nr.: 23.005.085 von MasaRatti am 24.07.06 09:17:53

oh, oh..das war ein schlechter Einstand.
20% minus in 2 Tagen..naja.
Würde in D jemand 8 Mio Forschungsgelder (Beteiligungen) bekommen, wär der Kurs um 20% nach oben gegangen.
Nunja...durchhalten !

[MasaRatti]

Moin Rudi,

joh, irgendwie verstehe ich das ganze auch nicht so ganz, die
letzten Meldungen waren eher positiv zu bewerten und der Kurs
kennt seit der Zusammenlegung mit Cancervax und dem Börsengang
nur eine Richtung

Hoffe mal die Zahlen Anfang August sind nicht zu schlecht,
damit wir wieder bessere Kurse sehen. Kaufe immer mal eine kleine
Position nach, aber zur Zeit eher mal abwarten, wo der Boden
eigentlich ist......

Also Augen zu und durch
MaRa

[rudiratlos51]

Antwort auf Beitrag Nr.: 23.057.730 von MasaRatti am 26.07.06 07:00:45

moin MaRa...
für heute würde ich mal vorschlagen...
du kaufst 7k in NY und beeinflusst den kurs um 15%, dann kann ich verlustfrei hier aussteigen...
(ne, ich bleib mal investiert..wer weiss warum..Bauchgfühl? )

[rudiratlos51]

Antwort auf Beitrag Nr.: 23.145.891 von rudiratlos51 am 28.07.06 09:36:56

sorry 30% Verlust in einer Woche...
scheint kein Vertrauen im Wert zu liegen.
Vielleicht in 1-2 Jahren.

[MasaRatti]

Moin,
ist ja schon merkwürdig was mit diesem Wert passiert.
Eigentlich sollten die Zahlen demnächst doch nicht so schlecht
sein, wenn kurz vorher ein Finanzinvestor 8 Mille reinbuttert,
aber wer weiß das schon....
Klar, der Preisverfall ist erheblich die letzten Wochen, aber
der letzte Kurssprung machte auch gleich mal 20% nach oben !
Also hoffe Du hast nicht alles Pulver verschossen und diese
Art von Wert sollte man sich in kleinen Stücken einverleiben
und dann hoffen, das die Pipeline gut voran kommt.

We will see

[rudiratlos51]

Antwort auf Beitrag Nr.: 23.277.218 von MasaRatti am 02.08.06 08:08:32

Na klar..mit kleinen Werten.
Man kann ja später noch günstig nachkaufen, wenn man am Ball bleibt.

[MasaRatti]

Wow, was geht hier denn eigentlich ab
Ich habe selten einen solchen Verlauf von Aktien gesehen,
wo die Forschungsaktivitäten von Partnern weitesgehend
finanziert werden (Serono etc.) und die Cash-Reserven auch
im 1.Quartal mehr als ausreichend waren.Entweder hier liegen
irgendwo erhebliche Leichen im Keller und es gibt einen
Wirbelsturm nächste Woche zu den Quartalzahlen oder ein paar
Jungs freuen sich über eine tolle Performance die nächsten Wochen.

Abwarten und einen beruhigenden Whisky trinken

[rudiratlos51]

Antwort auf Beitrag Nr.: 23.303.896 von MasaRatti am 03.08.06 20:10:10

Hallo MasaRatti,
nun ist der Q-10 raus.
Leider bedi "Edgar", sodass ich ihn nicht einsehen kann.
Hast du nähere Infos...aber es scheint nicht der Renner zu sein, sonst wäre im Vorfeld gegen Börsenschluss der Kurs gestiegen, weil immer was vorher durchsickert.

[MasaRatti]

Moin zusammen,

also nach den Zahlen, die nicht wirklich überrascht haben, bin
ich eigentlich weiterhin nicht negativ gestimmt. Der Ausverkauf
ist erstmal gestoppt und die Forschungsaktivitäten sind weiterhin,
meiner Meinung nach, positiv zu werten. Der Zusammenschluss mit Cancervax hat zwar etwas mehr liquide Mittel verbrannt wie gedacht,
aber die Umsätze und Kooperationen geben noch Grund zur Hoffnung !
Schaun mer ma, was die nächsten Termine und Konferenzen zu
den aktuellen Entwicklungsdaten bringen und ob der Kurs endlich
mal den Turnaround schafft und sich erholen kann. Die Umsätze
sind ja echt mau zur Zeit !!!

[Elisale]

Antwort auf Beitrag Nr.: 23.145.891 von rudiratlos51 am 28.07.06 09:36:56

Hallo,
ich habe mit auch eine kleine Position zugelegt und ihr werdet sehen dass der Boden erreicht ist.Die Pipeline läßt sich sehen so wie die Partner.Also auf steigende Kurse und viele gute Nachrichten.

[rudiratlos51]

Antwort auf Beitrag Nr.: 23.447.038 von Elisale am 14.08.06 22:26:53

Ich kann mir nicht helfen..ist schon ein lustiger Wert diese MITI !!
Da verkaufen entmutigte Kleinanleger Ihre Shares und einer sammelt sie teilweise zum Tagestiefstkurs auf. Ich glaube, wir schließen den Thread und melden uns wieder, wenn Phase2-Ergebnisse kommen.
Als Depot-Beimischung sollten wir den Wert aber immer beobachten.
Was meint Ihr ?

[MasaRatti]

Servus,
also ich für meinen Teil, kann diesen Kursverlauf überhaupt nicht
nachvollziehen - bin sehr zuversichtlich was die Weiterführung
der Projekte betrifft. Die nächsten 2 Monate sind laufend
Kongresse geplant, die auch sicherlich Aufmerksamkeit fördern
könnten ! Der Kursverlauf ist sowas von merkwürdig, mich wundert
das der neue Investor nicht gleich nochmal 8 Millionen in die
Hand nimmt und weitere Shares kauft, hat sich ja nichts geändert.

Ich bin immer noch positiv und werde immer mal unter 2 Euro / bzw.
unter 2,50 Dollar schauen was ich bekomme ;o)

Kopf hoch, nach 1 Jahr werden wir das ganze steuerfrei einacken
(was auch immer - Cash haben sie ja noch genug zum überleben :look

[rudiratlos51]

Antwort auf Beitrag Nr.: 23.491.505 von MasaRatti am 18.08.06 09:32:03

es kommt schon etwas Bewegung in den Kurs..siehe Micromet
http://www.micromet.de
auch Hinweis im Börsenportal über Hugin-Nwes

[MasaRatti]

Moin,

da schau her, den nächsten Finanzspender an Land gezogen...

Glaube weiterhin an die Story

[rudiratlos51]

Antwort auf Beitrag Nr.: 23.694.968 von MasaRatti am 31.08.06 09:27:15

ja, menno , wäre micromet bekannter, wär das die Hammermeldung:
Hugin-News: Micromet Inc.

Micromet vereinbart Kapitalbeteiligung über $25 Millionen

Carlsbad, USA - 31. August 2006 - Micromet, Inc. (NASDAQ: MITI), ein biopharmazeutisches Unternehmen, das neuartige antikörperbasierte Medikamente zur Behandlung von Krebs, Autoimmunerkrankungen und Entzündungen entwickelt, hat eine als Committed Equity Financing Facility (CEFF) strukturierte Kapitalbeteiligung mit Kingsbridge Capital Limited, einer privaten Investorengruppe, vereinbart. Im Rahmen dieser Vereinbarung verpflichtet sich Kingsbridge, über einen Zeitraum von bis zu drei Jahren Stammaktien der Micromet, Inc. im Wert von bis zu $25 Millionen zu kaufen. Micromet wird, abhängig von bestimmten Bedingungen, den Zeitpunkt und die Höhe der einzelnen Finanzierungstranchen bestimmen.
'Diese Kapitalbeteiligung erlaubt es Micromet, seine liquiden Mittel nach Bedarf aufzustocken, und zwar zu Konditionen, die für das Unternehmen günstig sind und eine minimale Verwässerung für unsere Aktionäre bedeuten', erklärte Dr. Christian Itin, President und Chief Executive Officer von Micromet, Inc. 'Micromet verfügt momentan über zwei Produktkandidaten zur Behandlung von Krebserkrankungen, die sich in der klinischen Entwicklung befinden. Darüber hinaus haben wir eine Pipeline von präklinischen Produktekandidaten, aus der wir weitere Programme in die klinische Erprobung bringen wollen.'
Der am weitesten fortgeschrittene Produktkandidat von Micromet ist MT201 (adecatumumab), ein humaner Antikörper, der derzeit in Phase-II-Studien als Monotherapie sowohl gegen Prostatakrebs als auch gegen Brustkrebs getestet wird. MT201 wird in Zusammenarbeit mit Serono entwickelt. Micromet's zweiter klinischer Produktkandidat ist MT103 (MEDI-538), ein BiTE® -Molekül, das in einer europäischen Phase-I-Studie gegen Non-Hodgkins Lymphom (NHL) untersucht wird. Micromet's Entwicklungspartner MedImmune hat kürzlich eine 'Investigational New Drug' (IND)-Zulassung bei der US-Zulassungsbehörde FDA für den Beginn klinischer Studien in den USA beantragt.
Die wichtigsten Bestimmungen der mit Kingsbridge Capital abgeschlossenen Kapitalbeteiligung (CEFF) lauten: -- Rahmen der Vereinbarungen der CEFF verpflichtet sich Kingsbridge über einen Zeitraum von bis zu drei Jahren Stammaktien zum Wert von bis zu $25 Millionen zu kaufen. Die im Rahmen der CEFF ausgegebenen Stammaktien müssen bei der US-Wertpapieraufsichtsbehörde Securities and Exchange Commission (SEC) zum Wiederverkauf registriert werden. -- Micromet kann das Kapital der CEFF in Tranchen von bis zu $5 Millionen oder 1-1,5% von Micromet's Marktkapitalisierung platzieren. -- Das Tranchenvolumen ist abhängig von der zum Zeitpunkt der Ausübung bestehenden Marktkapitalisierung. Der Aktienpreis berechnet sich aus dem gewichteten Durchschnitt der letzten acht Handelstage vor der Platzierung. -- Bei der Plazierung werden Kingsbridge Stammaktien mit einem Bewertungsabschlag von 6-14% erhalten. Auch der Bewertungsabschlag ist abhängig vom gewichteten Aktienpreis der letzten acht Handelstage vor der Platzierung. Falls der durchschnittliche Marktpreis an einem dieser acht Tage unter $2,00 oder unter 85% des letzten Schlusskurses unmittelbar vor Beginn der acht Handelstage liegen sollte, würde der betreffende Tag nicht zur Ermittlung der Anzahl der auszugebenden Aktien herangezogen werden und die gesamte Summe des abgerufenen Kapitals würde sich um ein Achtel verringern. -- Kingsbridge verpflichtet sich, während der dreijährigen Dauer der Vereinbarung keine Leerverkäufe (Shorting) der Stammaktien von Micromet zu tätigen. -- Micromet ist nicht verpflichtet, das durch die CEFF verfügbare Kapital teilweise oder ganz abzurufen. Es bestehen keine Vereinbarungen über eine minimale Abrufsumme oder damit zusammenhängende Vertragsstrafen. Die CEFF-Vereinbarung beinhaltet keinerlei Einschränkungen der operativen Geschäftstätigkeiten von Micromet, keine automatische Preiszurücksetzungen oder Einschränkungen hinsichtlich minimaler Marktvolumina. -- Die Vereinbarung hindert Micromet nicht an der Durchführung zusätzlicher Fremd- oder Eigenkapitalmaßnahmen abgesehen von Finanzierungsmaßnahmen, die der CEFF-Struktur ähnlich sind. -- In Zusammenhang mit der CEFF hat Micromet 285,000 Optionen zu einem Ausübungspreis von $3,2145 pro Aktie an Kingsbridge ausgegeben. Dies entspricht einem 25%igen Aufschlag gegenüber dem gewichteten Aktienpreis der letzten der fünf Handelstage, unmittelbar vor der Vertragsunterzeichnung. Die Optionen haben eine Laufzeit von fünf Jahren und können erstmals sechs Monate nach Unterzeichnung ausgeübt werden. -- Die maximale Aktienanzahl, die Micromet im Rahmen der CEFF an Kingsbridge veräußern kann, beträgt 6.251.193 (ohne Berücksichtigung der in Zusammenhang mit der Ausübung des Optionsscheins fälligen Aktien).
Die in Zusammenhang mit der CEFF und der Ausübung des Optionsscheins an Kingsbridge auszugebenden Wertpapiere waren bei Unterzeichnung nicht nach dem Wertpapiergesetzes von 1933 (Securities Act) registriert und dürfen in den USA nicht angeboten oder verkauft werden, sofern sie nicht unter dem Wertpapiergesetzes von 1933 und anderen anwendbaren Wertpapiergesetzen der Einzelstaaten registriert wurden oder eine Ausnahmeregelung zur Anwendung kommt. Micromet, Inc hat zugestimmt, die entsprechende Registrierung zum Wiederverkauf der Stammaktien, die im Rahmen der CEFF auszugebenden Aktien sowie die mit dem Optionsschein zusammenhängenden Stammaktien innerhalb von 60 Tagen nach Abschluss der Transaktion zu beantragen. Diese Pressemitteilung ist kein Angebot oder Werbung für ein Angebot zum Verkauf oder Kauf der hier genannten Wertpapiere. Darüber hinaus dürfen diese Wertpapiere in keinem Staat verkauft werden, in welchem ein solches Angebot, oder Werbung oder Verkauf gesetzeswidrig wäre, bevor eine Registrierung oder Zulassung nach den Wertpapiergesetzen dieses Staates erfolgt ist. ###

[MasaRatti]

Hallo,

sollten wir vielleicht den Boden endlich gefunden haben
und den Rebound einläuten, wäre ja mal was, jedoch fehlen
mir noch die nötigen höheren Umsätze, um das wirklich zu
glauben,


Happy Weekend

[rudiratlos51]

Antwort auf Beitrag Nr.: 23.823.873 von MasaRatti am 08.09.06 14:23:34

Ich denk mal, wir müssen das Ergebnis der ersten Studien in den USA abwarten. Es wird mindesten bis Ende September dauern.
Da es immer wieder Insider-Käufer gibt, ist es notwendig den Kurs genau zu beobachten.

[Giovanne]

Hey,
habe mir heute auch ein paar Stücke von Micromet ins Depot gelegt. Die Story ist meiner Meinung nach okay. Durch die letzte Kapitalerhöhung ist das Überleben die nächsten 3 Jahre gesichert. Ein Medikament in Phase 2 für zwei verschiedene Krebsarten. Ein Medikament in Phase 1. Darüber hinaus einige in vorklinischen Testphasen. Ende September spricht einer von Micromet bei einer Bio-Konferenz. Vielleicht wird das den Kurs positiv beeinflussen. Übrigens hat im Börsenspiel auf DAF, im Internet zu sehen, Bernd Förtsch den Wert in seinem Realdepot. Er meint, das die Medikamente gegen Krebs Blockbusterpotenzial haben, die Gesellschaft gut finanziert ist, mit Serono und Millennium gute Partner hat und wenn das Medikament gegen Krebs, was jetzt in Phase 2 ist, weiterhin gute Resultate liefert, sind 500 bis 1000 Prozent Kursgewinn möglich. Kurzfristig ist jederzeit bei guten Meldungen 50 Prozent drin. Da wollen wir mal hoffen, das uns nicht zuviel der Mund wässrig gemacht wurde.
Meine Meinung ist, wenn ein Medikament zur Marktreife geführt wird, dann kennt die Aktie kein Halten mehr und wir werden wohl einige hundert Prozent einfahren. Okay, warten wir mal ab. Es soll aber noch dieses Jahr News geben im Hinblick auf das Phase 2 Medikament. Dann hoffen wir mal, das die gut sind.
Grüße
Giovanne

[MasaRatti]

Servus,
so nun ist Merck noch mit bei uns an Bord (Übernahme von Serono),
das würde ich mal positiv für die weitere Entwicklung der
Antikörper in der Phase II werten. Die Jungs haben ja genug
Erfahrung (mit Cetuximab/Erbitux/Matuzumab gesammelt), hoffe ich mal... (falls Sie mitreden dürfen...)

Was die weiteren Aussichten betrifft, bin ich weiterhin sehr
zuversichtlich, das immer mehr der "möchte-gern- Analysten" mal
einen Blick auf die Pipeline werfen und mal darüber nachdenken,
warum der Kurs auf diesem Niveau bestimmt lukrativ ist

Also, ich würde mich nicht wundern, wenn wir schon bald die
"Untertassenformation im Chart" schön sehen könnten und die
Umsätze (Dank des Finanzinvestors) mal anziehen, oder

[rudiratlos51]

Antwort auf Beitrag Nr.: 24.080.979 von MasaRatti am 21.09.06 13:02:56

Geb dir Recht MassaRatti...
Kein Zocker investiert in einen Wert, der seitwärts geht.
Erst, wenn Erfolgsmeldungen kommen und der Kurs nachhaltig aus dem Keller kommt...wirds hektisch und teuer.
Da man eh sein Geld nicht an der OTC verspielen soll, heisst es sein Taschengeld (was man entbehren kann, mit 10% Verlust meinetwegen) für den Aufbau zu nutzen.
Wer billig einsammelt, ist nachher im Vorteil.

[rudiratlos51]

Antwort auf Beitrag Nr.: 24.080.979 von MasaRatti am 21.09.06 13:02:56

der Serono-Kurs..hmmmm
ich hoffe wir kommen auch mal auf diese Steigerungrate.

[rudiratlos51]

Antwort auf Beitrag Nr.: 24.100.105 von rudiratlos51 am 22.09.06 12:03:40

wär schön, wenn es wie bei GPC ginge

[MasaRatti]

Moin zusammen,
so die klinischen Endpunkte zur Phase II-Studie von MT201 sind
jetzt raus, alles noch relativ vernebelt finde ich, mal schauen,
wie das die Experten von Amiland heute werten werden. Finde die
Resultate ermutigend, aber nicht besonders euphorisch, alles etwas
zu sehr abhängig von dem "Epcam-Spiegel" der Patienten, nun ja sehr
spekulativ....

[rudiratlos51]

Antwort auf Beitrag Nr.: 24.337.447 von MasaRatti am 02.10.06 09:44:12

geb dir Recht....
aber besser eine vorsichtige Prognose , als ein "Wundermittel-Report", der nur zu einem Hype-Effekt führt.
Wie wir aber erkennen, beschäftigen sich eine Reihe kompetenter Kliniken mit den Präperaten.
Ich finde schon, dass bei dem hohen europäischen Maßstab, der in solche Studien gesetzt wird, dass Ganze zu einem guter Entwicklung führen könnte. Besser langsam und sorgfältige Forschungen, als später irgendwelche Schadensersatz-Prozesse in den USA.
Geld ist genug da, um die einzelnen Phasen zu begleiten.

[Giovanne]

Die Ergebnisse sind meiner Meinung nach nicht so gut, die primären Ziele wurden nicht erreicht. Steht ungefähr so in der Meldung. Der Kurs wird heute runtergehen. Die Frage ist nur, wie stark. Jetzt ist erstmal für einige Zeit die Luft aus dem Wert raus. Also stellt euch auf Kursverluste ein. Viel Spaß noch mit dem Wert.
Grüße
Giovanne

[rudiratlos51]

Antwort auf Beitrag Nr.: 24.342.282 von Giovanne am 02.10.06 14:19:11

danke Professor Giovanne...
Man muss wirklich in der Materie drinstecken, um das zu verstehen.
Aber den Satz deines Kölner Kollegen Prof.Heidenreich...

...Die Tatsache, dass diese Wirkung bei Patienten mit hoher EpCAM-Expression beobachtet wurde, ist ein weiterer Beleg für die Annahme, dass adecatumumab eine wirklich zielgerichtete Therapie sein könnte.

dürfen wir stehenlassen ?

[Giovanne]

Dasb wichtigste bei der Meldung ist der Satz: Das primäre Ziel wurde nicht erreicht! Was das wohl heißt! Den Professor, den Du zitierst, benutzt das Wort könnte! Das sind nicht gerade Fakten!
Aber Du kannst ja weiter hoffen! Träume soll der Mensch ja haben!
Mal sehen, wie denn Deine Laune ist, wenn es heute runtergeht!
Grüße
Giovanne

[rudiratlos51]

Antwort auf Beitrag Nr.: 24.343.006 von Giovanne am 02.10.06 14:57:25

Muss dir Recht geben, aber ist noch im Rahmen...der Kursverlust.
Das Interesse hat auch merklich nachgelassen.
Vielleicht kommen bald Studien über MT 103...denke mal nicht, dass der Investor in einen sinkenden Stern investiert...es sei denn aus steuerlichen Gründen ?

[rudiratlos51]

aus den News ..ein kleiner Auszug...
Matthias Alder worked as an in-house counsel for Novartis
Bei Erfolg vielleicht ein Fingerzeig??

[MasaRatti]

Hallo auch,

so, jetzt arbeitet die Aktie immer noch hart am Boden, der
bei 2,50 Dollar bzw. 2,00 Euro liegen könnte (m.E.)
Ein starker Ausbruch über diese Marke wäre langsam mal von
Vorteil - schaun mer ma. Ich werde jedenfalls weiterhin die
Company im Auge behalten und mal sehen was an newsflow noch
so kommt !

[MasaRatti]

Moin,

so der "newsflow" geht weiter !

Würde die news von heute mal positiv werten, jedoch mal
abwarten, ob sich das auf den Kurs auswirkt.

[rudiratlos51]

Antwort auf Beitrag Nr.: 24.837.640 von MasaRatti am 25.10.06 09:35:47

jep..
Man müsste wirklich Molekular-Medizin studiert haben, um über die Bedeutung dieser News sein Urteil bilden zu können.
Jedenfalls schläft man nicht ..bei MITI.
Und die Fördegelder werden nicht verschwendet.

[rudiratlos51]

Heute..9 Uhr Ortszeit...Quartals-Pressekonferenz

[rudiratlos51]

Antwort auf Beitrag Nr.: 25.237.579 von rudiratlos51 am 09.11.06 12:24:39

naja, Gewinne sind ja nicht zu erwarten gewesen...
Verluste wurden begrenzt...
Was zählt sind klinische Erfolge.
Warten, warten...

[MasaRatti]

Guten Morgen Rudi,

nun ja, die Integration von Cancervax und die fortlaufende
Forschung hinterläßt schon Spuren ...
... jedoch werden die nächsten Wochen zeigen, ob die Resultate
der Antikörper in die richtige Richtung weisen !Gibt ja noch
genügend "news" bis Ende des Jahres !
Ich bleibe jedoch bei meinem Urteil, das Kurse unter 2,50 Dollar
bzw. unter 2,00 Euro Kaufkurse sind. Und da ja Serono bald zu
Merck gehört und Merck auch genügend in Onkologie investiert, wer
weiß, ob nicht die Antikörper-Pipeline von Micromet (bei weiteren
positiven Forschungsergebnissen) zum "Einverleiben" anregt!

In diesem Sinne
Schönes Wochenende

[rudiratlos51]

Antwort auf Beitrag Nr.: 25.252.369 von MasaRatti am 10.11.06 06:35:18

Ich kann es kaum glauben...wieder eine fast 7 Mio-Beteiligung an MITI.
Absolutes "free cash" bei jetzt fast 30 Mio $...
Man investiert doch nicht so einfach in einen Wert, wenn man nicht überzeugt ist.

[MasaRatti]

Antwort auf Beitrag Nr.: 22.179.653 von MasaRatti am 20.06.06 07:09:17

Hi,
so mal wieder 10 Millionen von Serono mit in die Kasse
und abwarten was noch so alles im Dezember in Lyon usw.
präsentiert wird.

War schon gut, letzte Woche kleinere Positionen nachzulegen

[rudiratlos51]

Antwort auf Beitrag Nr.: 25.919.916 von MasaRatti am 04.12.06 09:58:35

das hat auch im Kurs gefetzt...

[rudiratlos51]

Antwort auf Beitrag Nr.: 25.924.964 von rudiratlos51 am 04.12.06 14:13:02

und jetzt ?

[rudiratlos51]

Antwort auf Beitrag Nr.: 25.930.586 von rudiratlos51 am 04.12.06 17:23:15

ui..sehe gerade, der Makler hat mir in NY bei 5,01$ die Hälfte verscherbert...so ein Schlingel..aber die Gebühr zahl ich gerne !
Der Rest bleibt auf dem Sparbuch !

[MasaRatti]

Moin zusammen, bin ehrlich habe auch mal 2 Limits (5,00 und 4,75)
an den Mann gebracht, von Gewinnen mitnehmen ist noch niemand
gestorben

Aber den restlichen Teil werde ich gut behütet etwas behalten, die
weiteren Aussichten werden ja immer besser und wer weiß was die
Story noch bringt. Ich für meinen Teil bin überzeugt, das die
AK-Pipeline besser ist als der Kurs verrät und die tollen Umsätze
in USA zeigen, das mehr Leute auf die Firma aufmerksam geworden sind !

Schönen Tag und up-up-away

[rudiratlos51]

Antwort auf Beitrag Nr.: 25.949.258 von MasaRatti am 05.12.06 08:01:50

Geduld hat sich eben ausgezahlt...und nun kann der Rest arbeiten...
ohne Streß...Verlust kann es kaum noch geben

[rudiratlos51]

Antwort auf Beitrag Nr.: 25.949.258 von MasaRatti am 05.12.06 08:01:50

Gestern nachmittag wurden weitere Gelder von Serono in Aussicht gestellt, dass sich MT201 nicht nur für Brustkrebsbehandlungen, sondern auch für andere Krebsarten bewährt.
http://www.pinksheets.com/quote/print_filings.jsp?url=%2Fred…
..sollte die 1b-Studie erfolgreich sein...sehe ich ein erhebliches
Wertseigerungspotential.
Eben...sollte...

[MasaRatti]

So,
heute weitere gute Nachrichten von Micromet (siehe WO-Bericht),
ist zwar alles noch in der frühen Testphase, aber immerhin ein
Lichtblick für die gebeutelten Longies !

Falls der news-flow so gut weitergeht, dann werden wir noch
viel Freude an den verbliebenen Stücken haben !

[MasaRatti]

So, nettes Jahr 2007 allen verbliebenen Aktionären von Micromet !

Schaun mer ma, was dieses Jahr bringt, aber denke mal wir werden
sicher noch weit höhere Kurse sehen, falls die gut gefüllte
Pipeline erste gute greifbare news bringt, hoffe es wenigstens !
Einen kleinen Vorgeschmack hatten wir ja mal mit den 5 Dollar !

[MasaRatti]

So hier mal die aktuellen Termine, hoffentlich gibt es danach mal
wieder einen positiven Effekt auf den Kurs, geht ja wieder in
Richtung früherer Tiefs !

Conferences

January 8 - 11, 2007

JPMorgan 25th Annual Healthcare Conference, San Francisco,

January 31 - February 1, 2007

7th SMI Conference on Therapeutic Antibodies, London


February 12 - 14, 2007

BIO CEO & Investor Conference 2007, New York, NY


March 12 - 14, 2007

BioSquare, Lyon, France

[MasaRatti]

Hallo aufgewacht !
In 5 Tagen ca 20% plus, und das ohne Nachricht !
Uns kann es egal sein, aber Fakt ist, das die grösseren Firmen
Ausschau halten nach Entwicklungspartnern aus der Onkologie und
da irgendwann (bei weiter positiven News) vielleicht mal auf
Micromet aufmerksam werden könnten ! Alles nur reine Spekulation
und wie schnell der Kurs wieder nach unten gehen kann, haben wir
auch erlebt ...

Ich bleibe am Ball !
Ach ja ab Freitag Handball-WM!

[Latinl]

hmm ganz schön ruhig hier

[MasaRatti]

[Latinl]

[MasaRatti]

Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2006 Financial Results

CARLSBAD, Calif., March 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced that the Company will conduct a conference call and audio webcast on Wednesday, March 14, 2007, at 10:00am Eastern Time (04:00pm Central European Time) in conjunction with the release of its financial results for the fourth quarter and year ended December 31, 2006. Micromet anticipates releasing its financial results at 7:00am, Eastern Time (01:00pm Central European Time) on Wednesday, March 14, 2007.

[Latinl]

Antwort auf Beitrag Nr.: 28.176.506 von MasaRatti am 08.03.07 06:49:48

das heißt ??

[MasaRatti]

So, scheinen wohl die Zahlen, die Freitag
kommen nicht zu schlecht zu werden, was meint Ihr ?
Kann aber auch nur eine techn. Reaktion auf die
miese Performance der letzten Tage sein.
Ich habe jedenfalls unter 2,50 D nochmal nachgelegt
und denke, war vielleicht nicht die schlechteste Wahl,
obwohl sich das bis Morgen noch rächen könnte !

[MasaRatti]

Joh, wenn sich die Aktion gestern nicht gelohnt hat !

[MasaRatti]

Micromet licenses cancer drug to Tracon

CARLSBAD, Calif. (AP) - Biotech drug developer Micromet Inc. (Nachrichten) said Friday it entered an exclusive worldwide licensing agreement with privately held Tracon Pharmaceuticals Inc. to develop a new cancer treatment.

Shares of Micromet jumped 80 cents, or 27.6 percent, to $3.70 in afternoon trading on the Nasdaq Stock Market at nearly 15 times their average volume. Shares have traded between $1.82 and $9.33 over the past 52 weeks.

Micromet will receive an upfront payment and potential milestone payments from Tracon worth up to $100 million. Micromet also stands to receive royalties on sales if the drug makes it to market.

Under the agreement, Tracon will be responsible for the development and sale of Micromet's D93 antibody, which is intended to stop the formation of blood vessels to cancerous tumors inhibit growth.

Micromet already filed an application with the Food and Drug Administration in 2006 to begin human trials of the drug, and Tracon plans to begin early stage clinical trials on the compound in the second half of this year.

Separately, Micromet posted a fourth-quarter profit of $3.4 million, or 11 cents per share, from a loss of $6.7 million, or 42 cents per share, in the year-ago period on revenue of $13.8 million, a 59 percent increase from 2005.

Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

[MasaRatti]

16.03.2007 18:01
Micromet swings to 4Q profit on payment

CARLSBAD, Calif. (AP) - Biotech drug developer Micromet Inc. (Nachrichten) said Friday it swung to a fourth-quarter profit primarily from a milestone payment received from Merck Serono SA, a division of German drug and chemical maker Merck KGaA.

Shares jumped 70 cents, or 24.1 percent, to $3.60 in afternoon trading on the Nasdaq Stock Market at nearly 15 times their average volume. The stock has traded between $1.82 and $9.33 over the past 52 weeks.

Micromet reported a profit of $3.4 million, or 11 cents per share, from a loss of $6.7 million, or 42 cents per share a year ago. Results from the year-ago period included a conversion charge of $4.8 million for the issuing of preferred shares.

Revenue rose 59 percent to $13.8 million from $8.7 million last year due to a $10 million milestone payment from Merck Serono following the completion of two mid stage clinical trials for the experimental breast cancer drug adecatumumab.

For the full year, the company posted a loss of $34 million, or $1.29 per share, from a loss of $19.1 million, or $3.70 per share, in 2005. Revenue rose to $28.3 million from $25.7 million.

Separately, the company announced it entered an exclusive worldwide license agreement with privately held Tracon Pharmaceuticals Inc. to develop a new cancer treatment in a deal that could be worth up to $100 million to Micromet.

Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

[Latinl]

also march sei dank

[Latinl]

meinte Merck :-)

[Latinl]

jemand da ??

[MasaRatti]

Morgen zusammen,
ja, dümpeln auf höherem Niveau um die 3 Dollar rum, wäre
jetzt mal an der Zeit, das diese Marke nachhaltig genommen wird
und die Umsätze etwas anziehen ! In der Biotechbranche tut sich
ja einiges und wer weiß, wenn die Pipeline weiterhin die Daten
bestätigen kann ...

Da auch die Nachrichtenlage nicht gerade übig ist, ist wohl etwas
Durchhaltevermögen angesagt !

Schönes Wochenende

[MasaRatti]

18.04.2007 18:07
Micromet and MedImmune Present Data From Preclinical Study of New BiTE(R) Molecule Targeting CEA

GAITHERSBURG, Md. and CARLSBAD, Calif., April 18 /PRNewswire-FirstCall/ -- Micromet, (Nachrichten) Inc. and MedImmune, (Nachrichten/Aktienkurs) Inc. today announced data from a preclinical study in which BiTE(R) molecules targeting carcinoembryonal antigen (CEA) were shown to prevent subcutaneous tumor growth and formation of lung metastases. An established marker for tumor progression, CEA is frequently expressed on breast, colon and other human carcinomas. These data, presented yesterday in a poster session at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), augment a growing body of preclinical and clinical research about the potential anti-cancer activity of BiTE molecules.

BiTE molecules represent a novel class of drugs that function as bi- specific T-cell engagers. They are unique in their ability to enable the body's killer T cells to recognize and attack tumor and target cells, leaving normal cells unharmed. In addition to demonstrating in vitro and in vivo anti- tumor activity, certain CEA-specific BiTE molecules also showed resistance to inhibition by soluble CEA. Because a soluble form of CEA is released from the surface of normal and tumor cells into the bloodstream, BiTE molecules targeting the antigen must not be inhibited by soluble CEA.

"In a joint effort, researchers at Micromet and MedImmune have developed CEA BiTE molecules that appear to be highly potent and to ignore levels of soluble CEA present in cancer patients while continuing to destroy tumor cells," said Patrick Baeuerle, Ph.D., Chief Scientific Officer at Micromet.

CEA is the second target in the research collaboration between Micromet and MedImmune against which new BiTE molecules were successfully generated and tested. The first target is the tyrosine kinase receptor EphA2, which is frequently overexpressed on a wide variety of solid tumors. Research published April 15, 2007 in Cancer Research demonstrated that the BiTE molecule targeting EphA2 killed tumor cells at dose levels considerably below those required by classical monoclonal antibody-based therapies in in vivo and in vitro proof-of-concept studies.

"The EphA2 and CEA antigens are the focus of ongoing preclinical research within MedImmune's broad pipeline of potential treatments for cancer," said Peter Kiener, MedImmune's Senior Vice President, Research. "Both have been implicated in the growth and survival of a range of tumor types, and we are encouraged by the preclinical study results to date with these two highly potent BiTE molecules."

About BiTE(R) Molecules

BiTE molecules are a novel class of antibody derivatives with the potential to selectively direct and activate an individual's cytotoxic T cells, the body's most potent killer cells, to act against cancer cells. MT103/MEDI-538, a BiTE molecule targeting the B cell antigen CD19, provided clinical proof-of-concept for the BiTE platform technology, as presented at the last meeting of the American Society for Hematology. In an ongoing phase 1 study, MT103/MEDI-538 has shown potent elimination of tumor target cells in peripheral blood, bone marrow, lymph nodes and spleen of therapy-refractory non-Hodgkins lymphoma patients.

[Latinl]

Antwort auf Beitrag Nr.: 28.883.863 von MasaRatti am 18.04.07 18:31:01

sehr schön

[Latinl]

ist heut was im busch ??

[MasaRatti]

Antwort auf Beitrag Nr.: 28.953.127 von Latinl am 23.04.07 14:24:29

23.04.2007 13:34
Micromet Achieves Milestone in BiTE(R) Research Collaboration with MedImmune

CARLSBAD, Calif., April 23 /PRNewswire-FirstCall/ Micromet, (Nachrichten) Inc. today announced the achievement of a milestone in its research collaboration with MedImmune, (Nachrichten/Aktienkurs) Inc. for the development of new BiTE(R) molecules targeting carcinoembryonal antigen (CEA), a validated tumor- associated antigen frequently expressed on various human carcinomas. Preclinical data recently presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) showed that CEA-BiTE molecules can prevent subcutaneous tumor growth and formation of lung metastases. Achievement of the preclinical proof-of-concept milestone in the CEA-BiTE program triggers an undisclosed payment from MedImmune to Micromet.

Micromet holds exclusive European rights to the CEA-BiTE program and is eligible for milestones and royalties for all other territories, including the U.S. Under the same agreement, both companies also collaborate on a new BiTE candidate targeting the tyrosine kinase receptor EphA2, which is frequently overexpressed on a wide variety of solid tumors.

"The achievement of this milestone further validates the versatility and power of the BiTE approach to treat various cancers by targeting different tumor antigens," said Patrick Baeuerle, Ph.D., Chief Scientific Officer of Micromet. "Following this initial success with the CEA-BiTE program, we are now advancing the second BiTE program through formal development with our partner MedImmune."

[MasaRatti]

Conferences

May 9, 2007

Q1 2007 Earnings Conference Call





May 21 - 22, 2007

BioEquity Europe 2007 Glasgow, Scotland





June 1 - 5, 2007

Annual Meeting of American Association for Clinical Oncology (ASCO), Chicago, IL





June 26 - 28, 2007

Recombinant Antibody Conference, Berlin, Germany





December 8 - 11, 2007

Annual Meeting of American Association for Oncology (ASH), Atlanta, GA

[Latinl]

Antwort auf Beitrag Nr.: 29.183.782 von MasaRatti am 07.05.07 10:21:05

weiß jemand was mit mirco los ist ... ? seit 3 tagen 30 % runter

[MasaRatti]

May 9th, 2007
Micromet, Inc. Reports First Quarter 2007 Financial Results

BETHESDA, Md., May 9 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) ("Micromet" or the "Company"), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2007. As a result of the reverse merger between Micromet AG and CancerVax Corporation that was completed on May 5, 2006, the financial information included herein for the first quarter ended March 31, 2006 is based solely on Micromet AG's historical financial statements without the inclusion of the financial results of CancerVax for such quarter.

Recent Highlights:
-- Micromet granted TRACON Pharmaceuticals exclusive worldwide rights to
develop and commercialize Micromet's D93 antibody with a novel mode of
action for the treatment of cancer. Under the terms of the agreement,
Tracon has paid Micromet an upfront license fee, and will pay milestone
payments of more than $100 million, if D93 is successfully developed
and commercialized.
-- Micromet and its partner MedImmune presented data from a preclinical
study at the 2007 Annual Meeting of the American Association for Cancer
Research (AACR) in which BiTE(R) molecules targeting carcinoembryonal
antigen (CEA) were shown to prevent subcutaneous tumor growth and
formation of lung metastases.
-- Micromet received an undisclosed preclinical proof-of concept milestone
payment from MedImmune pursuant to its research collaboration with
MedImmune for the development of new BiTE molecules targeting CEA.
-- Micromet and its partner MedImmune published proof-of-concept data with
a new BiTE molecule (bscEphA2xCD3) showing that the compound killed
tumor cells at dose levels considerably below those required by
classical monoclonal antibody-based therapies. The in vitro and in vivo
data, collected from cell culture experiments conducted under the two
companies' BiTE technology research collaboration, were published in
the April 15, 2007 issue of Cancer Research.
-- Micromet recently opened its new U.S. headquarters in Bethesda,
Maryland, in the Maryland Biotech Corridor and greater Washington, DC
area. The new U.S. headquarters address now is 6707 Democracy
Boulevard, Suite 505, Bethesda, MD 20817 and the main phone number is
[phone]. The former headquarters office in Carlsbad, California
has been closed.

Financial Results:

Quarter Ended March 31, 2007

For the three months ended March 31, 2007, Micromet recognized total revenues of $2.8 million, compared to $4.1 million for the same period in 2006. Total operating expenses were $10.3 million for the three months ended March 31, 2007, compared to $5.7 million for the same period in 2006. For the three months ended March 31, 2007, Micromet reported a net loss of $7.6 million, or $0.24 per basic and diluted share, compared to a net loss of $2.2 million, or $0.12 per basic and diluted share, for the same period in 2006. Revenue recognized under collaboration agreements decreased by $1.3 million during the first quarter of 2007, as compared to the first quarter of 2006, as the phase 2a studies for adecatumumab (MT201) were in progress during 2006. Research and development expenses increased $2.2 million over the prior year due to stock compensation charges of $0.6 million not incurred by Micromet AG in the first quarter of 2006, license fees of $0.5 million, clinical trial materials manufacturing of $0.3 million, and patent filing costs of $0.3 million. General and administrative expenses increased by $2.4 million over the prior year due to stock-based compensation charges of $0.6 million not reflected in 2006 and increased costs of being a public company.

Summarizing the quarter, Christian Itin, Ph.D., President and Chief Executive Officer of Micromet said: "With the move of our U.S. headquarters to Bethesda, Maryland we have essentially completed the post merger integration process. This quarter we have reported on significant progress of our new BiTE programs in collaboration with our partner MedImmune, underlining the broad applicability of the BiTE platform in oncology, and established a new partnership with Tracon Pharmaceuticals for our product candidate D93. We expect to announce additional results of our clinical and preclinical programs during the first half of 2007."

2007 Outlook:
-- Micromet and its partner MedImmune plan to initiate a first clinical
trial with our BiTE molecule targeting CD19, MT103/MEDI-538, in non-
Hodgkins lymphoma patients in the U.S. and a phase 2 clinical trial in
acute lymphatic leukemia in Europe.
-- Micromet and its partner Merck Serono are continuing their ongoing
phase 1b trial in metastatic breast cancer with adecatumumab (MT201) in
combination with docetaxel and are preparing to initiate a phase 1
clinical trial to test adecatumumab in other solid tumors.
-- Micromet and its partner Merck Serono expect to release additional data
from their phase 2a clinical trials at the 2007 Annual Meeting of the
American Society of Clinical Oncology (ASCO).
-- Micromet plans to advance its preclinical development program for our
BiTE molecule targeting EpCAM, MT110, with a goal of an IND/IMPD filing
in 2007.
-- Micromet's partner TRACON Pharmaceuticals plans to initiate a phase 1
clinical trial for TRC093 (formerly D93), a monoclonal antibody
targeting denatured collagen, in the second half of 2007.
Micromet's partner Morphotek plans to file for an IND for MORAb28 in
the second half of 2007.
-- Micromet plans to establish strategic collaborations with respect to
MT203, a monoclonal antibody neutralizing GM-CSF, and MT204, a
monoclonal antibody neutralizing IL-2.
-- Micromet intends to continue its research and development programs for
the discovery of new BiTE product candidates.


Haben wohl einige die Zahlen nicht so toll gefunden !!!

Jedoch der Ausblick und die zukünftigen "events" sind eigentlich
noch recht positiv zu sehen, die Zusammenarbeit mit den anderen
Partnern läuft weiter und die Pipeline ist nicht zu unterschätzen!

[Latinl]

Antwort auf Beitrag Nr.: 29.262.499 von MasaRatti am 11.05.07 08:24:49

ich meine was erwarten sie... wo gewerkelt wird da fallen auch spähne...

[MasaRatti]

Für die Vollständigkeit!

Micromet Collaborating With Nycomed
Thursday May 24, 10:59 am ET
Micromet to Receive Research Payments in Antibody Collaboration With Privately Held Nycomed

BETHESDA, Md. (AP) -- Biotechnology company Micromet Inc. said Thursday it is collaborating with privately held pharmaceutical group Nycomed to develop a class of antibodies in a deal potentially worth $167 million.

ADVERTISEMENT
The anti-GM-CSF antibodies have the potential to treat inflammatory and autoimmune diseases. The lead development product is Micromet's MT203, which is expected to enter clinical trials in 2008.

Micromet will receive an upfront license fee of 5 million euros, or about $7 million, the company said. It is eligible to receive reimbursements and payments of more than 120 million euros, or about $160 million.

The company will be responsible for preclinical development and manufacturing during early clinical trials. Nycomed, which is relocating to Switzerland from Denmark, will be responsible for clinical development and commercialization worldwide and will fund development activities.

Shares of Micromet surged 46 cents, or 19 percent, to $2.91 in morning trading. The stock has traded between $1.82 and $5.30 over the last 52 weeks.

[Latinl]

gibt es was neues von micromet ??

[Frankcom]

Antwort auf Beitrag Nr.: 29.624.125 von Latinl am 04.06.07 08:03:55

Ja, gibt es, ganz aktuell.

Micromet Says Final Data From Phase 2 Trial Presented [MITI]

6/4/2007 10:57:16 AM Micromet, Inc. (MITI) reported final data from the randomized phase 2 clinical trial of adecatumumab or MT201 in metastatic breast cancer or MBC patients, including recent exploratory posthoc subgroup analyses.

The product candidate, a fully human monoclonal antibody targeting tumor cells overexpressing the epithelial cell adhesion molecule (EpCAM), was tested as a single agent at two dose levels to assess its efficacy and safety in patients with EpCAM-positive metastatic breast cancer (N=109). EpCAM expression has been implicated to be a negative prognostic marker associated with strongly decreased overall survival in MBC patients.

[MasaRatti]

Die nächsten Termine und Konferenzen ...


Conferences

June 26 - 28, 2007

Recombinant Antibody Conference, Berlin, Germany





July 10 - 12, 2007

CEUT Emerging Growth Conference 2007 New York, NY





August 2, 2007

ThinkEquity Partners LLC Second Annual ThinkBIG Conference New York, NY





December 8 - 11, 2007

Annual Meeting of American Association for Oncology (ASH), Atlanta, GA

[Latinl]

Antwort auf Beitrag Nr.: 30.002.342 von MasaRatti am 18.06.07 18:03:12

und dann, was kommt danach

[MasaRatti]

Hi!
Es bestehen genug Cooperationen in verschiedenen Bereichen, auch
in versch. Zulassungsphasen - vieles entwickelt sich sehr positiv,
die Finanzierung für die Forschungsprodukte steht und in den
kommenden Konferenzen wird es hoffentlich auch die Eine oder Andere
positive News geben, hoffe ich ...
Bleibe dabei, wie auch schon vor vielen Monaten - unter 2,50 Dollar
sehe ich immer Kurse zum Einsammeln !
Natürlich nicht zu vergessen auch mal "Gewinne" mitzunehmen, gab es
ja auch schon ein paar Gelegenheiten
Mein Einschätzung-aber alles sehr spekulativ !

[MasaRatti]

20.06.2007 15:25
Micromet Announces Definitive Agreement for $25.0 Million Private Placement

BETHESDA, Md., June 20 /PRNewswire-FirstCall/ -- Micromet, (Nachrichten) Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced that it has entered into a definitive agreement with various institutional investors to raise $25.0 million in a private placement of its common stock. Under the terms of the financing, Micromet is expected to sell approximately 9.2 million shares of common stock and warrants to purchase approximately 4.6 million shares of common stock at a total purchase price of $2.7525 per unit. The warrants are exercisable at $3.09 per share at any time on or after the date that is 180 days after issuance (the "Initial Exercise Date") and until the five-year anniversary of the Initial Exercise Date. RBC Capital Markets served as lead placement agent and C.E. Unterberg, Towbin served as the co-agent on the offering.

The net proceeds of the financing will be used for continued research and development of Micromet's product candidates and operational expenses.

[Latinl]

Antwort auf Beitrag Nr.: 22.179.653 von MasaRatti am 20.06.06 07:09:17

masaratti.. es hilft nix...

ich galub wir sind die einzigen beiden die in micro investiert sind in deutschland

die dreckischen zwei

[Frankcom]

Antwort auf Beitrag Nr.: 30.099.094 von Latinl am 21.06.07 19:13:48

Hallo Ihr zwei!

Ihr seid nicht allein, ich bin schon seit ca 3 Jahren dabei
und habe die letzte Zeit immer mal zum aufstocken genutzt.
Ich denke, man muss Geduld haben und weiter in die Zukunft sehen.
Die Pipeline ist gut gefüllt und wenn es mal durchlägt, dann müssen wir uns festhalten, damit uns nicht schwindelig wird.

Gruß
Frankcom

[MasaRatti]

Servus,

auf der Ab-Konferenz in Berlin wird hoffentlich mal dem Kurs wieder
auf die Beine geholfen ... obwohl inb diesem Marktumfeld eher
schwer!
Aber bleibe bei meiner Meinung, das Kurse unter 2,50 Dollar zum
reingehen in den Wert animieren !!!

[Latinl]

Antwort auf Beitrag Nr.: 30.102.282 von Frankcom am 21.06.07 21:51:03

wann soll den mal was aus der ipeline kommen bin sehr klein investiert

[MasaRatti]

Publication Confirms that EpCAM, the Target for Two of Micromet's Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers

BETHESDA, Md., June 26 /PRNewswire-FirstCall/ -- Micromet, (Nachrichten) Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, announced that a study published recently in the Proceedings of the National Academy of Sciences (1) supports the findings of several other studies that EpCAM (CD326), which is used as the target for Micromet's product candidates adecatumumab (MT201) and MT110, may be suitable as a target for eradication of so called "cancer stem cells" (CSCs). The other studies showed that CSCs from colon (2), breast (3), pancreatic (4) and prostate (5) cancers all express high levels of EpCAM, which, according to these studies, makes these cells particularly capable of causing tumors.

CSCs constitute a small percentage of tumor cells that have the potential to self-renew and to permanently repopulate a tumor with new cancer cells. CSCs appear to be resistant to various chemotherapies, which may be one of the key reasons why most current therapies cannot cure cancer through elimination of all tumor cells (6). Micromet scientists believe that the findings of EpCAM expression by CSCs in many cancers and of EpCAM being a frequently and highly expressed tumor-associated antigen (7, 8), supports Micromet's use of EpCAM for targeted therapeutics.

EpCAM is the target for Micromet's clinical-stage product candidate adecatumumab (MT201), a fully human monoclonal antibody being co-developed with Merck Serono. In addition, Micromet's BiTE(R) product candidate MT110, an anti-EpCAM/CD3-bispecific antibody construct, is currently in late preclinical development. Both product candidates are designed to recognize EpCAM- expressing cancer cells and to instruct cytotoxic cells of the immune system to eliminate such cancer cells.

"The 'seek and destroy' mechanism of our EpCAM-directed therapeutic drug candidates may be capable of finding and eradicating cancer stem cells in various indications," commented Patrick Baeuerle, Ph.D., Micromet's Chief Scientific Officer. "In addition, EpCAM is also expressed on the progeny of cancer stem cells, which may lead to a reduction of tumor mass by these drugs alone or by combining them with standard therapies."

[Latinl]

Antwort auf Beitrag Nr.: 30.347.175 von MasaRatti am 27.06.07 13:36:22

dem kursverlauf zu folge nicht gut

[MasaRatti]

05.07.2007 16:07
Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference

BETHESDA, Md., July 5 /PRNewswire-FirstCall/ -- Micromet, (Nachrichten) Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, Inc., will present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference in New York on Thursday, July 12, 2007 at 10:00am, eastern.

A webcast of Dr. Itin's remarks will be available live. You can access the webcast at: http://www.micromet-inc.com/. An archived version of the remarks will also be available through the Company's web site for a limited time following the conference.

[MasaRatti]

[Latinl]

Antwort auf Beitrag Nr.: 30.596.730 von MasaRatti am 09.07.07 18:48:27

das heißt

[MasaRatti]

Antwort auf Beitrag Nr.: 30.597.344 von Latinl am 09.07.07 19:25:40

Das heißt 11% im plus bei höheren Umsätzen und nächste
Woche kommt noch eine Präsentation ...
Hatte bei 2,40 Dollar etwas eingesammelt, leider Abstauberlimit zu
2,25 knapp verpaßt (Kurs ging nur bis 2,27 grmpf), aber damit bin
ich erstmal besänftigt
Jedoch geht´s wahrscheinlich ohne Nachrichten demnächst wieder in
den Keller !!!

[Latinl]

Antwort auf Beitrag Nr.: 30.598.760 von MasaRatti am 09.07.07 20:46:26

wann kann man den aus der Pipeline was erwarten ?

[MasaRatti]

Antwort auf Beitrag Nr.: 30.619.712 von Latinl am 10.07.07 19:17:13

Pipeline:
http://www.micromet.de/en/pipe/overview.php

Die Produkte befinden sich in Phase II oder darunter, kann also
noch eine Zeit lang dauern, weiß man nie ...

Aber die meisten sind in Kooperation mit Partnern und daher
auch gut finanziert - eijo schaun mer ma- ist halt alles sehr
spekulativ, aber wenn es mal wieder etwas positive Nachrichten
geben sollte, dann .... Bumm !

[MasaRatti]

11.07.2007 13:07
TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial with TRC093 (D93), a Humanized Antibody for Cancer Treatment

SAN DIEGO, and BETHESDA, Md., July 11 /PRNewswire-FirstCall/ -- TRACON Pharmaceuticals, Inc. (TRACON), a biopharmaceutical company focused on the development of products for oncology and ophthalmology treatment, and Micromet, (Nachrichten) Inc., , a biopharmaceutical company focused on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, announced today that TRACON has started the treatment of the first cancer patient in a Phase 1 clinical trial with TRC093.

TRC093 is a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen, a component of the extracellular matrix of tumors that serves as the scaffold for new blood vessel and tumor growth. TRC093 has shown activity, as monotherapy or when combined with chemotherapy, in pre-clinical studies of melanoma, breast and pancreatic cancer.

TRC093 is currently being developed by TRACON in oncology and Age-Related Macular Degeneration (AMD), following execution of a license agreement with Micromet, Inc. in March 2007, granting TRACON worldwide rights to develop and commercialize D93 (now TRC093). TRC093 (D93) was generated and developed by Micromet up to the filing and acceptance of the IND.

"TRACON's management team is cohesive and focused on execution. These qualities, combined with our excellent working relationship with Micromet and top-notch Phase 1 sites, have allowed us to initiate dosing within four months of execution of the license agreement," said Charles Theuer, M.D., Ph.D., President and Chief Executive Officer of TRACON Pharmaceuticals, Inc. "Moving a humanized antibody into the clinic, that has the potential to treat multiple solid tumors in combination with chemotherapy and targeted agents, is a major milestone for TRACON in what will be a busy year for the company. We anticipate dosing two additional first-in-class cancer treatments later this year."

The Phase 1 trial is designed to assess the safety, tolerability and pharmacokinetics, as well as preliminary anti-tumor activity, of TRC093 in patients with advanced cancer.

"We are very pleased to see that TRACON has initiated a broad development program very shortly after receiving the license from us in March of this year. The initiation of the Phase 1 study is an important milestone for the product and we are looking forward to the expansion of the program into age- related macular degeneration," said Jens Hennecke, Vice President Business Development of Micromet.

[MasaRatti]

19.07.2007 14:10
Micromet Promotes Carsten Reinhardt to Chief Medical Officer

BETHESDA, Maryland, July 19 /PRNewswire/ --

- Company Expects Four Antibodies in Clinical Development by End of 2007 -

Micromet, (Nachrichten) Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for the treatment of cancer, inflammatory and autoimmune diseases, announced today the promotion of Carsten Reinhardt, M.D. from Senior Vice President of Clinical Development to Senior Vice President and Chief Medical Officer. Dr. Reinhardt joined Micromet in 2005 from Roche (Basel, Switzerland) where he was the International Medical Leader of the Herceptin(R) program. As Chief Medical Officer, he will continue to be responsible for the overall clinical development of Micromet's product candidates.

Micromet expects to initiate clinical trials for one additional antibody program by the end of the year, bringing the total number of antibodies in clinical development to four. In addition, up to four preclinical antibodies are anticipated to reach the clinical stage during 2008 and 2009. Building on its clinically validated next generation antibody technology platform known as BiTE(R) molecules, Micromet will continue to broaden its pipeline with a focus on cancer, inflammation and autoimmune diseases.

"Carsten has built an outstanding clinical development group at Micromet, and has demonstrated the leadership and expertise we need in order to take advantage of the opportunities arising from our strong development pipeline," said Christian Itin, Ph.D., President and Chief Executive Officer of Micromet. "Thanks to Carsten and his team, we are well positioned to expand our clinical stage pipeline based on our BiTE antibody technology over the next two years, while continuing to advance our antibody product candidates that are currently in clinical trials."

[Latinl]

Antwort auf Beitrag Nr.: 30.768.717 von MasaRatti am 20.07.07 07:43:24

hier nix neues was

[Latinl]

[Frankcom]

Antwort auf Beitrag Nr.: 31.083.694 von Latinl am 08.08.07 18:09:00

Guten morgen!

Waren denn die Zahlen so schlecht?

??????????

Gruß
Frankcom

[Latinl]

Antwort auf Beitrag Nr.: 31.089.330 von Frankcom am 09.08.07 07:27:19

ich habe keinen plan.. weiß nur das es krass nach unten ging

[MasaRatti]

Moin zusammen,
die Zahlen waren so olala, nicht besonders berauchend, aber
der Abwärtshype war schon eher übertrieben. Auch stehn in
nächster Zeit genug Termine an (siehe Homepage), wo es ja auch
mal gute news geben könnte! Hab jedenfalls mal eine kleine
Position unter 2,20 eingesammelt, schaun mer ma - bin ja noch
sehr positiv gestimmt für die Aktie und wundere mich, das trotz
der relativ guten Pipeline der Wert immer noch gedrückt wird ...
halt alles sehr spekulativ bei diesen kleinen Firmen, aber die
Kooperationen und Vertragsabschlüsse der letzten Zeit lassen hoffen!
Bin noch dabei

[Latinl]

Antwort auf Beitrag Nr.: 31.123.352 von MasaRatti am 11.08.07 09:24:10

Bin auch noch dabei So wie es aussieht sind wir die einzige deutsche Aktionäre

[Latinl]

nix los hier...

[Latinl]

ist gestern was passiert

[panik]

2007-08-20
Purchase 2007-08-22
6:40 pm MICROMET, INC. MITI Johann Peter
(Director) 5,000 $1.92 $9,600 5,000
(Direct)

[MasaRatti]

Moin,
ja die Umsätze sind zwar noch recht gering, aber vielleicht
haben wir langsam mal den Boden gefunden und können mal
die lächerliche 2 Dollar-Marke hinter uns lassen und mal schauen,
was die ganzen Konferenzen bewirken werden ...

Investor Calendar

September 4 - 5, 2007

Sal. Oppenheim-European Healthcare Investor Conference, Frankfurt, Germany





September 24 - 27, 2007

2007 UBS Global Life Sciences Conference, New York, NY





October 2 - 3, 2007

Sachs Associates-7th Annual Biotech in Europe Investor Forum, Zurich, Switzerland





October 9 - 11, 2007

BIO Investor Forum 2007, San Francisco, CA





November 5 - 7, 2007

Acumen Biofin Rodman & Renshaw-9th Annual Healthcare Conference, New York, NY





November 7, 2007

Q3 2007 Earnings Conference Call





January 7 - 10, 2008

JPMorgan 26th Annual Healthcare Conference, San Francisco, CA

[MasaRatti]

19.09.2007 13:07
Micromet to Present at the UBS Global Life Sciences Conference

BETHESDA, Md., Sept. 19 /PRNewswire-FirstCall/ -- Micromet, (Nachrichten) Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will present at the UBS Global Life Sciences Conference in New York City, on Wednesday, September 26, 2007 at 11:00am Eastern time (5:00pm central European time).

An audio webcast of Dr. Itin's remarks will be available live and accessible through Micromet's website at http://www.micromet-inc.com/. A replay and a download of the presentation will also be available via the website.

About Micromet, Inc. (http://www.micromet-inc.com/)

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammation and autoimmune diseases. Three product candidates are currently in clinical trials. MT103, also known as MEDI-538, is the first product candidate based on Micromet's novel BiTE(R) antibody product development platform and is being evaluated in a phase 1 clinical trial for the treatment of patients with non- Hodgkin's lymphoma. The BiTE antibody product development platform is based on a unique, antibody-based class of drugs that leverages the cytotoxic potential of T cells in the treatment of cancer. T cells are the most powerful 'killer cells' of the human immune system. Micromet has established a collaboration with MedImmune, Inc. for MT103/MEDI-538. The second clinical stage product candidate is adecatumumab, also known as MT201, a recombinant human monoclonal antibody which targets EpCAM expressing tumors. Adecatumumab is being developed for the treatment of patients with breast cancer. A phase 2a clinical trial in this indication has been completed and a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. Our third clinical stage product candidate is D93, also known as TRC093, a first-in- class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. This product candidate is in phase 1 clinical trials and is being developed by TRACON Pharmaceuticals for the treatment of patients with cancer and age-related macular degeneration pursuant to a license agreement under which Micromet has granted TRACON the worldwide rights to develop and commercialize D93/TRC093. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as autoimmune diseases.

[Latinl]

Antwort auf Beitrag Nr.: 31.664.037 von MasaRatti am 19.09.07 17:11:23

das heißt ?

[Latinl]

bin ich der einzige deutsche aktionär

[Latinl]

15.10.2007 10:19 Übernahmefantasie in Biotech-Branche
Mit deutschen Biotech-Aktien hatten Anleger in den letzten Monat wenig Freude. Nun kommt wieder Bewegung in die Branche. Der US-Biotech-Riese Biogen soll verkauft werden.
Die Banken Goldman Sachs und Merrill Lynch seien mit der Käufersuche beauftragt worden, teilte das weltweit fünftgrößte Biotech-Unternehmen am Wochenende mit. Es gebe bereits Interessenten, hieß es. Konkrete Namen fielen aber nicht.

Icahn legt angeblich Milliarden-Gebot vor
Laut einem Bericht des "Handelsblatts" soll der Investor Carl Icahn ein Übernahmeangebot von 23 Milliarden Dollar gemacht haben. Icahn ist seit Ende August an Biogen beteiligt und hält inzwischen rund vier Prozent der Anteile.

Als mögliche Interessenten für Biogen gelten auch die Pharma-Konzerne wie Sanofi-Aventis und Pfizer. Sanofi hatte sich bereits Anfang des Jahres Interesse an Biogen signalisiert. In den vergangenen Jahren wurden zahlreiche Biotech-Firmen von etablierten Pharmakonzernen übernommen. Patentabläufen und ein Mangel an neuen Produkten zwingen Pfizer & Co zu Zukäufen.

Zweiter Mega-Biotech-Deal in diesem Jahr?
Käme der Verkauf zustande, wäre dies bereits die zweite große Biotech-Großübernahme in diesem Jahr. Anfang des Jahres hatte der britische Konzern Astra Zeneca Medimmune für rund 15 Milliarden Dollar geschluckt.

Biogen hatte zuletzt mit schleppenden Absätzen seines Hauptprodukts Avonex zu kämpfen. Das Mittel wird gegen die Nervenkrankheit Multipler Sklerose eingesetzt. Biogen konkurriert in diesem Bereich mit Bayer und Merck. Vor zwei Jahren erlitt Biogen einen Rückschlag mit dem neuen MS-Medikament Tysabri. Wegen Sicherheitsbedenken musste es vorübergehend vom Markt genommen werden. Das Mittel ist inzwischen unter verschärften Sicherheitsauflagen wieder zugelassen.

Aktie von Biogen steigt zweistellig
Nachbörslich stieg die Aktie von Biogen um rund 16 Prozent. Damit notiert das Papier auf dem höchsten Stand seit Mitte 2002. Das 1978 gegründete Unternehmen gehört zu den Biotech-Firmen der ersten Generation.

Die Kursgewinne von Biogen konnten die deutschen Biotech-Titel jedoch kaum beflügeln. Während Morphosys und BB Biotech leicht zulegen, geben GPC Biootech und Qiagen nach. In den letzten Monaten waren die deutschen Biotech-Aktien schwach gelaufen. Allein GPC Biotech verlor in den vergangenen sechs Monaten fast 60 Prozent an wert und war größter TecDax-Verlierer.

Deutsche Biotech-Firmen hinken hinterher
Die meisten deutschen Biotech-Firmen haben bisher kaum ein Medikament im Markt. Viele der entwickelten Mittel sind inzwischen weit fortgeschritten und müssen nun in der Phase 3 ihre Wirksamkeit und Verträglichkeit beweisen. Da sind Rückschläge vorprogrammiert – wie zuletzt bei GPC mit ihrem Prostakrebs-Mittel Satraplatin.


http://boerse.ard.de/content.jsp?key=dokument_256010

[wayne99]

Press Release Source: Micromet, Inc.


Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
Thursday October 18, 7:00 am ET


BETHESDA, Md., Oct. 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI - News), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for the treatment of cancer, inflammatory and autoimmune diseases, announced today that the Paul-Ehrlich Institute has approved an Investigational Medicinal Product Dossier (IMPD) for the conduct of a phase 2 clinical trial testing MT103 in patients with acute lymphoblastic leukemia (ALL) in Germany. MT103, a BiTE® antibody targeting the CD19 antigen, which is expressed on most malignant B lymphoma cells, is also being evaluated in an ongoing phase 1 clinical trial in Europe in non- Hodgkin's lymphoma (NHL). Micromet and MedImmune, a subsidiary of AstraZeneca plc, are currently developing MT103 (also known as MEDI-538). Under a 2003 agreement, Micromet granted MedImmune exclusive rights for MT103 for North America.


Acute lymphoblastic leukemia is a highly aggressive form of B-cell leukemia. Currently, patients are initially treated with complex and toxic chemotherapy regimens that can be followed by bone marrow stem cell transplantation. If patients have low amounts of residual tumor cells after chemotherapy (also known as "minimal residual disease" or MRD) they are at a very high risk of relapse. This phase 2 clinical trial will test whether MT103 can remove residual tumor cells and thereby convert patients from a MRD- positive to a MRD-negative status with an improved time to relapse.

"When MRD is detectable, the median relapse free survival in patients is only 4.1 months. In the German Multicenter Study Group for Adult ALL (GMALL) studies, patients with MRD after induction and the first consolidation treatment are identified as high risk and are candidates for stem cell transplantation. Optimization of treatment and reduction of relapse of patients with MRD-positive ALL represent an absolute medical need especially in patients for whom stem cell transplantation is not an option. Although CD19 is widely expressed in ALL, no antibody against this tumor associated antigen target has been developed thus far. The current clinical trial is set up to address the question of treating MRD positive ALL with a novel anti-CD19 antibody derivative," said Professor Hoelzer, Chairman of the GMALL study group.

Early observations of MT103 clinical activity were recently reported from an ongoing phase 1 clinical trial evaluating MT103 as single-agent therapy in a population of heavily pre-treated patients with NHL. These observations included complete and partial responses confirmed by independent review. In addition, MT103 not only eliminated tumor target cells in peripheral blood but also cleared lymphoma cells from heavily infiltrated bone marrow. These data were presented at the 48th Annual Meeting of the American Society for Hematology in December 2006.

"The upcoming phase 2 clinical trial in ALL is an important step to establish activity of MT103 in aggressive B cell leukemias and lymphomas," said Carsten Reinhardt, Micromet's Senior Vice President and Chief Medical Officer. "Investigating the effect of MT103 on minimal residual disease may open a highly promising new treatment concept in these diseases, that is, consolidation therapy with a BiTE antibody (MT103) after initial treatment with a chemotherapeutic regimen."

About BiTE® Antibodies

BiTE® antibodies are designed to direct the body's cytotoxic, or cell- destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target tumor cells. Through the process of killing cancer cells, T cells proliferate, which leads to an increased number of T cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE product development platform. The most advanced BiTE antibody is MT103 (MEDI-538), targeting CD19, which has provided proof-of-concept in an ongoing phase 1 clinical study in advanced non-Hodgkin's lymphoma patients. Three other BiTE antibodies, targeting EpCAM (CD326), CEA and MCSP, are in pre-clinical development.

About MT103 (MEDI-538)

MT103, which is being co-developed with MedImmune as MEDI-538, is a BiTE® antibody being developed with the intent to treat patients with certain types of B-cell lymphomas. MT103 received orphan drug designation from the EMEA for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. In February 2006, the U.S. Food and Drug Administration (FDA) also approved an orphan drug designation for MT103 for the treatment of certain indolent B-cell lymphomas. MT103 specifically targets the CD19 antigen, which is present on B-cells and B cell-derived tumors but not on other types of blood cells or healthy tissues.

About Micromet, Inc. (www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the first antibody developed using the BiTE ®technology platform to be clinically validated in Micromet's product pipeline, is being evaluated in a phase 1 clinical trial for the treatment of patients with non- Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with AstraZeneca plc's subsidiary MedImmune, Inc. The second clinical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM expressing tumors. Adecatumumab is being developed by Micromet in collaboration with Merck Serono in a phase 1b clinical trial evaluating MT201 in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody is MT293 (formerly D93), also known as TRC093, a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. MT293, which is currently being tested in a phase 1 clinical trial, is licensed to TRACON Pharmaceuticals, Inc. and is being developed for the treatment of patients with cancer and age-related macular degeneration. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. You are urged to consider statements that include the words "ongoing", "may", "will", "would", "could", "should", "believes", "estimates", "projects", "potential", "expects", "suggests", "plans", "anticipates", "intends", "continues", "forecast", "designed", "goal", or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in our periodic reports and other filings with the SEC.




--------------------------------------------------------------------------------
Source: Micromet, Inc.

[MasaRatti]

Hallo zusammen,
na sammelt Ihr fleißig ein, vielleicht ist es ja der
Boden und jetzt geht es aufwärts

Die nächste Woche mit den beiden Terminen wird interessant, mal
schauen wo wir dann am 09.10. stehen, evtl. sind es diese Woche
noch gute Einstiegskurse, aber wer weiß, wie die Quartalszahlen
wirklich aussehen ...

[Latinl]

Antwort auf Beitrag Nr.: 32.200.332 von MasaRatti am 30.10.07 10:56:21

du meinst 09.11

[MasaRatti]

Joh, sorry

[Latinl]

Antwort auf Beitrag Nr.: 32.200.332 von MasaRatti am 30.10.07 10:56:21

ist den was durchgesickert bei den zahlen

[Latinl]

noch jemand dabei

[MasaRatti]

Antwort auf Beitrag Nr.: 32.547.844 von Latinl am 24.11.07 12:51:16

News:
Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE® Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin´
Leser des Artikels: 28


Bethesda and Gaithersburg, MD - November 29, 2007 - Micromet, Inc.
(Nasdaq: MITI) and MedImmune, Inc. today announced that new data from
an ongoing Phase 1 clinical trial of MT103 in patients with
late-stage non-Hodgkin´s lymphoma (NHL) will be presented at the 2007
Annual Meeting of the American Society of Hematology (ASH) on
December 9 in Atlanta, Georgia. MT103, also known as MEDI-538, is a
recombinant T-cell engaging antibody, or BiTE® antibody, targeting
the CD19 antigen, which is uniquely expressed on B-cells. As the
first BiTE antibody studied in humans, MT103 is currently being
evaluated in Phase 1 and 2 clinical trials for the treatment of
patients with various B-cell malignancies.

New data from the ongoing Phase 1 dose-escalating trial show evidence
of objective complete and partial responses in relapsed follicular
lymphoma (FL), mantle cell lymphoma (MCL), and chronic lymphocytic
leukemia (CLL) patients. At the time of the analysis, dose levels
tested ranged from 0.0005 to 0.030 mg/m² per day, respectively. Among
the 15 evaluable patients at dose levels of 0.015 and 0.030 mg/m² per
day, two complete responses, two partial responses, and two minimal
responses were observed. One of the complete responses was in a
patient with MCL. In addition, six patients experienced stable
disease and three patients progressed during treatment. The full data
set, which will include additional patients at a higher dose level
than reported in the abstract, will be presented at ASH.

Six patients at dose levels 0.015 and 0.030 mg/m² per day had tumor
infiltration in the bone marrow, a location from which relapses of
these diseases potentially emanate. The bone marrow infiltration in
five out of six patients decreased during treatment with MT103, with
a complete clearance of tumor cells from the bone marrow in three
patients and partial clearance in the other two patients.

Complete and partial clinical responses were assessed according to
Cheson criteria, and all responses were confirmed by a central
review. Clinical responses and tumor clearance from the bone marrow
demonstrate clinical activity of the BiTE antibody in those patients
who received higher doses.

"We are pleased to see the number of objective responses to MT103 in
a relapsed patient population, and are looking forward to providing a
more detailed update at ASH about our exciting new clinical data with
the first BiTE antibody in clinical trials," commented Christian
Itin, Ph.D., President and Chief Executive Officer of Micromet.

MT103 is a novel, highly-specific and highly-potent drug, with which
objective responses are being seen in patients with FL and MCL who
have progressed after multiple prior treatments. The most common
adverse events observed in this study were fever, chills, leukopenia,
lymphopenia, pyrexia and elevated liver enzymes. The majority of the
adverse events have been fully reversible and in many cases resolved
without discontinuation of MT103 administration. Less common adverse
events included central nervous system events, which were fully
reversible after
discontinuation of the infusion. Dose escalation continues.

"These clinical responses to MT103 in patients with various B-cell
malignancies are an important achievement in our partnership with
Micromet,´´ commented Dirk Reitsma, M.D., vice president, clinical
development, oncology, MedImmune. "The expansion of research into the
potential of BiTE technology in a clinical setting represents another
pioneering effort by MedImmune to develop novel targeted cancer
treatments for patients in need.´´

[MasaRatti]

Morgen zusammen,
diese Woche könnte nochmal spannend werden ...schaun mer ma !

Conferences

December 8 - 11, 2007

Annual Meeting of the American Society of Hematology (ASH), Atlanta, GA




December 12 - 13, 2007

RBC Capital Markets Healthcare Conference, New York, NY






January 7 - 10, 2008




JPMorgan 26th Annual Healthcare Conference, San Francisco, CA

[MasaRatti]

Antwort auf Beitrag Nr.: 22.179.653 von MasaRatti am 20.06.06 07:09:17

Micromet and MedImmune Present New Clinical Data for MT103 at the American Society of Hematology Annual Meeting Suggesting Potent Single-Agent Activity in Patients with Relapsed Mantle Cell and Follic



Patients Treated With BiTE® Antibody Experience Dose-Dependent
Complete and Partial Responses

Bethesda and Gaithersburg, MD - December 10, 2007 - Micromet, Inc.
(Nasdaq: MITI) and MedImmune, Inc. yesterday presented new data from
an ongoing Phase 1 clinical trial showing potent single-agent
activity of MT103 in patients with late-stage non-Hodgkin´s lymphoma
(NHL). MT103, also known as MEDI-538, is a recombinant T-cell
engaging antibody, or BiTE® antibody targeting the CD19 antigen,
which is uniquely expressed on B-cells. MT103 is currently being
evaluated in Phase 1 and 2 clinical trials for the treatment of
patients with various B-cell derived cancers.

Data was presented yesterday at the 2007 Annual Meeting of the
American Society of Hematology in Atlanta, Georgia. In the higher
dose cohorts, clinical responses were observed in patients with
mantle cell lymphoma (MCL) and follicular lymphoma (FL). Among the 18
evaluable patients at dose levels of 0.015 to 0.06 mg/m2 per day,
three complete responses (CR) and four partial responses (PR) were
observed. At 0.06 mg/m2 per day, three clinical responses were
observed in three evaluable patients (one CR and two PR). No
responses were observed among 12 evaluable patients at dose levels
0.0005, 0.0015 and 0.005 mg/m2 per day. In the subgroup of patients
with MCL treated at 0.03 and 0.06 mg/m2 per day, three of five
evaluable patients experienced a clinical response (two CR and one
PR). All responses reported were assessed according to standardized
Cheson criteria and were confirmed by central review.

In addition, MT103 showed reduction or clearance of tumor cells from
various affected organs, including infiltrated bone marrow and liver.
Complete or partial clearance of tumor cells from bone marrow was
shown in eight of nine patients with bone marrow infiltration.

"The clinical responses observed in relapsed MCL patients are
promising, and support additional evaluation of MT103 as a potential
treatment for patients with MCL, who are in need of new therapeutic
options," commented Carsten Reinhardt, M.D., Ph.D., Chief Medical
Officer, Micromet. "The anti-tumor activity and safety profile of
MT103 demonstrated in this trial support the potential that BiTE
antibodies have as a new class of therapeutic antibodies."

The most common adverse events observed in this study were fever,
chills, leukopenia, lymphopenia, pyrexia and elevated liver enzymes.
The majority of the adverse events have been fully reversible and in
many cases resolved without discontinuation of MT103 administration.
Less common adverse events included central nervous system events,
which were fully reversible after discontinuation of the infusion.
Dose escalation continues.

All patients treated in this study had relapsed NHL and were
refractory after multiple treatments, and most patients were
diagnosed with stage III or IV MCL and FL. Patients were dosed with
MT103 for four or eight weeks, depending on their response to
treatment.

"As seen in this trial, MT103 is a novel, highly specific and highly
potent drug, with which objective responses are being seen in
patients with various forms of non-Hodgkin´s lymphoma who have
progressed after multiple prior treatments," commented Dirk Reitsma,
M.D., Vice President of Clinical Development and Oncology, MedImmune.
"These Phase 1 clinical responses have prompted our partnership to
expand our evaluation of MT103. We recently began a Phase 2 trial in
adult acute lymphocytic leukemia, and also anticipate beginning a
clinical trial in patients with chronic lymphocytic leukemia during
the first quarter of 2008."

Weiß zwar nicht, ob viele diese Meldung gelesen haben, aber zeigt
doch relativ klar, das MT103 in den Patienten in höheren Dosen
wirkungsvoll anspricht und auch die Aussagen der Verantwortlichen
zeigt doch deutlich, das die Kooperation und die Entwicklung
weiter geht! Die Verträglichkeit/Bioverfügbarkeit ist gut und
wenn die Phase 2 in 2008 anlaufen soll ... alles doch recht
interessant ... schaun mer ma ... noch find ich die Aktie doch
günstig ... wer weiß ...

[MasaRatti]

Hi !
Wünsch Euch und mir eine bessere Performance 2008 und
natürlich viel Gesundheit !

Immer schön bleiben, wird schon ...

[Latinl]

gibts was neues ??

[MasaRatti]

22.01.2008 13:10
Preclinical Study Published in Cancer Research Demonstrates Anti-Tumor Activity of Micromet's BiTE Antibody at Well Tolerated Doses

BETHESDA, Md., Jan. 22 /PRNewswire-FirstCall/ -- Micromet, (News) Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of a new preclinical study in Cancer Research(1) demonstrating that efficacious doses of a BiTE(R) antibody targeting epithelial cell adhesion molecule (EpCAM or CD326) are well tolerated in two mouse cancer models. BiTE antibodies join cytotoxic T cells with cancer cells for a tightly controlled elimination of cancer cells.

EpCAM is one of the most frequently and highly expressed tumor-associated antigens and is found on the majority of colon, lung, breast, prostate, ovarian, gastric, pancreas and on cancer stem cells. Like other tumor- associated antigens used as targets for antibody-based therapeutics, EpCAM is expressed on certain normal tissues. In order to assess the safety profile of an EpCAM-specific BiTE antibody, Micromet's researcher constructed a murine- specific BiTE antibody, called muS110, that is similar to the human-specific BiTE antibody MT110 with respect to structure, binding strength, efficacy and epitope recognition on EpCAM. EpCAM was found to be similarly expressed by mice and humans.

Low doses of muS110 that prevented growth of orthotopic breast cancer and formation of lung metastases in mice were well tolerated. Treatment with MuS110 did not lead to any damage of EpCAM-expressing normal tissues at any dose studied. This indicates that the EpCAM-specific BiTE antibody did recognize EpCAM on tumor cells but not on cells of normal tissues.

"We were pleased to see that an EpCAM-specific BiTE antibody showed anti- tumor activities at well tolerated doses," commented Patrick Baeuerle, Micromet's Chief Scientific Officer. "It appears that normal tissues expressing EpCAM are not affected by our BiTE antibody. We are now looking forward to testing the safety and clinical activity of MT110, a human EpCAM- specific BiTE antibody, in a phase 1 clinical trial in the near future."

[MasaRatti]

Antwort auf Beitrag Nr.: 22.179.653 von MasaRatti am 20.06.06 07:09:17

BETHESDA, Md., Feb. 7 /PRNewswire-FirstCall/ -- Micromet, (News) Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will present at two upcoming investor conferences; one sponsored by the Biotechnology Industry Organization (BIO) and the other by Roth Capital Partners.

Dr. Itin will present at the 2008 BIO CEO and Investor Conference in New York, on Wednesday, February 13, 2008 at 2:00 pm Eastern Time (8:00 pm Central European Time). An audio webcast of Dr. Itin's remarks will be available live and accessible through Micromet's website at http://www.micromet-inc.com/, as well as a replay and download of the presentation slides following the event.

Dr. Itin will also present at the Roth Capital Partners 2008 OC Growth Stock Conference in Dana Point California, on Tuesday, February 19, 2008 at 9:30 am Pacific Time.

[MasaRatti]

Investor Calendar



January 7 - 10, 2008




JPMorgan 26th Annual Healthcare Conference, San Francisco, CA







February 11-13, 2008





BIO CEO Investor Conference 2008, New York, NY







February 17-20, 2008





ROTH 20th Annual OC Growth Stock Conference, Laguna Niguel, CA







March 4-5, 2008





Susquehanna Financial Group: 2nd Annual Significant Options in Healthcare Conference, New York, NY







April 12-16, 2008





AACR Annual Meeting, San Diego, CA







May 28-29, 2008





BioEquity Europe 2008, Amsterdam, Netherlands







May 30 - June 4, 2008




ASCO Annual Meeting, Chicago, IL







June 17-20, 2008




BIO International Convention 2008, San Diego, CA



Na, vielleicht steigt so langsam mal das Interesse an Micromet

[MasaRatti]

06.03.2008 16:07
Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results

BETHESDA, Md., March 6 /PRNewswire-FirstCall/ -- Micromet, (News) Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, March 13, 2008, at 9:00 am Eastern Time (2:00 pm Central European Time) to discuss its fourth quarter and full year 2007 financial results. Micromet anticipates releasing its financial results at 7:00 am Eastern Time (12:00 pm Central European Time) on Thursday, March 13, 2008.

To participate in this conference call, dial 800-561-2813 (U.S.) or 617-614-3529 (international), passcode: 29595857. The audio webcast can be accessed at: http://www.micromet-inc.com/ in the investor relations section of the website.

A replay of the call will be available from 11:00 am Eastern Time on March 13, 2008 (4:00 pm Central European Time) through Thursday, March 20, 2008. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 40638317.

[MasaRatti]

Moin - es gibt doch wirklich "Analysten", die Micromet
mit einem Rating ausstatten ...

Micromet initiated with "buy"
03/10/08 - Punk Ziegel & Co.
NEW YORK, March 10 (newratings.com) - Analysts at Punk Ziegel & Co initiate coverage of Micromet Inc (MITI) with a "buy" rating. The target price is set to $4.

[MasaRatti]

13.03.2008 12:07
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results

BETHESDA, Md., March 13 /PRNewswire-FirstCall/ -- Micromet, (News) Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the fourth quarter and the full year ended December 31, 2007. As a result of the reverse merger between Micromet AG and CancerVax Corporation that was completed on May 5, 2006, the financial information included below for the fiscal year 2006 consists of Micromet AG's historical financial results for the period of January 1, 2006 to May 5, 2006 without the inclusion of the financial results of CancerVax, and the combined results of the two companies thereafter.

Summary of Recent Events: -- Micromet published data on its BiTE(R) antibody MT103 at the annual meeting of the American Society of Hematology in December, showing that MT103 induces dose-dependent objective complete and partial responses in late stage lymphoma patients. The BiTE antibody could also clear the bone marrow and other infiltrated organs from tumor cells. Particularly encouraging was the observation of complete responses in patients with mantle cell lymphoma (MCL) -- a disease that is difficult to treat. In Europe, Micromet has initiated a phase 2 study in acute lymphoblastic leukemia, one of the most aggressive blood cancers. -- Micromet has completed preclinical development for its second BiTE antibody MT110. MT110 binds to EpCAM, a cell surface molecule that is highly expressed on many solid tumors and on cancer stem cells -- those cancer cells responsible for metastasis and resistance of tumors to chemotherapies. -- In 2007, Micromet partnered two of its earlier stage programs. The company is collaborating with Nycomed on the development of MT203, a human antibody that neutralizes GM-CSF, a key cytokine involved in autoimmune diseases and chronic inflammation. In addition, Micromet has licensed MT293 to TRACON Pharmaceuticals, Inc. MT293 is an anti-angiogenic antibody that aims to limit tumor growth by preventing blood vessels to reach the tumor. TRACON initiated a phase 1 clinical trial in July 2007. -- In June 2007, Micromet closed a $25 million PIPE transaction, adding to its shareholder base a number of experienced U.S.-based biotech funds. Several of Micromet's existing shareholders participated in this financing round.

Summarizing the events, Christian Itin, Ph.D., President and Chief Executive Officer of Micromet said: "In 2007, we have made significant progress with our BiTE antibodies demonstrating strong clinical activity for MT103 in late-stage non-Hodgkin's lymphoma patients and completing preclinical development of MT110, our first BiTE antibody targeting solid tumors. In 2008, we will broaden the clinical program for MT103 and initiate a first clinical trial for MT110. We will also advance our earlier-stage BiTE antibodies and report on results at clinical and scientific conferences. In addition, we expect to start a phase 2 clinical trial with adecatumumab (MT201) in adjuvant disease in the second half of 2008. Finally, we will continue to explore opportunities for new collaborations in 2008."

Financial Results: Quarter Ended December 31, 2007

For the three months ended December 31, 2007, Micromet recognized revenues of $7.0 million, compared to $13.8 million for the same period in 2006. Included in 2006 revenues was the receipt of a $10.0 million milestone payment from Merck Serono following the completion of two phase 2 clinical trials for adecatumumab. Total operating expenses were $13.1 million for the three months ended December 31, 2007, compared to $10.9 million for the same period in 2006. For the three months ended December 31, 2007, Micromet reported a net loss of $3.8 million, or $0.09 per basic and diluted share, compared to net income of $3.4 million, or $0.11 per basic and diluted share, for the same period in 2006. The positive net income in 2006 was due primarily to the milestone payment received from Merck Serono.

Year Ended December 31, 2007

Revenues for the year ended December 31, 2007 were $18.4 million, compared to $27.6 million for 2006. For the year ended December 31, 2007, Micromet reported operating expenses of $43.6 million, compared to $61.2 million for the same period in 2006. In connection with the merger with CancerVax, Micromet recorded a non-recurring, non-cash charge of $20.9 million in the second quarter of 2006 due to the immediate write-off of CancerVax's in- process research and development programs. For the year ended December 31, 2007, net loss was $20.1 million, or $0.55 per basic and diluted share, compared to $34.0 million, or $1.29 per basic and diluted share, for 2006.

Micromet's cash and cash equivalents were $27.1 million as of December 31, 2007. Net cash used in operating activities was $14.3 million for the year ended December 31, 2007 and $15.4 million in 2006. Based on the status of our development programs, management believes that the cash balance at December 31, 2007 is sufficient to fund operations into the second quarter of 2009.

2008 Outlook: -- Micromet will present an update on its proprietary BiTE antibody technology platform and new BiTE antibody programs at the conference of the American Association of Cancer Research (AACR) in April 2008. -- A phase 1/2 clinical trial evaluating MT103 in patients with chronic lymphocytic leukemia is expected to be started in the United States by Micromet's collaboration partner MedImmune. In addition, at the conference of the American Society of Hematology (ASH) in December 2008, Micromet anticipates that it will provide an update on the clinical data of the ongoing clinical trials with MT103. -- Micromet expects to initiate dosing of patients in a phase 1 clinical trial of MT110 in patients with solid tumors in the first half of 2008. -- Micromet is currently developing the study design for a clinical trial to evaluate adecatumumab (MT201) in an adjuvant setting and plans to initiate this clinical trial in the second half of 2008. In addition, data of the ongoing phase 1b combination trial with docetaxel are expected to be presented in the second half of 2008. -- Micromet expects to initiate IND-enabling studies with MT203 as part of its collaboration with Nycomed.

Conference Call and Audio Webcast Today, March 13, 2007, at 9:00am Eastern Time

To participate in this conference call, dial 800-561-2813 (U.S.) or 617-614-3529 (international), passcode: 29595857. The audio webcast can be accessed at: http://www.micromet-inc.com/ in the investor relations section of the website.

A replay of the call will be available from 11:00 am Eastern Time on March 13, 2008 (4:00 pm Central European Time) through Thursday, March 20, 2008. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 40638317.

About Micromet, Inc. (http://www.micromet-inc.com/)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the efficacy, safety, and intended utilization of Micromet's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research, discovery of new product candidates, and clinical trials, and plans regarding partnering and outlicensing activities and the participation at upcoming scientific conferences. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in larger- scale or later clinical trials, the risk that the Company will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, the risks associated with reliance on collaborative partners for future revenues under the terms of its existing collaboration agreements, the risks associated with further clinical trials, development and commercialization of product candidates, and the risks associated with recruiting and retention of individuals in key management functions. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in Micromet's periodic reports and other filings with the SEC, including the "Risk Factors" sections of such reports.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Micromet, Inc. Condensed Consolidated Balance Sheets (In thousands, except par value) December 31, December 31, 2007 2006 Assets Current assets: Cash and cash equivalents $27,066 $24,301 Accounts receivable 4,689 2,319 Prepaid expenses and other current assets 2,579 2,048 Total current assets 34,334 28,668 Property and equipment, net 4,390 3,357 Goodwill 6,462 6,917 Patents, net 7,680 8,850 Other assets 196 321 Restricted cash 3,190 3,059 Total assets $56,252 $51,172 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $2,335 $1,680 Accrued expenses 4,765 10,153 Warrant liabilities 5,218 - Other liabilities 520 366 Short-term note - 1,320 Current portion of long-term debt obligations 2,401 599 Current portion of deferred revenue 3,360 2,972 Total current liabilities 18,599 17,090 Deferred revenue, net of current portion 8,366 195 Other non-current liabilities 2,055 1,961 Long-term debt obligations, net of current portion 2,254 7,408 Commitments Stockholders' equity: Preferred stock, $0.00004 par value; 10,000 shares authorized; no shares issued and outstanding - - Common stock, $0.00004 par value; 150,000 shares authorized; 40,778 and 31,419 shares issued and outstanding at December 31, 2007 and December 31, 2006, respectively 2 1 Additional paid-in capital 184,014 163,482 Stock subscription receivables - (27) Accumulated other comprehensive income 5,895 5,869 Accumulated deficit (164,933) (144,807) Total stockholders´ equity 24,978 24,518 Total liabilities and stockholders' equity $56,252 $51,172 Micromet, Inc. Condensed Consolidated Statements of Operations (In thousands, except per share amounts) Three Months Ended Year Ended December 31, December 31, 2007 2006 2007 2006 Revenues Collaboration agreements $6,751 $12,596 $17,366 $25,449 License fees and other 234 1,211 1,018 2,134 Total revenues 6,985 13,807 18,384 27,583 Operating expenses Research and development 9,471 7,385 29,191 28,252 In-process research and development - - - 20,890 General and administrative 3,590 3,495 14,430 12,012 Total operating expenses 13,061 10,880 43,621 61,154 Income (loss) from operations (6,076) 2,927 (25,237) (33,571) Other income (expense) Interest income (expense) 419 (32) 429 (982) Change in fair value of warrants 41 - 1,750 - Other income (expense), net 1,817 500 2,932 561 Net income (loss) attributable to common stockholders $(3,799) $3,395 $(20,126) $(33,992) Basic net income (loss) per common share $(0.09) $0.11 $(0.55) $(1.29) Diluted net income (loss) per common share $(0.09) $0.11 $(0.55) $(1.29) Weighted average shares used to compute basic diluted net income (loss) per share 40,757 31,416 36,362 26,366 Weighted average shares used to compute diluted net income (loss) per share 40,757 31,966 36,362 26,366

[Latinl]

Antwort auf Beitrag Nr.: 33.637.263 von MasaRatti am 14.03.08 06:40:40

also kommt in April was

[MasaRatti]

18.03.2008 12:07
Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research

BETHESDA, Md., March 18 /PRNewswire-FirstCall/ -- Micromet, (News) Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that five posters will be presented on April 14, 2008, at the annual meeting of the American Society for Cancer Research (AACR) to be held at the San Diego Convention Center, California. The five posters showcase recent progress on the company's proprietary BiTE(R) antibody platform and present preclinical data for new BiTE antibodies. BiTE antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy.

A first poster reports that BiTE antibody MT110, which has completed preclinical development for the treatment of patients with EpCAM-expressing adenocarcinoma, can be administered to primates with good bioavailability by subcutaneous delivery (abstract no. 2403).

Jointly with its partner Medimmune, a second poster is presented where BiTE antibody MT103 (MEDI-538), which is in phase 1 and 2 clinical studies, is shown to exhibit anti-tumor activity when subcutaneously delivered to mice (abstract no. 2131).

A third poster describes the conversion of the commercial antibodies trastuzumab and cetuximab (Genentech's and Roche's Herceptin(R) and Imclone Systems Incorporated, Bristol-Myers Squibb's and Merck KGaA's Erbitux(R)) into highly active BiTE antibodies.

A fourth poster presents data on the in vivo and in vitro activity of human BiTE antibodies to CD33 and MCSP for the treatment of acute myelogenous leukaemia and melanoma, respectively (abstract no. 2404).

A fifth poster explores the therapeutic index of an anti-EpCAM BiTE antibody in a mouse model (abstract no. 2130)). It is also shown that under continuous treatment of mice with BiTE antibody, T cells do not lose their cytotoxic and prolific potential but cease to release inflammatory cytokines.

The complete abstracts can be viewed on the web site of AACR (http://www.aacr.org/).

"Our presentations at AACR highlight the significant progress Micromet has made in advancing the BiTE antibody platform," comments Patrick A. Baeuerle, Micromet's chief scientific officer. "We present several new BiTE candidates on a novel human BiTE antibody platform, demonstrate that BiTE antibodies can be delivered subcutaneously, and show that cytotoxic T cell activity is not impaired by long-term BiTE treatment and finally, that we can convert marketed therapeutic antibodies into highly active BiTE antibodies."

[MasaRatti]

Neues Rating für Micromet: Outperform KZ: 3,50 Dollar (s.u.)

Wird schon ...


Micromet Inc.
$ 1.760 +0.19 (+12.10%)




Date Rating Target Price Analyst
03/20/08 -""/ Outperform $ 3.50 RBC Capital Markets
03/10/08 Buy $ 4.00 Punk Ziegel & Co.

[MasaRatti]

25.03.2008 12:07
Micromet Establishes New Scientific Advisory Board for Its BiTE Antibody Technology with Leading Experts in the Fields of Oncology, Immunotherapy and Drug Development

BETHESDA, Md., March 25 /PRNewswire-FirstCall/ -- Micromet, (News) Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today named five leading oncology and immunology researchers to its newly formed panel of BiTE(R) antibody advisors. Richard A. Flavell (Yale University, New Haven, Connecticut), Michael J. Keating (MD Anderson Cancer Center, Houston, Texas), Ronald Levy (Stanford University, Stanford, California), Jeffrey V. Ravetch (Rockefeller University, New York, New York), and Anthony W. Tolcher (South Texas Accelerated Research Therapeutics, San Antonio, Texas) will support the company in the further development of its BiTE antibodies directed against a variety of existing and new anti-cancer targets.

Micromet's BiTE antibodies activate the body's T cells to seek and destroy cancer cells in a tightly controlled manner. This approach is believed to provide the basis for a new generation of drugs that could potentially overcome some of the most significant therapeutic limitations of monoclonal antibodies and other conventional approaches to cancer treatment.

Richard A. Flavell, Ph.D., is a Sterling Professor and Chairman of Immunobiology at Yale School of Medicine, and investigator at the Howard Hughes Medical Institute. He was previously chief scientific officer at Biogen Corporation, and is member of both the Royal Society and National Academy of Sciences. He is a leading expert on activation and differentiation of T cells.

Michael J. Keating, M.B., B.S., is Professor of Medicine and internist for the Department of Hematology at University Texas, MD Anderson Cancer Center. His awards include the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research and the 1996 'Best Doctor of America Leukemia Award.' Dr. Keating is a leading expert on chronic lymphocytic leukemia (CLL), and remarked, "The first efficacy data of BiTE antibody MT103/MEDI-538 in the treatment of late- stage lymphoma patients showing complete or partial responses are highly impressive and give hope that this and other BiTE antibodies will add significantly to the future armentarium of hemato-oncologists."

Ronald Levy, M.D., is the Robert K. Summy and Helen K. Summy Professor of Medicine, Chief of the Division of Oncology, at Stanford University School of Medicine. Highly regarded for his achievements in the therapy of B cell malignancies, Dr. Levy pioneered the clinical development of the anti-CD20 monoclonal antibody rituximab (Rituxan(R)). "MT103, the BiTE molecule the furthest along in clinical development, targets CD19. Treatments directed at CD19 are considered highly promising for the treatment of a broad range of patients with B cell malignancies," commented Dr. Levy.

Jeffrey V. Ravetch, M.D., Ph.D. is a Theresa and Eugene M. Lang Professor at Rockefeller University. He is a member of National Academy of Sciences and received numerous awards for his groundbreaking research in immunology. As a leading expert on antibody-mediated effector mechanisms and immune regulation, Dr. Ravetch comments, "By engaging T cells, BiTE antibodies have the potential to surpass the efficacy of conventional monoclonal antibody therapies."

Anthony W. Tolcher, M.D., FRCP(C), is the Director of START (South Texas Accelerated Research Therapeutics) and Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio. He is a pioneer in the clinical development of novel anti- cancer agents for which he received numerous awards. "Unlike most other antibody-based approaches, BiTE antibodies promise to be effective as monotherapy in patients both with early- and late-stage disease," said Dr. Tolcher.

"Micromet assembled a scientific advisory board of world-renowned oncology and immunology researchers to provide guidance in the further development of our BiTE antibody technology," commented Micromet CEO Christian Itin, Ph.D. "We also look forward to the support and insight they can provide to the academic, industry and investor communities."

[Latinl]

nix neues bei micromet

[MasaRatti]

Micromet Announces Feasibility Results From Subcutaneous Administration Of BiTE Antibodies - Update [MITI]

4/14/2008 3:41:53 PM Monday, Micromet, Inc. (MITI), a biopharmaceutical company, announced results from the primate study demonstrating the bioavailability and predictable serum levels of subcutaneously administered BiTE antibodies, which are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy.

The Bethesda, Maryland-based Micromet said that it conducted a pharmacokinetic study in non-human primates exploring different routes of administration of its BiTE antibody MT110, which is targeting EpCAM and is the most advanced BiTE antibody with potential application for the treatment of solid tumors.

Continuous intravenous administration was compared to subcutaneous administration by daily repeated bolus injection and continuous administration using mini-pumps, which are commercially available and routinely used by patients with diabetes for the delivery of insulin.

Results showed that both subcutaneous regimens resulted in bioavailability of MT110 of 30% - 40% with constant serum trough levels over the six-day treatment period.

In a separate press release, Micromet announced results from the preclinical studies of two new human BiTE antibodies targeting CD33 and MCSP, for the treatment of acute myelogenous leukaemia, or AML, and melanoma.

As per the results, CD33-specific and MCSP-specific BiTE antibodies were equally potent in eliminating tumor cells expressing the respective target antigens in cell-based assays. The CD33-specific BiTE antibody showed in macaques a dose-dependent depletion of CD33-expressing blood cells, whereas the MCSP-specific BiTE antibody did not show any activity, even at very high doses.

Additionally, the company revealed results showing that commercial anti-cancer antibodies trastuzumab, cetuximab and panitumumab can be converted to highly potent BiTE antibodies. The company also noted that the anti-IgE antibody omalizumab for the treatment of asthma could also be successfully converted into a BiTE antibody.

Results showed that the BiTE antibodies are active in eliminating cells expressing the respective target antigens of human and Macaque origin. The four BiTE antibodies with specificity for EGFR, HER2/neu and IgE target antigens, all showed high potency as demonstrated by redirected lysis of respective target cells at half maximal concentrations below 1 ng/ml.

MITI's shares are currently trading at $2.05, up a penny or 0.49% from its previous closing.

[MasaRatti]

So, die news werden immer besser ....


Micromet starts Phase I cancer trial
23rd April 2008
By Staff Writer
Biopharmaceutical firm Micromet has initiated a Phase I clinical trial with its BiTE antibody MT110.


The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers.

Carsten Reinhardt, chief medical officer of Micromet, said: "Having obtained clinical proof of concept for our BiTE antibody technology with MT103 in haematological cancers, we are excited about exploring the potential of MT110 in treating solid tumors. Based on its unique mode of action, MT110 may be suited to treat established tumors as well as disseminated cancer cells, which frequently give rise to metastases."

[Latinl]

Ist was im Busch

[MasaRatti]

Antwort auf Beitrag Nr.: 33.726.564 von MasaRatti am 26.03.08 10:13:37

Micromet, Inc. Reports First Quarter 2008 Financial Results

BETHESDA, Md., May 8 /PRNewswire-FirstCall/ -- Micromet, (News) Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2008.

Summary of Recent Events: -- In April, Micromet announced the initiation of the first phase 1 clinical trial with its BiTE(R) antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung cancer and patients with gastrointestinal cancer. MT110 targets the epithelial cell adhesion molecule (EpCAM or CD326), which is highly expressed on colon, lung, breast, prostate, ovarian, gastric and pancreas cancers and on cancer stem cells of colon, breast, prostate and pancreas cancers. Cancer stem cells are believed to cause metastases and recurrence of these cancers. -- Also in April, Micromet presented five posters at the American Association for Cancer Research (AACR) showing recent progress on the company's proprietary BiTE antibody platform and new BiTE antibodies: -- Commercial anti-cancer antibodies Herceptin(R), Erbitux(R) and Vectibix(R) and asthma antibody Xolair(R) can be converted to highly potent BiTE antibodies. -- Animal data indicate feasibility of subcutaneous administration of BiTE antibodies MT103 and MT110. -- Animal data provided proof of concept for a BiTE antibody targeting CD33 with potential use in the treatment of acute myelogenic leukemia (AML), and a BiTE antibody targeting MCSP with potential use in the treatment of melanoma. -- Animal data suggest a therapeutic window of a BiTE antibody targeting EpCAM in a relevant animal species. -- In March, Micromet established a scientific advisory board and named five leading oncology and immunology researchers to its newly formed panel of BiTE antibody advisors. The scientific advisory board will provide guidance for the further development of our BiTE antibody technology.

Summarizing the events, Christian Itin, Ph.D., President and Chief Executive Officer of Micromet said: "We have made significant progress with the BiTE antibody platform and individual BiTE programs, demonstrating the potential utility of BiTE antibodies for the treatment of cancer and other severe diseases. The successful conversion of commercial antibodies Herceptin(R), Erbitux(R), Vectibix(R) and Xolair(R) to highly potent BiTE antibodies with differentiated product profiles may represent an intriguing option for life cycle management of those therapeutic antibodies."

Financial Results: Quarter Ended March 31, 2008

For the three months ended March 31, 2008, Micromet recognized total revenues of $5.9 million, compared to $2.8 million for the same period in 2007. Total operating expenses were $13.3 million for the three months ended March 31, 2008, compared to $10.3 million for the same period in 2007. For the three months ended March 31, 2008, Micromet reported a net loss of $5.9 million, or $0.14 per basic and diluted share, compared to a net loss of $7.6 million, or $0.24 per basic and diluted share, for the same period in 2007.

Micromet's cash and cash equivalents were $27.7 million as of March 31, 2008. Net cash provided by operating activities was $0.4 million for the quarter ended March 31, 2008, compared to $7.9 million used in operating activities for the same period in 2007. Based on the status of our development programs, we believe this cash balance is sufficient to fund our operations through the second quarter of 2009.

2008 Outlook: -- On June 5, 2008, Micromet will present an update on MT103 clinical results from the ongoing phase 1 clinical trial in non-Hodgkin's Lymphoma at the 10th International Conference on Malignant Lymphoma, Lugano, Switzerland. -- Also in the second quarter, Micromet expects to initiate IND-enabling toxicology studies with MT203 in its collaboration with Nycomed. -- A phase 1 clinical trial evaluating MT103 in patients with chronic lymphocytic leukemia is expected to be started in the United States by Micromet's collaboration partner MedImmune. In addition, at the conference of the American Society of Hematology (ASH) in December 2008, Micromet anticipates providing an update on the clinical data of the ongoing clinical trials with MT103. -- Micromet plans to initiate a phase 2 clinical trial to evaluate adecatumumab (MT201) in an adjuvant setting. In addition, first data from the ongoing phase 1b combination trial of adecatumumab with docetaxel are expected to be presented in the second half of 2008.

Conference Call and Audio Webcast Today, May 8, 2008, at 9:00 am Eastern Time

[MasaRatti]

Antwort auf Beitrag Nr.: 34.055.636 von MasaRatti am 08.05.08 14:19:08

22.05.2008 20:46
Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas

BETHESDA, Md., May 22 /PRNewswire-FirstCall/ -- Micromet, (News) Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that the company will provide an update on the phase 1 clinical trial underway for its BiTE(R) antibody MT103/MEDI-538 at the 10th International Conference on Malignant Lymphomas, taking place June 4-7 in Lugano, Switzerland.

The presentation, entitled, "Anti-CD19 BiTE Antibody MT103 (MEDI-538) Induces Durable Objective Responses in Patients with Relapsed Non-Hodgkin's Lymphoma (NHL). Update from Ongoing Phase I Study MT103-104" will take place during Poster Session I from 8:00am to 6:00pm on June 5th, 2008 in the Marquee Parco Ciani. Meeting abstracts will first be available during the week of the conference.

The 10th International Conference on Malignant Lymphoma gathers 3,000 leading physicians from all over the world: hematologists, clinical oncologists, pathologists and leading researchers involved in the study and treatment of lymphoid neoplasms, including multiple myeloma and CLL.

[Latinl]

geht hier was

[MasaRatti]

Antwort auf Beitrag Nr.: 34.217.629 von Latinl am 02.06.08 14:02:02

05.06.2008 13:33
Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma

BETHESDA, Md., June 5 /PRNewswire-FirstCall/ -- Micromet, (News) Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented an update of an ongoing phase 1 clinical trial for its BiTE(R) antibody blinatumomab (MT103/MEDI-538) at the 10th International Conference on Malignant Lymphomas (ICML) in Lugano, Switzerland. The new data(1) with the CD19-specific BiTE antibody show that all seven patients in the highest dose cohort tested so far (0.06 mg/m2/day) achieved complete or partial responses.

In the study, relapsed, incurable non-Hodgkin's lymphoma (NHL) patients who previously failed a median of three (and up to 12) conventional therapies were treated with increasing doses of blinatumomab (MT103/MEDI-538) for four to eight weeks. Dose-dependent clinical activity was observed. At the recently completed cohort of 0.06 mg/m2 per day, seven out of seven patients showed either complete or partial responses. Remissions in this and the previous dose cohort continue in all patients, with the longest remission ongoing for more than one year. Most frequent side effects observed so far were lymphopenia, pyrexia, and leukopenia. Less common adverse events included transient neutropenia and thrombocytopenia, transient increase of liver enzymes, and central nervous system events, all of which were fully reversible.

"The high response rate and apparently durable remissions in this heavily pre-treated patient population support blinatumomab as a single agent therapy with the potential for accelerated development," said Micromet's Senior Vice President and Chief Medical Officer, Dr. Carsten Reinhardt.

"ICML brings together thousands of the world's leading specialists and researchers to present the latest advancements and insights in the treatment of malignant lymphomas," said Dr. Michael J. Keating, University of Texas MD Anderson Cancer Center professor of medicine, internist for the department of hematology, ICML advisory board member and a member of Micromet's BiTE Antibody Scientific Advisory Board. "The data on blinatumomab show that it holds the promise to become an effective therapy for a number of lymphomas and leukemias."

(1) Bargou R. et al. (2008). Anti-CD19 BiTE Antibody MT103 (MEDI-538) Induces Durable Objective Responses in Patients with Relapsed Non-Hodgkin's Lymphoma (NHL). Update from Ongoing Phase I Study MT103-104. ICML, Lugano, 2008. About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells. Through the process of killing cancer cells, T cells proliferate, which leads to an increased number of T cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE antibody platform. The most advanced BiTE antibody is MT103 (MEDI-538), targeting CD19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting EpCAM (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with lung or gastrointestinal cancers. Two additional BiTE antibodies, targeting CD33 and MCSP, are in preclinical development.

About Micromet, Inc.

Micromet, Inc. (http://www.micromet-inc.com/) is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

[MasaRatti]

Micromet und MedImmune beginnen mit Phase II-Studie des BiTE-Antikörpers Blinatumomab (MT103/MEDI-538)
Behandlung von Patienten mit akuter lymphoblastischer Leukämie
16.06.2008 - Micromet, Inc. hat mitgeteilt, dass im Rahmen der deutschen, multizentrischen Phase II Studie des BiTE®-Antikörpers Blinatumomab (MT103/MEDI-538) in der Indikation akute lymphoblastische Leukämie (ALL) mit der Behandlung des ersten Patienten begonnen wurde. Blinatumomab ist ein Antikörper, der die für B-Zellen charakteristische CD19-Zielstruktur erkennt und das zytotoxische Potenzial von T-Zellen gegen diese Zielstruktur aktiviert. Das klinische Entwicklungsprogramm von Blinatumomab wurde um die Indikation ALL erweitert, nachdem Daten einer noch laufenden Phase I Studie zeigten, dass dieser BiTE®-Antikörper als Einzelmedikament bei Patienten mit Non-Hodgkins-Lymphom (NHL) im Spätstadium hohe Wirksamkeit zeigt.
"Diese Phase II-Studie in ALL ist ein wichtiger Schritt, um die Wirksamkeit von Blinatumomab bei aggressiven malignen Formen von B-Zell-Tumoren zu untersuchen. Sie wird uns helfen, das volle therapeutische Potenzial dieses hoch spezifischen und potenten BiTE®-Antikörpers bei B-Zell-Tumoren im Menschen zu bestimmen", sagte Dr. Carsten Reinhardt, Senior Vice President und Chief Medical Officer von Micromet.

ALL ist eine sehr aggressive Form von B-Zell-Leukämie. ALL-Patienten werden zunächst nach einem komplizierten Schema mit hoch toxischen Chemotherapeutika behandelt, wonach bei geeigneten Patienten u. U. eine Transplantation mit Knochenmarksstammzellen folgt. Patienten, die nach einer Chemotherapie eine geringe Zahl von residualen Tumorzellen in ihrem Knochenmark aufweisen (auch als minimale Resterkrankung bzw. "minimal residual disease" / MRD bezeichnet), tragen ein sehr hohes Risiko für einen frühen Rückfall. Die jetzt begonnene Phase II-Studie rekrutiert Patienten mit MRD und wird untersuchen, ob Blinatumomab residuale Tumorzellen eliminieren und die Zeit bis zu einem Rückfall verlängern kann. Dazu wurde ein systematischer Screening-Prozess bei der deutsche ALL Studiengruppe (GMALL) auf MRD-positive ALL-Patienten etabliert. Patienten, die im Rahmen dieses Screenings als MRD-positiv identifiziert werden, werden auf die klinische Studie hingewiesen.

[schnappi]

Woche für Woche immer ein kleines Stückchen weiter die Umsätze sind auch gut man darf gespannt sein wie es weitergeht

[Latinl]

gibts was neues

[schnappi]

Antwort auf Beitrag Nr.: 34.462.187 von Latinl am 08.07.08 16:59:53

ne aber seid März kennt die Aktie nur eine Richtung hab nun über 100% Plus vielleicht gibts hier die nächste Übernahme

[MasaRatti]

Was glaubt Ihr denn, warum ich schon lange an die Aktie
glaube, die Pipeline ist voll und verspricht einiges...

Übernahme... wer weiß ...

[MasaRatti]

Micromet Climbs Over Recent Range, Hits Highest Level In Over A Year


(RTTNews) - Micromet, Inc. (MITI) has been climbing in stages since Tuesday's open. The stock is currently at $3.01 up $0.23 from Monday's close.

The advance has lifted the stock over a recent trading range and to its highest level since late May 2007.

[Latinl]

Antwort auf Beitrag Nr.: 34.472.718 von MasaRatti am 09.07.08 18:03:37

habe auch schon überlegt zu schmeissen.. aber wenn eien aktie in solchen zeiten läuft dann soll man sie laufen lassen... übernahme wäre sowas von

[MasaRatti]

Party !

Umsätze ziehen an, was kommt jetzt ... ?

[schnappi]

Antwort auf Beitrag Nr.: 34.530.278 von MasaRatti am 17.07.08 16:07:28

einfach nur Geil die letzten Wochen

[Latinl]

Antwort auf Beitrag Nr.: 34.530.278 von MasaRatti am 17.07.08 16:07:28

gibt es anzeichen einer übernahme oder stehen klinische daten an

[schnappi]

Antwort auf Beitrag Nr.: 34.534.570 von Latinl am 18.07.08 08:30:59

es geht sei März nur in eine Richtung sollte sich jemand einkaufen müßte bald mal ein Info vom Käufer wegen der Meldegrenze kommen denk ich.

[schnappi]

Hallo keiner da Micromet steigt und steigt so langsam wirds ja unheimlich wirklich schaaaaaaaaade das sich hier so wenige dafür interessieren.

[lordknut]

Antwort auf Beitrag Nr.: 34.589.155 von schnappi am 25.07.08 18:38:11

Erzähl halt mal was darüber so wie eck. Oder schick mir ne Boardmail, warum Du so auf Micromet abfährst, welche Chancen und Werte Du siehst.

[schnappi]

Antwort auf Beitrag Nr.: 34.593.369 von lordknut am 27.07.08 10:58:14

Hallo Lordknut also was schreiben wie Eck ne,
ich will niemand versuchen zu überzeugen Geld in eine Aktie zu investieren das muß jeder selbst für sich tun lesen kann jeder auf der Hompage oder Google und dann mach dir ein Bild.

[MasaRatti]

Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results


BETHESDA, Md., July 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, August 7, 2008, at 9:00 am Eastern Time (3:00 pm Central European Time) to discuss its second quarter 2008 financial results. Micromet anticipates releasing its financial results at 7:00 am Eastern Time (1:00 pm Central European Time) on Thursday, August 7, 2008.

To participate in this conference call, dial 866-356-4279 (U.S.) or 617-597-5394 (international), passcode: 19440822. The audio webcast can be accessed at: www.micromet-inc.com in the investor relations section of the website.

A replay of the call will be available from 11:00 am Eastern Time on August 7, 2008 (5:00 pm Central European Time) through Thursday, August 14, 2008. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 13099911.

About Micromet, Inc. (www.micromet-inc.com)

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody blinatumomab, also known as MT103, is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's own immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293, which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. You are urged to consider statements that include the words "ongoing," "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "suggests," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in our periodic reports and other filings with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Micromet, Inc.

[Latinl]

heut gings aber gut runter gabs was es ist aber ganz schön hohes gehandeltes volumen...

[schnappi]

Antwort auf Beitrag Nr.: 34.619.494 von Latinl am 31.07.08 00:13:31

irgendwann müßen ja mal Gewinne realisiert werden nach dem steilen Anstieg auf die Zahlen am 7.8. sollte man schauen evt. Update dann auch zur Pipe

[MasaRatti]

EquityStory AG
DGAP-News: 4SC AG successfully completes transaction of Nycomed oncology projects
Donnerstag 31. Juli 2008, 09:11 Uhr

Aktienkurse
EquityStory AG
E1S.DE
20.01
-2.25%
4SC AG / Strategic Company Decision

31.07.2008

Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG (Xetra: 549416 - Nachrichten) . The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Planegg-Martinsried, 31 July 2008 - Martinsried-based drug discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC) today announced the finalisation of the acquisition of eight projects from the
Anzeige
oncology division of pharmaceuticals firm Nycomed. With the receipt of the payment of 14 million EURO in cash Nycomed transferred full ownership of the eight projects to 4SC, while Nycomed retains rights to research, develop and commercialise outside the scope of the patents sold.

With this transaction 4SC AG strengthens its development pipeline by adding small molecules, which have promising market potentials for a number of oncological indications. 4SC AG took this transaction as an occasion to redesignate its existing and newly acquired developmental substances in a move designed to enhance transparency. Substance SC12267 (for the treatment of autoimmune diseases including rheumatoid arthritis) is thus now designated 4SC-101; SC71492 (for autoimmune diseases including rheumatoid arthritis and inflammatory bowel disease) is now 4SC-102; SC68896 (oncology) is now 4SC-206; SC71710 (oncology, e.g. acute myeloid leukaemia) is now 4SC-203; and SC75741 (for the treatment of viral infections) is now designated 4SC-301.

4SC-201, a drug candidate from the Nycomed pipeline, is an orally-administered inhibitor of enzymes with histone-deacetylase (HDAC) activity in clinical phase I development. This substance has already shown clear anti-cancer activity on solid and haematological tumours in numerous animal trials. 4SC-201 differs from other HDAC inhibitors in its superior oral bioavailability and is thus regarded to display a larger therapeutic window. The substance is currently being tested in clinical phase I trials to assess its safety and tolerability profile in cancer patients. Initial results of the study are expected to be released in the fourth quarter of this year. Another oral HDAC inhibitor (4SC-202) is currently completing all preclinical development steps required to file for approval to conduct clinical studies on cancer patients. 4SC-202, in contrast to 4SC-201, is a selective inhibitor of class I HDAC enzymes and comprises a specific cell division inhibiting effect (anti-mitotic). These specific properties of 4SC-202 afford clinical development for the treatment of cancers, particularly manifestations with rapidly proliferating tumour cells.

The substance 4SC-205, an oral EG5 kinesin inhibitor, is likewise currently in final preclinical studies. The anti-mitotic mechanism of 4SC-205 is already clinically validated via vinca alkaloids and taxanes, and combined with its oral availability, offers major potential for broad usage in the treatment of solid and haematological tumours.

In addition to two other HDAC inhibitor projects, the portfolio acquired includes three more innovative research projects. 'The new PLK1, TLR7 and Cell Cycle Blocker projects, which have been already successfully tested in animal models, are a terrific complement to our research portfolio,' said Dr. Daniel Vitt, CSO of 4SC AG, 'We are now able to select next-generation drug candidates from an even richer project pool, affording optimal potential for our developmental pipeline in terms of sustained appreciation in value.'

The new development projects, including the three oncological candidates presented above, are already being integrated into the existing 4SC development pipeline. The capital raised in the share offering of 14 July 2008 has ensured the company's ability to pursue further development of already existing and new projects without delay.

'Having strengthened our innovative development pipeline in the field of oncological and autoimmune indications, we are now in an excellent position to substantially increase our enterprise value through successful clinical development and licensing partnerships,' commented Dr. Ulrich Dauer, CEO of 4SC AG.

Dr. Bernd Hentsch, CDO of 4SC AG, added: 'Because of our experienced development personnel and our distinguished clinical network, we firmly believe that everything is in place to allow us to rapidly move both our existing and newly acquired projects into the next value adding clinical phases.'

Nycomed arbeitet mit Micromet zusammen am MT203-Projekt !!!

[Latinl]

Hallo

langsam geht das volumen ganz schön nach oben, wie realisitsch ist eine Übernahme Könnte micromet für UN interssant sein im mom tut sich viel im Biosector

[Latinl]

Bayer erwirbt Onkologie-Programm von Nycomed
07.08.2008 | 10:56 Uhr | Berlin (BoerseGo.de)

Die Bayer Schering Pharma AG hat ein präklinisches Onkologie-Programms des Pharmaunternehmens Nycomed mit Hauptsitz in der Schweiz übrnommen und damit ihre Forschungspipeline gestärkt. Die Vereinbarung umfasse zwei potenzielle Entwicklungskandidaten und weitere Wirkstoff-Verbindungen, teilte Bayer am Donnerstag mit. Bayer Schering Pharma erhält dem Vernehmen nach sämtliche Entwicklungs- und Vermarktungsrechte aus diesem Programm.

Bayer leistet für die Übernahme eine Vorabzahlung. Weitere Beträge sind für das Erreichen bestimmter präklinischer und regulatorischer Meilensteine vereinbart. Das Gesamtvolumen der Transaktion kann bis zu 52 Millionen Euro erreichen.


© BörseGo AG 2008, Autor: Gansneder Thomas, Redakteur, © GodmodeTrader - http://www.godmode-

[MasaRatti]

Antwort auf Beitrag Nr.: 34.667.840 von Latinl am 07.08.08 11:28:14

Micromet, Inc. Reports Second Quarter 2008 Financial Results

BETHESDA, Md., Aug. 7 /PRNewswire-FirstCall/ -- Micromet, (News) Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the second quarter and six months ended June 30, 2008.

Summary of Recent Events:

In June, Micromet and MedImmune presented a clinical update for the BiTE(R) antibody blinatumomab (MT103/MEDI-538) at the International Conference on Malignant Lymphoma in Lugano, Switzerland. All seven patients with relapsed non-Hodgkin's lymphoma treated with blinatumomab at the highest dose level presented at the conference responded to the treatment with partial or complete responses. Responses also appeared to be durable. The most frequent side effects observed so far were lymphopenia, pyrexia and leukopenia. Less common adverse events included transient neutropenia and thrombocytopenia, transient increase of liver enzymes and central nervous system events, all of which were fully reversible. In addition, Micromet and MedImmune commenced treatment of patients with acute lymphoblastic leukemia in a phase 2 clinical trial of blinatumomab.

Also in June, Micromet received a milestone payment of $775,000 from Nycomed in connection with the initiation of formal preclinical safety studies for antibody MT203, which has potential applications in the treatment of inflammatory and autoimmune diseases.

In April, Micromet announced the initiation of the first phase 1 clinical trial with its BiTE antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung cancer and patients with gastrointestinal cancer. MT110 targets the epithelial cell adhesion molecule (EpCAM or CD326), which is highly expressed on colon, lung, breast, prostate, ovarian, gastric and pancreatic cancer cells and on cancer stem cells of colon, breast, prostate and pancreas cancers. Cancer stem cells are believed to cause metastases and recurrence of these cancers.

Also in April, Micromet presented five posters at the American Association for Cancer Research (AACR) showing recent progress on the company's proprietary BiTE antibody platform and new BiTE antibodies:

-- Anti-cancer antibodies in marketed products Herceptin(R), Erbitux(R) and Vectibix(R) and the anti-asthma antibody in Xolair(R) were successfully converted to highly potent BiTE antibodies.

-- Animal data from two studies indicated feasibility of subcutaneous administration of BiTE antibodies MT103 and MT110.

-- Animal data provided proof of concept for a BiTE antibody targeting CD33 with potential use in the treatment of acute myelogenic leukemia (AML), and a BiTE antibody targeting MCSP with potential use in the treatment of melanoma.

-- Animal data suggested a therapeutic window for a BiTE antibody targeting EpCAM in a relevant animal species.

Summarizing the events, Christian Itin, Ph.D., President and Chief Executive Officer of Micromet said: "We have made significant progress with the BiTE antibody platform introducing new BiTE antibodies that target a wide range of tumor indications and converting currently marketed therapeutic antibodies into potent BiTE antibodies with much increased activity against tumor cells. We believe that the progress on our proprietary BiTE antibody platform will allow us to expand our own product pipeline, while at the same time engaging in new collaborations on selected BiTE antibody programs."

Financial Results: Quarter Ended June 30, 2008

For the three months ended June 30, 2008, Micromet recognized total revenues of $8.5 million, compared to $3.1 million for the same period in 2007. Total operating expenses were $14.4 million for the three months ended June 30, 2008, compared to $11.1 million for the same period in 2007. For the three months ended June 30, 2008, Micromet reported a net loss of $8.6 million, or $0.21 per basic and diluted common share, compared to a net loss of $6.5 million, or $0.20 per basic and diluted common share, for the same period in 2007.

Six Months Ended June 30, 2008

For the six months ended June 30, 2008, Micromet recognized total revenues of $14.4 million, compared to $5.8 million for the same period in 2007. Total operating expenses were $27.6 million for the six months ended June 30, 2008, compared to $21.4 million for the same period in 2007. For the six months ended June 30, 2008, Micromet reported a net loss of $14.5 million, or $0.36 per basic and diluted common share, compared to a net loss of $14.1 million, or $0.44 per basic and diluted common share, for the same period in 2007.

Micromet's cash and cash equivalents were $22.4 million as of June 30, 2008. Net cash used in operating activities was $4.7 million for the six months ended June 30, 2008 compared to $7.9 million used in operating activities for the same period in 2007.

2008 Outlook:

-- At the annual meeting of the European Society for Molecular Oncology (ESMO) in September in Stockholm, Sweden, Micromet will present data from the ongoing phase 1b clinical trial of patients with metastatic breast cancer treated with adecatumumab (MT201) in combination with docetaxel. Further, Micromet plans to initiate a phase 2 clinical trial later in 2008 to evaluate adecatumumab in an adjuvant setting.

-- At the annual meeting of the American Society for Hematology (ASH) in December, Micromet expects to provide a further update on the currently ongoing phase 1 clinical trial of blinatumomab in patients with non-Hodgkins lymphoma.

-- Also at ASH, Micromet expects to present initial results on the currently ongoing phase 2 clinical trial of blinatumomab in patients with acute lymphoblastic leukemia (ALL).

-- Finally, Micromet expects that its collaboration partner MedImmune will begin a phase 1 clinical trial in the United States evaluating blinatumomab in patients with chronic lymphocytic leukemia by the end of 2008.

Conference Call and Audio Webcast Today, August 7, 2008, at 9:00 am Eastern Time

[MasaRatti]

Micromet "buy," target price raised
08/08/08 - Roth Capital

NEW YORK, August 8 (newratings.com) - Analysts at Roth Capital reiterate their "buy" rating on Micromet Inc (MITI). The target price has been raised from $3 to $5.

[Latinl]

komisch das immer wieder zu 3 € gekauft wird...

habt ihr eine erklärung

[welke91]

Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab

"These results represent significant progress of a T cell engaging antibody for treatment of lymphoma patients as single agent therapy.

Die hohe Ansprechrate und die offensichtlich dauerhaften Remissionen in dieser stark vorbehandelten Patientenpopulation stützen die Entwicklung von Blinatumomab als Einzelmedikament und lassen Potenzial für eine beschleunigte Entwicklung erkennen", erklärte Dr. Carsten Reinhardt, Senior Vice President und Chief Medical Officer von Micromet.

Tja der Minger Gert Riethmüller hat es wohl geschafft!

Die ergebnisse sind sehr vielversprechend:

Wenn man bedenkt, wie die Patienten davor behandelt wurden und welche Lebenserwartungen sie hatten.
Jetzt haben sie u.U. über ein Jahr lang Remissionen und weitere viel versprechende Ergebnisse.

Das Thema mit dem antikörper + der T Killerzelle ist schon fast zu gut um wahr zu sein.

hätte ich nicht elan PLC wäre mein einstieg klar!

viel glück!!!

[welke91]

a na Riethmüller sollte es so einfach sein???

Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non–Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell–engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.

heißt praktisch mit so einer kleinen minidosis können wir den krebs eliminieren!

ne oder?
das ding muss explodieren heute! zu schade dos so viele insti drin sind!

viel glück

[Latinl]

um wieviel uhr kam die meldung

[welke91]

Antwort auf Beitrag Nr.: 34.732.841 von Latinl am 15.08.08 08:33:01

14:00 Uhr MEZ gestern!

[Latinl]

dann ist die nachricht schon in den us kursen eingepreist

[welke91]

Antwort auf Beitrag Nr.: 34.732.900 von Latinl am 15.08.08 08:44:49

jo hier aber nicht!

und ausserdem -- -- auert das bei den amis immer etwas länger um so etwas zu realisieren!

[MasaRatti]

Der angesprochene Artikel !

DJ HUGIN NEWS/Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab

DJ HUGIN NEWS/Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
=---------------------------------------------------------------------
=-------------

First T cell engaging antibody (BiTE) showing clinical benefit in
cancer patients;
Blinatumomab enables patients own T cells to recognize and attack
cancer cells

BETHESDA, MD - August 14, 2008 -- Micromet, Inc. (Nasdaq: MITI), a
biopharmaceutical company developing novel, proprietary antibodies
for the treatment of cancer, inflammation and autoimmune diseases,
today announced publication of a Phase 1 clinical study[1] on its
BiTE® antibody blinatumomab (MT103/MEDI-538) in this week's issue of
Science. The article is available at www.sciencemag.org. Blinatumomab
is being co-developed with MedImmune.

Blinatumomab is a novel antibody therapy that activates a patient's
T-cells to seek out and destroy cancer cells. The phase 1 study
demonstrated tumor regression, and in some cases, complete remission,
in non-Hodgkin's lymphoma patients who relapsed after previous
treatments and were considered to have incurable disease. Most of
the remissions are reported to continue, with the longest remission
ongoing for more than one year. Results from this ongoing Phase 1
clinical trial with the CD19-specific BiTE antibody blinatumomab show
that all seven patients treated to date at 0.06 mg/m2 per day
achieved complete or partial responses. The safety profile observed
in this study supports continued blinatumomab development.

"These results represent significant progress of a T cell engaging
antibody for treatment of lymphoma patients as single agent therapy.
We observed tumor regression in patients at serum levels of
blinatumomab, which are approximately five orders of magnitude lower
than serum levels needed by conventional monoclonal antibodies for
achieving a tumor regression in this disease. This may relate to the
high anti-tumor activity of cytotoxic T cells recruited by
blinatumomab," commented Micromet Senior Vice President and Chief
Scientific Officer Patrick Baeuerle.

"This first observation of durable objective responses in relapsed,
incurable patients indicates the potential blinatumomab and BiTE
antibodies in general may have in fighting cancer," added Micromet
Senior Vice President and Chief Medical Officer Carsten Reinhardt,
M.D.

(more)

Typically antibodies cannot engage T cells because T cells lack the
appropriate receptors for binding antibodies. Previous attempts have
shown the potential of T cells to treat cancer, but the therapeutic
approaches tested to date have been hampered by cancer cells' ability
to escape recognition by T cells. The use of antibodies that are
specifically designed to engage T cells for attacking cancer cells
may provide a more effective anti-tumor approach than conventional
monoclonal antibodies, which require much higher doses and are
typically combined with chemotherapies.

Micromet has additional clinical trials with BiTE antibodies
underway, including a phase 2 clinical trial to evaluate blinatumomab
for the treatment of patients with acute lymphoblastic leukemia
(ALL), and a phase 1 trial investigating MT110, a BiTE antibody
targeting EpCAM, in patients with lung or gastrointestinal cancers.

Micromet will host a webcast and a conference call on Monday, August
18 at 10:00 a.m. Eastern Time , (4:00 p.m. Central European Time), to
discuss these results. The webcast can be accessed at:
www.micromet-inc.com/sciencepub. To participate in the conference
call, dial 866-202-4367 (U.S.) or 617-213-8845 (international),
passcode: 31176615.

[1]Bargou R et al. (2008) Tumor regression in cancer patients by very
low doses of a T cell-engaging antibody. Science 321: 974-977 (2008)

[MasaRatti]

Was Umsätze ! 80.000 Stück auf einmal, einfach mal so!
- so genehmige mir mal einen
ordentlichen Schluck leckeren Shiraz !

[Latinl]

was kann den jetzt noch kommen

[Latinl]

ist mir alles zu heiß.. meine 900 stück raus...

lieber paar % weniger als ärgern wenn es runterrauscht...

trotzdem ein mieses gefühl was verpaßt zu haben

[Latinl]

also es ist nicht normal was in FFM abgeht... da wissen einige mehr, evtl welche aus München

naja allen die noch drin sind , viel erfolg

[schnappi]

Antwort auf Beitrag Nr.: 34.746.500 von Latinl am 18.08.08 09:30:20

heut mittag gibts doch noch ein Webcast 16 Uhr

[Latinl]

was soll da kommen

[schnappi]

Antwort auf Beitrag Nr.: 34.748.452 von Latinl am 18.08.08 13:04:53

Steht doch in der letzten AD- HOC

[schnappi]

im Amiland geht die Party weiter mal sehn wie lange

[MasaRatti]

Moin zusammen, toller Anstieg und ja, habe mir
auch mal einen Teilverkauf gegönnt

Nasdaq:

Elsewhere, Ladenburg Thalmann downgraded Micromet(MITI - Cramer's Take - Stockpickr) to neutral from buy. Shares were up 9.4% for the day, having risen 23% in the last week, arriving at $5.97 late this Monday.


Bleibe an der "Story" dran ...

[Latinl]

ich warte bis es runter geht, aber micro ist konstant nur dieses hin und her ging mir auf den

[MasaRatti]

Micromet Hits 2-Year High On Increased Volume


(RTTNews) - Micromet, Inc. (MITI) is picking up volume and climbing sharply. Currently, the stock is at its highest level in over two years, trading at $6.66 up $0.31 from Wednesday's close.

[Latinl]

war ja klar immer dann wenn ich raus bin, naja 150 % war auch net schlecht

[MasaRatti]

Antwort auf Beitrag Nr.: 34.805.119 von Latinl am 22.08.08 07:51:17

Micromet: Another Seal of Approval
by: Ohad Hammer posted on: August 21, 2008 | about stocks: MITI

*
Font Size:
*
Print
* Email

There is always a debate regarding market efficiency and to what extent stock prices represent the available information about a company. Micromet’s (MITI) surge last week shows that in some cases, the market is far from being efficient. The spike of more than 35% in the last two trading sessions is attributed to the publication of a short article in Science Magazine, one of the world’s most prestigious scientific journals. The article contained clinical data from an ongoing phase I trial of Micromet’s lead candidate, MT103 (partnered with Medimmune). The data was spectacular, showing a strong, dose dependent response in concert with a good safety profile, exactly the kind of data that can put a small biotech in the spotlight. Ironically, the article contained data which has already been presented more than two months ago at the ICML in Switzerland.

Regardless of whether market reaction was justified, publishing clinical data at such an early stage in Science should be viewed as an indication for the scientific community’s embrace of Micromet and its BiTE platform. The BiTE platform relies on monoclonal antibodies for stimulating the patient’s immune system to attack cancer cells that have managed to evade or suppress the body’s immune response. Although most attention is given to the first product from the platform, MT103, it can generate an unlimited number of agents against a variety of cancers, making it a potential revolution in the way cancer is treated.

It still remains to be seen whether additional BiTE agents will be as promising as MT103, but examination of the clinical data leads to the conclusion that Micromet now has one of the most exciting technologies in the biotech industry. The BiTE platform represents a truly novel class of anti-cancer agents and is not like anything else out there. It facilitates the construction of bi-specific antibodies that simultaneously bind cancer cells and the body’s most potent immune cells (T cells), leading to a strong, long lasting and escalating immune response against tumors. In the past decades, there have been numerous attempts to create effective bi-specific antibodies, all of which failed. One exception may be a Biotest’s HRS3/A9, which showed promising efficacy but could not be produced in sufficient quantities for further clinical evaluations. The area of bi-specific antibodies has been long abandoned by the antibody industry and MT103 can be seen as the long anticipated breakthrough that overcame most of the hurdles. It seems that Micromet found the ideal formula for generating a potent yet safe anti-tumor response with bi-specific antibodies.

BiTE antibodies are small enough to get T- cells within sufficient proximity to cancer cells and unleash their lethal mechanisms in a targeted and specific manner. Their small size may also help them penetrate areas inaccessible for other agents. In addition, because the actual attack is done by the patient’s most potent immune cells, which can proliferate and multiply upon activation, it takes a tiny amount of BiTE antibodies for generating a systemic response. This may explain the incredibly low doses of MT103 that led to clinical responses in the phase I clinical trial. When compared to other antibodies and chemotherapeutic agents on a normalized basis, MT103 is certainly one of the most potent compounds to have ever been tested in humans, if not the most potent one.

Promising Data

The Science article reported data for thirty eight NHL (non-Hodgkin lymphoma) patients, who received various doses of MT103. The trial focused on two subtypes of NHL, follicular lymphoma [FL] and Mantle cell lymphoma [MCL], which together represent around 35% of the NHL market. There were 11 cases of objective response (four complete and seven partial), which appeared primarily in the cohorts who received the higher doses. Strikingly, all seven patients who received the highest dose responded to the treatment, two of whom had a complete response. As of the latest follow up (June 1st) all these responses were ongoing for a period of 1-8.5 months, on top of one response in a patient who had received a lower dose that was ongoing for more than a year. The issue of response duration is cardinal because many treatments, especially Rituxan containing regimens manage to achieve long lasting responses of more than a year in similar patient populations, so in order to be regarded as a viable alternative, MT103 must keep patients in remission for substantial periods of time.

It is important to understand that the significance of the data is not necessarily in the commercial opportunity of MT103 for these patient populations, which fortunately have a slower disease onset and enjoy an abundance of treatment options. The challenging competitive landscape leads to high entry barriers for new therapies for FL and MCL patients. Furthermore, there are additional antibodies in development that bind the same target MT103 binds, CD19. The most advanced of these agents is Sanofi-Aventis’ (SNY) SAR3419, based on Immunogen’s (IMGN) technology, which is currently in two phase I trials. Additional CD19 targeting agents are being developed preclinically in the hands of Genentech (DNA), Seattle Genetics (SGEN), Medarex (MEDX) and Xencor. MT103’s results are actually the first validation of CD19 as a target and are therefore likely to motivate these companies to advance their candidates into the clinic as soon as possible.

Hopefully, MT103 will find its way to the NHL market as the next line of defense for certain subsets of patients, but the real potential lies somewhere else. Because the BiTE platform is a universal and modular platform, it could be utilized to generate a plethora of candidates for indications with limited treatment options, primarily solid tumors. Solid tumors, such as lung and breast cancers are less sensitive to available treatments due to poor accessibility and are consequently responsible for over 90% of cancer related deaths worldwide. BiTE antibodies may have a competitive edge over other therapies due to their small size and certain properties of the immune cells they activate. They may also be advantageous for targets that cannot be hit by other antibody-based platforms, because they do not require internalization in order to be effective. For more on the mechanism by which BiTE antibodies operate and why they are considered so promising, click here. The first BiTE antibody for solid tumors, MT110, recently entered the clinic, and is expected to generate initial data next year.

Substantial Risks

Investors should be aware of the long list of risks associated with MT103 in particular and the BiTE platform in general. With respect to MT103, the data is preliminary and based on a limited number of patients, so it may turn out to be less effective in larger trials. In addition, the NHL market is full of promising compounds, some of which demonstrated comparable or even better efficacy in similar patient populations. A closer look at patient demographics reveals that patients in the highest cohort were younger and less heavily pretreated compared to patients in lower doses, which might explain the 100% response rate.

Despite the explosive potential of the BiTE platform, there is the obvious unpredictability associated with early stage drug development. There is no guarantee that additional BiTE antibodies will replicate MT103’s success, and even if some do, it might be after multiple failures, like is often the case with novel disrupting technologies.

Safety is also a concern, especially in therapies that manipulate the immune system, and until a compound is evaluated in large enough populations the fear of unexpected adverse events is always there. This explains Micromet’s decision not to escalate the dose in the MT103’s trial further, despite the fact that the maximum tolerated dose [MTD] was not reached. Because MT103 is the first product of the BiTE platform, safety issues can lead to delays or even jeopardize the entire platform. Therefore, when a dose escalation study reaches a sufficiently active dose, there is much more to lose from increased toxicity than to gain from better efficacy. In the case of solid tumors, however, it will probably take dose levels near or at the MTD in order to achieve the needed efficacy, so the risk there is obviously higher.

Three Main Events

For the remainder of the year, there will be three important events for Micromet.

Most importantly, the company will publish additional data in December at the Annual Society of Hematology [ASH] annual meeting. The data set will include an update from the ongoing trial in NHL patients as well as preliminary results from a phase II study that evaluates MT103 in Acute lymphoblastic leukemia [ALL]. Choosing ALL as a second indication makes sense because it is estimated that over 90% of ALL cases express CD19.

The data from the NHL trial is very important not only because it will include additional patients and an update on the durability of the responses, but also because data from Sanofi-Aventis’ SAR3419 will be presented. This will give investors the opportunity to assess the BiTE platform relatively to competing platforms.

The ALL study has important implications as well, because it represents an attractive route for commercialization for MT103. ALL is an aggressive blood cancer with a dismal prognosis and very few treatment options, in contrast to the NHL subtypes in the phase I trial. If MT103 demonstrates sufficient activity against ALL, this indication represents a faster route to market, with very little competition upon approval. In addition, the ALL study is very significant for the future development of MT103, because it represents a different treatment modality. The study does not evaluate MT103 as a primary treatment, but as consolidation in patients who receive chemotherapy but still have leukemia remnants in their bone marrow. The company views this study as a probe for the utility of MT103 as a secondary treatment as well as for the potential of the compound for other aggressive blood cancers.

The second event, which is supposed to take place before ASH, is rumored to be a partnership deal for one of Micromet’s pre-clinical programs or a technology licensing deal with a major pharmaceutical company. Such a development will serve as another validation of Micromet’s potential, provide highly needed cash infusion and decrease the overall risk.

The third event will be some sort of a capital raising deal, which will probably happen sooner rather than later given the recent stock movement. This may put some pressure on the stock in the coming months.

I have been getting a lot of questions from investors with respect to Micromet’s target price. My answer is that the huge potential of the company warrants holding it as long as the BiTE platform continues to produce impressive clinical results. Nevertheless, with a market cap of $220M and a year to date return of over 170%, Micromet is not a cheap stock. The recent jump following the Science article, coupled with the anticipated round of financing might imply that now is a good time to take some gains off the table with the purpose of waiting for a lower entry point down the road, prior to the ASH annual meeting.

Disclosure: Author is Long MITI, IMGN, SGEN

[andyinweinheim]

NASDAQ zieht an

http://www.nasdaq.com/aspx/dynamic_charting.aspx?symbol=MITI…

gibts einen Grund ?

[MasaRatti]

Financial Results: Quarter Ended September 30, 2008

For the three months ended September 30, 2008, Micromet recognized total revenues of $7.0 million, compared to $5.6 million for the same period in 2007. Total operating expenses were $13.4 million for the three months ended September 30, 2008, compared to $9.2 million for the same period in 2007.

Loss from operations for the three months ended September 30, 2008 was $6.3 million, compared to a loss from operations of $3.6 million for the same period in 2007.

For the three months ended September 30, 2008, Micromet reported a net loss of $12.9 million, or $0.31 per basic and diluted common share, compared to a net loss of $2.3 million, or $0.06 per basic and diluted common share, for the same period in 2007. The net loss for the three months ending September 30, 2008 includes a non-cash charge of $6.8 million reflecting a change in the fair value of warrants issued in connection with a 2007 PIPE financing. The Company recorded a $1.2 million non-cash gain for this item in the third quarter of 2007.

Nine Months Ended September 30, 2008

For the nine months ended September 30, 2008, Micromet recognized total revenues of $21.4 million, compared to $11.4 million for the same period in 2007. Total operating expenses were $41.0 million for the nine months ended September 30, 2008, compared to $30.6 million for the same period in 2007.

Loss from operations for the nine months ended September 30, 2008 was $19.6 million, similar to the $19.2 million dollar loss from operations over the same period in 2007.

For the nine months ended September 30, 2008, Micromet reported a net loss of $27.4 million, or $0.67 per basic and diluted common share, compared to a net loss of $16.3 million, or $0.47 per basic and diluted common share, for the same period in 2007. The net loss for the nine months ending September 30, 2008 includes a non-cash charge of $8.5 million reflecting a change in the fair value of warrants issued in connection with a 2007 PIPE financing, compared to a $1.7 million non-cash gain for this item in the same period of 2007.

Net cash used in operating activities was $8.7 million for the nine months ended September 30, 2008 compared to $11.1 million used in operating activities for the same period in 2007. Micromet's cash and cash equivalents were $15.9 million as of September 30, 2008. The net proceeds of $37.4 million from the PIPE financing were received on October 2, 2008 and are not included in the Company's cash balance as of September 30, 2008.

2008 Outlook:

Micromet will present data at the annual meeting of the American Society for Hematology (ASH) on December 8th and 9th in San Francisco. The Company expects to provide a further update on the currently ongoing phase 1 clinical trial of blinatumomab in patients with non-Hodgkin's lymphoma, and initial results of the currently ongoing phase 2 clinical trial of blinatumomab in patients with acute lymphoblastic leukemia.

Conference Call and Audio Webcast Today, November 6, 2008, at 9:00 am Eastern Time.

To participate in this conference call, dial 800-299-0148 (U.S.) or 617-801-9711 (international), passcode: 70506651. The audio webcast can be accessed at: http://www.micromet-inc.com/ in the investor relations section of the website. A replay of the call will be available from 12:00 pm Eastern Time on November 6, 2008 (6:00 pm Central European Time) through Thursday, November 13, 2008. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 99269687.

About Micromet, Inc.

Micromet, Inc. (http://www.micromet-inc.com/) is a biopharmaceutical company with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE(R) antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights MT 110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT 293, to TRACON Pharmaceuticals, Inc. MT 293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT 203 being developed in collaboration with Nycomed. MT 203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

[MasaRatti]

Die Erfolgsgeschichte geht weiter ???!!!



Micromet Key Events for 2009

Key Presentations and Milestones Expected for 2009

BETHESDA, Md., Jan. 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, provides an outlook on key events anticipated for the year 2009.

Micromet intends to provide an update on its research and development programs at the following events:

-- April 12 to 16, 2009: Update on several preclinical BiTE antibodies at the American Association for Cancer Research (AACR) in Denver, CO;

-- April 24, 2009: The company will hold an R&D meeting in New York, NY for investors and analysts to provide a review of its product pipeline;

-- May 29 to June 5, 2009: Update on a phase 1b clinical trial combining adecatumumab with docetaxel in late stage metastatic breast cancer patients at the annual meeting of the American Society for Clinical Oncology (ASCO) in San Francisco, CA;

-- June 4 to 7, 2009: Update on phase 2 clinical trial with blinatumomab in acute lymphoblastic leukemia (ALL) patients at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany;

-- September 20 to 24, 2009: First interim data from a phase 1 clinical trial with MT110, an EpCAM-targeting BiTE antibody, in patients with metastatic gastro-intestinal and lung cancers at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO) in Berlin, Germany;

-- December 5 to 8, 2009: Update on a phase 2 clinical trial with blinatumomab in ALL patients and final results from a phase 1 clinical trial in late stage NHL at the annual meeting of the American Society for Hematology (ASH) in New Orleans, LA.

Additional expected milestones in 2009:

-- Adecatumumab, an EpCAM-targeting human monoclonal antibody in development with Merck-Serono is expected to start a randomized, controlled, multicenter phase 2 clinical trial in relapsed colorectal cancer patients after complete resection of liver metastasis in Q1 2009;

-- Blinatumomab, a CD19-targeting BiTE antibody in development with MedImmune, is expected to start an additional phase 2 clinical trial in patients with non-Hodgkin's lymphoma (NHL) towards the end of 2009;

-- MT203, a GM-CSF neutralizing human monoclonal antibody in development with Nycomed for the treatment of chronic inflammatory and autoimmune diseases, is expected to start a first clinical phase 1 trial in mid 2009;

-- MT228, a glycolipid binding human antibody in development by Eisai for the treatment of melanoma, is expected to start a first phase 1 clinical trial in 2009;

-- MT293, a humanized monoclonal antibody targeting denatured collagen, in development by Tracon Pharmaceuticals, Inc. for the treatment of solid tumors is expected to complete a clinical phase 1 trial.

Micromet intends to publish results from the research and development of its programs in peer-reviewed scientific and clinical journals throughout the year. Micromet also intends to enter into one to two new collaborations with corporate partners in 2009.

Our next formal company presentation will be at the BIO CEO Conference February 9 and 10, 2009, in New York, NY.

[MasaRatti]

Micromet to Host an Investor Meeting and Ring the Closing Bell of the NASDAQ Stock Exchange on April 24, 2009 in New York City


BETHESDA, Md., April 15 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host an investor meeting and will ring the closing bell of the NASDAQ stock exchange in New York City on Friday, April 24, 2009. A simultaneous webcast of the investor meeting will be available on the company's website at www.micromet-inc.com.

Forum: Micromet, Inc. Investor Meeting
Date: Friday, April 24, 2009
Time: 8:00 to 10:30 am U.S. Eastern Time
Place: The Yale Club of New York CityNew York City, New York
Webcast: www.micromet-inc.com

[MasaRatti]

Guten Morgen !

http://seekingalpha.com/article/132973-bright-prospects-for-…

[MasaRatti]

Micromet, Inc. Reports First Quarter 2009 Financial Results


BETHESDA, Md., May 6 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2009.

In the first quarter of 2009, Micromet achieved a number of significant milestones illustrating its continued progress in the clinic and in corporate development. The milestones include the execution of an option, collaboration and license agreement with a major pharmaceutical company to develop a new BiTE antibody, the initiation of a new phase 2 clinical trial for adecatumumab (MT201), the filing of a clinical trial application for MT203, the publication of new scientific data on EpCAM, which is the target of two of its clinical product candidates, and regaining North American rights to blinatumomab (MT103). These developments are summarized below:

-- On January 12, Micromet announced the execution of an option,
collaboration and license agreement with Bayer Schering Pharma AG.
Under the terms of this agreement, Micromet granted Bayer Schering
Pharma an exclusive option until January 2010 to obtain the rights to
develop and commercialize a specific BiTE antibody against an
undisclosed solid tumor target. Bayer Schering Pharma paid an option
fee of approximately $6.0 million and may exercise the option with the
payment of an additional option exercise fee, which would trigger a
formal collaboration to develop this BiTE antibody. Micromet would be
eligible to receive from Bayer Schering Pharma approximately Euro 290
million in total, including the option exercise fee and potential
milestone payments, and up to a double-digit royalty based on tiered net
sales of the product. In addition, Micromet would be reimbursed for
development expenses incurred in this collaboration.

-- On January 13, Micromet together with the Ludwig-Maximilian-University
in Munich, Germany published data in the peer reviewed journal Nature
Cell Biology revealing a novel signaling function of the epithelial cell
adhesion molecule, or EpCAM, which is expressed at high frequency on
many tumor types. The data indicate that only cancer cells have an
active signaling form of EpCAM that promotes tumor formation. This data
further supports the scientific and clinical rationale behind two of
Micromet's most advanced clinical product candidates, adecatumumab
and MT110, both of which target EpCAM.

-- On February 23, Micromet announced the addition of Kapil Dhingra, M.D.
to the Board of Directors. Dr. Dhingra has been active in oncology
clinical research for over 20 years, most recently as head of Oncology
Development at Hoffman La-Roche, where he built the largest oncology
clinical development department in the industry. Dr. Dhingra brings
deep oncology development experience and perspective to Micromet's
Board of Directors.

-- On March 12, Micromet announced that it had regained North American
rights to its most advanced product candidate, blinatumomab (MT103),
from MedImmune. Micromet is responsible for the further clinical
development and commercialization of blinatumomab. MedImmune is
obligated to complete the development of the commercial scale
manufacturing process for blinatumomab at its cost. Upon the first
marketing approval of blinatumomab in the United States, MedImmune will
have a one-time option to reacquire the commercialization rights in
North America at pre-defined terms.

-- On March 23, Micromet announced the initiation of a new phase 2 clinical
trial with its human anti-EpCAM IgG1 antibody adecatumumab (MT201).
This randomized, controlled phase 2 trial will evaluate adecatumumab in
the treatment of patients with colorectal cancer after complete
resection of liver metastases.

-- On April 2, Micromet announced the filing of a clinical trial
application in Europe by its partner Nycomed for the anti-GM-CSF
antibody MT203. The filing triggered a milestone payment to Micromet of
approximately $2.0 million.

"We are very pleased with our accomplishments during the first quarter of 2009, and we look forward to presenting clinical data at the American Society of Clinical Oncology meeting and the European Hematology Society meeting in the second quarter," stated Christian Itin, President and CEO of Micromet, Inc.

Financial Results:

Quarter Ended March 31, 2009

For the three months ended March 31, 2009, Micromet recognized total revenues of $7.5 million, compared to $5.9 million for the same period in 2008. Total operating expenses were $12.4 million for the three months ended March 31, 2009, compared to $13.3 million for the same period in 2008.

Loss from operations for the three months ended March 31, 2009 was $4.9 million, compared to a loss from operations of $7.3 million for the same period in 2008.

For the three months ended March 31, 2009, Micromet reported a net loss of $0.3 million, or a loss of $0.01 per basic and diluted common share, compared to a net loss of $5.9 million, or $0.14 per basic and diluted common share, for the same period in 2008. The net loss for the three months ending March 31, 2009 includes a non-cash gain of $4.4 million, reflecting a decrease during the quarter in the fair value of warrants issued in connection with a private placement transaction in 2007. The Company recorded a $1.3 million non-cash gain for this item in the first quarter of 2008.

Net cash provided by operating activities was $1.1 million for the three months ended March 31, 2009 compared to $0.4 million provided by operating activities for the same period in 2008. Micromet's cash, cash equivalents and investments were $47.1 million as of March 31, 2009. Based on our current operating projections, we believe the cash and cash equivalents as of March 31, 2009 will be sufficient to fund operations into the second half of 2010.

Conference Call and Audio Webcast Today, May 6, 2009, at 9:00 am Eastern Time.

To participate in this conference call, dial 800-320-2978 (U.S.) or 617-614-4923 (international), passcode: 90696322. The audio webcast can be accessed at: www.micromet-inc.com. A replay of the call will be available from 12:00 pm Eastern Time on May 6, 2009 (6:00 pm Central European Time) through Wednesday, May 13, 2009. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 58046416.

[MasaRatti]

Servus zusammen,

der Kursverlauf sieht doch nett aus, mal sehen
was uns am 08.06. erwartet

[Ville7]

Antwort auf Beitrag Nr.: 37.332.522 von MasaRatti am 05.06.09 19:57:43

Hi, ich bin auch sehr gespannt. MITI hat mit BITE eine sehr vielversprechende Technologie. Mal sehen, was man am Montag so interessantes hört - von Blinatumomab und dem Rest..

[Ville7]

Micromet und deren BITE Technologie könnte wahrlich der Überflieger im AK Onkologie Bereich werden!

"Itin said 13 of 16 patients treated with blinatumomab and evaluated so far, or 81 percent, no longer have detectable tumor cells -- and the drug has therefore met its primary goal before completion of the study. The trial goal was for 22 percent of patients to achieve undetectable tumor levels, the CEO said."

http://www.forbes.com/feeds/reuters/2009/06/06/2009-06-06T07…

[SLGramann]

Antwort auf Beitrag Nr.: 37.335.807 von Ville7 am 06.06.09 15:58:05

Klingt wirklich fast zu gut, um wahr zu sein.

(Ich überlege gerade, ob ich aus einer "lächerlich-kleinen Position" eine "kleine Position" mache. Es ist zwar alles extrem spekulativ, aber wenn der BiTE-Ansatz wirklich nachhaltig funktionieren sollte und verträglich ist, dann verändert das hier die Welt. Verwirrend bleibt für mich indes, dass Medimmune (bzw. AstraZeneca) kürzlich de facto aus dem Blinatumomab-Projekt ausgestiegen ist.)

[Ville7]

Antwort auf Beitrag Nr.: 37.335.882 von SLGramann am 06.06.09 16:36:57

Ich habe bereits vor Wochen zugeschnappt und werde im Run nicht nachkaufen. Ich werde -sofern die Technologie weiter starke Meldungen liefert- bei Schwäche nachkaufen. Sollte es aber keine Schwäche geben, lasse ich die Aktie laufen.

[VaJo]

Antwort auf Beitrag Nr.: 37.340.339 von Ville7 am 07.06.09 23:49:27

Da hat sich heute jemand weit aus dem Fenster gelehnt ;-)
40% Plus in FF. Der Kurs ist in Dollar nun genauso hoch wie in EUR.
Danke Ville für den Hinweis mit Micromet ich habs auf der Watch. Für mich persönlich ist die Aktie im Moment viel zu teuer. Bei 1,80 EUR wäre mein Einstiegspunkt. Vermutlich ist der Zug aber erstmal abgefahren. Gibt noch andere Aktien.

[SLGramann]

Antwort auf Beitrag Nr.: 37.341.960 von VaJo am 08.06.09 11:23:36

Ich war das nicht...

(würde generell eher den US-Handel bevorzugen)

[MasaRatti]

08.06.2009 13:03
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients / German Multicenter ALL Study Group Presented Data at the 14th Congress of the European Hematology Association Showing High Response Rate in Pat

BERLIN, June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that the German Multicenter ALL Study Group (GMALL) presented phase 2 clinical data of the BiTE(R) antibody blinatumomab (MT103) at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany, showing a high response rate in acute lymphoblastic leukemia (ALL) patients with minimal residual disease (MRD)(1). Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out and destroy cancer cells.

The patients included in this phase 2 clinical trial were in complete hematological remission following intense chemotherapy regimens, but retained a detectable level of ALL cancer cells in their bone marrow -- so called minimal residual disease (MRD). Various studies have confirmed that ALL patients with MRD following chemotherapy have a significantly worse prognosis than patients without MRD.

The primary endpoint of the phase 2 study is MRD response within four cycles of treatment. MRD response is defined as the elimination of ALL cancer cells in patients with MRD below the limit of detection. The achievement of the primary endpoint requires that at least 22% of 21 patients have an MRD response. Currently, 13 of 16, or 81% of evaluated patients have shown an MRD response, thus qualifying the trial as having met its primary endpoint before the completion of the study. Patients in all subgroups responded to treatment with blinatumomab, including bcr-abl positive patients after failure of treatment with bcr-abl inhibitors, and patients with t(4;11) translocations. Side effects were observed primarily in the first 24 to 48 hours with transient pyrexia and lympho-/leukopenia being the most frequent adverse events.

"Blinatumomab is one of the most active agents the GMALL has tested in the adult ALL consolidation setting," said Dr. Ralf Bargou, principal investigator of the trial. "We are excited about the significant activity of blinatumomab in ALL and the favorable safety profile observed in this study. These results are particularly important for these patients who are in a disease stage with extremely poor prognosis and for which we lack treatment options except for patients eligible for allogenic stem cell transplantations."

"The ALL interim data showing an MRD response rate above 80% significantly exceeds the rate which was considered to be clinically meaningful and was set as the hurdle for the achievement of the primary end point," said Micromet's Senior Vice President and Chief Medical Officer, Carsten Reinhardt, M.D. "We are now looking forward to discussing a pivotal ALL program with the regulatory authorities later this year."

(1) Topp, M.S. et al (2009). Blinatumomab (anti-CD19 BiTE(R)) for targeted therapy of minimal residual disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing Phase II study. 14th Congress of the EHA 2009, abstract no. 482 Webcast/Conference Call

Micromet will host a webcast/conference call this morning from 9:00 am to 11:00 am U.S. Eastern time to discuss the blinatumomab data presented at the 14th Congress of the European Hematology Association. The webcast will be available on the company's website at http://www.micromet-inc.com/. To participate in the conference call, dial 866-543-6403 (U.S.) or 617-213-8896 (international), passcode: 12594792.

A replay of the call will be available from 1:00 pm Eastern Time on June 8, 2009 (7:00 pm Central European Time) through June 15, 2009. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 67386852.

[Ville7]

Antwort auf Beitrag Nr.: 37.342.965 von MasaRatti am 08.06.09 13:36:40

Premarket schon weit über 6 USD.

[VaJo]

Antwort auf Beitrag Nr.: 37.343.452 von Ville7 am 08.06.09 14:37:13

Vielleicht hast Du recht und das GAP schließt sich heute in den USA. Dann könnte es Kurse um 3,30 EUR geben. Mit ein wenig Glück unter 2 EUR.

[VaJo]

Antwort auf Beitrag Nr.: 37.343.452 von Ville7 am 08.06.09 14:37:13

Sorry, unter 3 EUR wollte ich schreiben.

[VaJo]

Antwort auf Beitrag Nr.: 37.351.953 von VaJo am 09.06.09 13:07:30

So, jetzt kanns wieder hochgehen

[Ville7]

Antwort auf Beitrag Nr.: 37.353.876 von VaJo am 09.06.09 16:18:53

Kann sein, muss nicht sein. Micromet ist ultra volatil.

[SLGramann]

So, jetzt habe ich meine Wunschposition. Mal sehen, wie es in 5 Jahren aussieht.

[SLGramann]

BETHESDA, Md., June 18, 2009 /PRNewswire-FirstCall via COMTEX/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the initiation of the first clinical trial for the anti-granulocyte macrophage colony-stimulating factor (GM-CSF) human antibody MT203 by its collaboration partner Nycomed.

The double-blind, randomized, placebo controlled study will investigate the safety and pharmacokinetics of MT203.

[VaJo]

Antwort auf Beitrag Nr.: 37.423.177 von SLGramann am 18.06.09 22:11:32

Perfekt!
Dürfte dem Kurs einen Tritt geben - nach oben

[Ville7]

Antwort auf Beitrag Nr.: 37.423.990 von VaJo am 19.06.09 06:48:16

Glaube ich nicht. Was bei Morphosys nicht eingepreist wurde, wird bei Micromet bestimmt nicht eingepreist. Zumal Micromet bei anti-GM-CSF den schlechteren Patentschutz haben könnte, da Morphosys exklusive Patente in USA besitzt. Zudem ist Morphosys fast 1,5 Jahre in der Entwicklung voraus. Während Micromet gerade die P1 an gesunden Freiwilligen startet ist es nur noch eine Frage von Tagen bis Morphosys die Ergebnisse ihrer Phase 1, ebenfalls an gesunden Freiwilligen, veröffentlicht.

[Ville7]

Micromet jetzt neu auch im ZDF Videotext.

Frankfurt: S.683, Unterseite 2

[SLGramann]

Aided by a boost in stock prices, Micromet Inc. has sold more shares in return for $2.75 million in funding as part of a long-term stock purchase agreement it inked in December.

The Bethesda biotech said it sold almost 656,000 shares, at an average price of $4.19 apiece, to a stockholder, Kingsbridge Capital Ltd., between June 4 and June 15. The sale was the latest move in an agreement the two parties signed at the end of last year for Micromet to offer up to 10.5 million shares to Kingsbridge if it wished, in return for as much as $75 million in potential funding through Dec. 1, 2011.

Micromet (NASDAQ: MITI) sold the stock this month at a discount of 10 percent to 12 percent per share. By the end of the trading period on June 15 under this agreement, Micromet’s shares were $4.38.

This latest sale follows on the heels of another that Micromet had initiated in May, when it drew down $2.5 million after selling 764,700 shares in an eight-day period to Kingsbridge. Those shares, averaging $3.27 apiece, came at a 12 percent discount at that time.

But this month, Micromet benefited from a stock surge during the eight-day trading period to Kingsbridge, after it released mid-stage clinical data results that showed its leukemia treatment elicited a higher-than-expected response rate from patients.

On June 8, the day the results were announced, Micromet’s shares rose as much as 39 percent to a trading high of $6.40 before settling back down to close that day at $4.95, a 7 percent bump from the previous day’s closing price.


Interessante Option, die Kingsbridge da hat...

[Ville7]

Der heutige Runup hat wohl mit der Aufnahme von Micromet in den Russel 3000 (und 2000) Index zu tun, am Montag erscheint die endgültige Liste (auf der vorläufigen war Micromet zu finden). Scheint so als hätten daher noch einige Indexfonds zugefasst.

[quepos]

Moin,

BMS schluckt MEDX für 16$ die Aktie...

Auf die kleine MITI dürfte das auch "ein wenig" abfärben. Erfreulich, da die Lage auch charttechnisch interessant ist!
(habe allerdings nicht viele MITI, ist mir zu riskant).
Die Technologie halte ich allerdings für hochinteressant. Kann auch jederzeit eine Übernahme erfolgen, obwohl ich aufgrund der wenig vorangeschrittenen Pipeline im Moment nicht daran glaube.

Gruß
quepos

[VaJo]

Antwort auf Beitrag Nr.: 37.627.991 von quepos am 23.07.09 07:57:10

obwohl ich aufgrund der wenig vorangeschrittenen Pipeline im Moment nicht daran glaube.

So anfänglich ist die Pipeline doch nicht.

Adecatumumab (MT201) vor P3
Blinatumomab Mitte P2
MT110 P1
MT293 (TRC093) P1

[SLGramann]

BETHESDA, Md., July 30 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI - News), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the pricing of its public offering of 14,000,000 shares of its common stock at a public offering price of $5.00 per share. All of the shares are being offered by Micromet. The gross proceeds to Micromet, before expenses, from the sale of the shares are expected to be approximately $70 million. The closing of the offering is expected to take place on August 4, 2009. The underwriters have a 30-day option to purchase up to an additional 2,100,000 shares of common stock to cover over-allotments, if any.

--------------

Das sind gute 30% Verwässerung - aber die Börse freut sich gerade darüber und schickt den Kurs auf mehr als 6 Dollar...

Vielleicht feiert man das Erreichen dieses "Meilensteins finanzieller Flexibilität"? Vielleicht durchaus zurecht?

[VaJo]

Warum geht die jetzt so ab? Ich wollte eigentlich nochmal nachkaufen

[VaJo]

Verwässerung, Verwässerung - verkaufen!!!!

[dottore]

Antwort auf Beitrag Nr.: 37.685.084 von VaJo am 31.07.09 11:05:37

genau! schnell verkaufen! Heute in AmiLand wird abverkauft!
und ich will auch noch welche

[SLGramann]

Micromet Inc. Closes $80.5 Million Public Offering Of Common Stock
10:48am EDT

Micromet Inc. announced the closing of its previously announced public offering of 14,000,000 shares of common stock. The Company also announced that the underwriters for the offering have exercised in full their over-allotment option to purchase an additional 2,100,000 shares, bringing the total shares sold to 16,100,000 at a price of $5.00 per share for gross proceeds of $80.5 million. The Company received net proceeds of approximately $75.0 million, after deducting underwriting discounts and estimated offering expenses. Piper Jaffray & Co. acted as the sole book running manager with RBC Capital Markets and Merriman Curhan Ford as co-managers in this offering.


------------------

KE hat 75 Mio. Netto in die Kasse gebracht. Und das ist alles so locker über die Bühne gegangen, dass der Kurs während und nach der KE 20% über dem Ausgabepreis der neuen Aktien notiert. Da müssen bedeutende Investoren im Vorfeld ja wohl einen ziemlichen Bedarf angemeldet haben.

[VaJo]

Wo sind eigentlich die "Dilution" Schreier?

[VaJo]

Micromet Poised To Reach Cancer-Drug Market With $75M

By Brian Gormley

Publicly traded Micromet Inc., which raised $75 million in net proceeds from several of its venture capital backers Tuesday, is poised to find out whether its novel immunotherapeutic technology can deliver on the promise venture capitalists saw when they began investing last decade.

Micromet, which formed in 1993 and went public through a 2006 reverse merger with CancerVax Corp., raised the capital from existing venture backers, such as Abingworth Management and SV Life Sciences, and mutual funds. The company now has at least two years’ worth of cash, said Chief Executive Christian Itin.

With this financing, Micromet can push its lead drug, the leukemia therapy MT103, into and perhaps through pivotal clinical trials, which are set to begin in mid 2010, Itin said.

MT103 showcases the technology that drew firms such as SV, which first invested in 1998 and has now positions in Micromet through three funds, including its current fund, said Managing Partner Kate Bingham. Micromet’s antibodies physically link tumor cells to T cells, the body’s most efficient killers, to create an immune response that is a few thousand to 100,000-fold more potent against tumor cells than traditional antibody drugs, which do not recruit T cells to fight tumors, Itin said.

In a Phase II study of acute lymphoblastic leukemia patients, Micromet delivered strong results. It tested patients who were in complete hematological remission following chemotherapy, but retained a detectable level of cancer cells in their bone marrow. Patients with so-called minimal residual disease, or MRD, have a poor prognosis.

Thirteen of 16, or 81%, of patients treated with MT103 had an MRD response – the reduction of residual cancer cells below the limit of detection. When freed of cancer cells, these patients’ chance of relapse is zero to 6%, Itin said. Micromet plans to begin its pivotal studies in Europe and intends to launch a corresponding U.S. study by the end of 2010, Itin said.

Several antibody companies have been bought up recently, including Medarex Inc., which in July agreed to merge with Bristol-Myers Squibb Co. in a $2.1 billion deal. Micromet’s recent clinical-trial success has venture investors thinking that the company will be a similarly attractive target if it can deliver equally strong results in larger trials. Public-market investors seem to agree. Micromet, which sold 16.1 million shares at $5 per share, closed at $6.05 on Tuesday.

“The company has a platform technology in the antibodies space that has the potential of producing therapeutics that are more potent than anything else we have seen,” said Jerry Benjamin, a senior advisor to Advent Venture Partners, which invested in private Micromet rounds but did not participate in the new financing.

Micromet’s approach has potential in other cancers and autoimmune and inflammatory disease, but a strong showing in large-scale leukemia trials alone would likely be enough to drive an acquisition, said Andrew Vaino, an analyst with Roth Capital Partners.

Micromet has a total of five antibodies in clinical trials. In addition to MT103, which is also in a Phase I trial of patients with non-Hodgkin’s lymphoma, its other products include MT110, an antibody in a Phase I trial for the treatment of solid tumors.

[VaJo]

“The company has a platform technology in the antibodies space that has the potential of producing therapeutics that are more potent than anything else we have seen,” said Jerry Benjamin

Eine sehr nachdenkliche Aussage

[Latinl]

Antwort auf Beitrag Nr.: 37.729.092 von VaJo am 07.08.09 06:55:14

bist du noch drin ich hatte vor nem jahr mit gewinn verkauft

will evtl wieder rein

[VaJo]

Antwort auf Beitrag Nr.: 37.737.959 von Latinl am 08.08.09 13:06:22

Ja bin noch drin.

[VaJo]

Antwort auf Beitrag Nr.: 37.737.959 von Latinl am 08.08.09 13:06:22

Die Verwässerung und die Bewertung ist aber Ambitioniert. Bei anderen Aktien wäre das Geschrei groß

[Latinl]

Antwort auf Beitrag Nr.: 37.738.777 von VaJo am 08.08.09 19:56:40

wann ist die KE durch

[SLGramann]

Antwort auf Beitrag Nr.: 37.739.339 von Latinl am 09.08.09 09:39:57

In #215 hatte ich ja versucht, dazu etwas zu sagen. Offensichtlich ist mir das misslungen.

[SLGramann]

Hammer hat einen neuen Artikel zu Micromet draußen, in dem vor allem auf die Konkurrenz zu Blinatumomab (CD 19) eingegangen wird. Hammer spekuliert über einen Rückkauf der US-Rechte und fordert eine baldige (Neu)Verpartnerung des Projekts, um mehr Dampf in die Entwicklung zu bekommen.

Zum MT110 (BiTE gegen solide Tumore) gibt es nächsten Monat Daten. Sollten die positiv ausfallen, dürfte das einen Kurssprung auslösen imho.

http://www.hammerstockblog.com/the-clock-is-ticking-on-micro…

[quepos]

Moin und Hallo,

nach MEDX bin ich auch bei MITI erstmal raus nach dem schönen Anstieg, ist ohnehin ein bischen dünn gehandelt in D. Man weiß nie, zu welchen Kursen man die Stücke wieder loswird.
Gäbe es die Spekufrist noch, hätte ich gehalten. Der Wegfall ermuntert zum Zocken.
Hatte aber eh nur ein winziges Quäntchen (müßte es mit Neuschreib wohl heißen), wollte ja akkumulieren. Aber stieg ja nur...
Ist ja aber nicht schlechtes...


Falls MITI mir wieder attraktiv erscheint, kaufe ich trotzdem wieder.
Gründe für den Kursanstieg sucht man vergebens.
?

Gruß q.

[Ville7]

Antwort auf Beitrag Nr.: 37.923.542 von quepos am 04.09.09 21:10:03

Glückwunsch. Könnte ein guter Ausstieg gewesen sein.

Ich bleibe erst mal drin. Bei der magischen Marke von 10 USD könnte ich mir vorstellen die Hälfte rauszunehmen und dadurch mehr als meinen Einsatz rauszunehmen (Kaufkurs: 3,67 USD).

Ich denke MITI wird immer noch befeuert durch das freie Medarex Geld, das wieder angelegt werden will. Es gibt nicht wirklich viele börsengehandelte cutting edge Technologien im Antikörperbereich mehr.

Wir werden sehen...

[SLGramann]

Antwort auf Beitrag Nr.: 37.923.542 von quepos am 04.09.09 21:10:03

Gründe für den Kursanstieg sucht man vergebens.

Wir hier kennen keine Gründe. Das heißt aber nicht, dass sie nicht vielleicht doch existieren.

Was ist bspw., wenn das hier gut läuft:

-- September 20 to 24, 2009: First interim data from a phase 1 clinical trial with MT110, an EpCAM-targeting BiTE antibody, in patients with metastatic gastro-intestinal and lung cancers at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO) in Berlin, Germany

?

Die Studie ist nicht verblindet.

http://clinicaltrials.gov/ct2/show/NCT00635596?term=MT110&ra…

Das Abstract musste bis spätestens 05.08.2009 vorliegen.

Alles was ich damit sagen will, ist, dass relevante Daten zu MT110 "in der Welt" sind. Doch wie undurchlässig ist die Mauer zw. der wissenschaftlichen und der Finanzwelt eigentlich?

Villes 10 Dollar könnten wir sehr schnell sehen, falls hier besonders gute Daten kommen sollten, das heißt, falls erste Hinweise auf Wirksamkeit vorliegen sollten. In zwei Wochen wissen (auch) wir es.

[quepos]

Antwort auf Beitrag Nr.: 37.934.021 von SLGramann am 07.09.09 21:10:00

Moin,

wird sich zeigen, ob´s gut war rauszugehen, jetzt schon über 7...
Ihr werdet es in zwei Wochen wissen, ich wohl nicht, da ich dann immer noch im Urlaub sein werde und dann auf das Börsengeschehen weitgehend verzichte. Zeitung gibts noch ab und zu aber Internet nur in dringenden Fällen. Handy bleibt auch aus.
Hoffe nur, dass es nicht wieder irgendeinen blöden Kurssturz gibt (war leider schon oft der Fall, wenn ich mal ein paar Wochen abschalte).


Bis denne und gute Kurse

q.

P.S.: Noch mehr MOR eingebunkert zu 15, habe aber auch noch tiefere Limits.

[SLGramann]

Antwort auf Beitrag Nr.: 37.934.263 von quepos am 07.09.09 22:01:36

und dann auf das Börsengeschehen weitgehend verzichte. Zeitung gibts noch ab und zu aber Internet nur in dringenden Fällen. Handy bleibt auch aus.


Sehr vernünftig! Schönen Urlaub.

[MasaRatti]

Hallo zusammen,
so langsam nähern wir uns wieder Niveau´s, die die Aktie verdient,
bei der guten Pipeline

Schönes Wochenende

[mitleser3108]

Micromet to Present at the 16th Annual NewsMakers in the Biotech Industry Conference on September 16, 2009

BETHESDA, Md., Sept. 15 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its President and CEO, Dr. Christian Itin, will present at the 16th Annual NewsMakers in the Biotech Industry Conference on September 16, 2009 in New York City. A simultaneous webcast of the event will be available on the company's website at www.micromet-inc.com.


Forum: 16th Annual NewsMakers in the Biotech Industry Conference
Date: Wednesday, September 16, 2009
Time: 11:00 am to 11:25 am U.S. Eastern Time
Place: Millennium Broadway Hotel
New York City, New York
Webcast: www.micromet-inc.com

[mitleser3108]

Micromet to Present at the UBS Global Life Sciences Conference on September 22, 2009


BETHESDA, Md., Sept. 16 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its President and CEO, Dr. Christian Itin, will present at the UBS Global Life Sciences Conference on September 22, 2009 in New York City. A simultaneous webcast of the event will be available on the company's website at www.micromet-inc.com.



Forum: UBS Global Life Sciences Conference
Date: Tuesday, September 22, 2009
Time: 8:00 am to 8:30 am U.S. Eastern Time
Place: Grand Hyatt New York
New York City, New York
Webcast: www.micromet-inc.com

[mitleser3108]

http://www.dddmag.com/article-BiTE-Antibody-Induces-High-Res…

[SLGramann]

BETHESDA, Md., Sept. 17 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and webcast on September 22, 2009 at 7:00 am U.S. Eastern Time to discuss the data from a phase 1 clinical trial with Micromet's anti-EpCAM BiTE antibody MT110, which was presented on September 21, 2009 at the joint 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO) in Berlin, Germany.

[Ville7]

September 17th, 2009
Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO/ESMO on September 22, 2009

BETHESDA, Md., Sept. 17 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and webcast on September 22, 2009 at 7:00 am U.S. Eastern Time to discuss the data from a phase 1 clinical trial with Micromet's anti-EpCAM BiTE antibody MT110, which was presented on September 21, 2009 at the joint 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO) in Berlin, Germany. The webcast will be available on the company's website at www.micromet-inc.com.

Forum: Micromet, Inc. Conference Call and Webcast
Date: Tuesday, September 22, 2009
Time: 7:00 am to 7:30 am U.S. Eastern Time
Webcast: www.micromet-inc.com

To participate in this conference call, dial 1-866-314-9013 (U.S.) or 1-617-213-8053 (international), passcode: 47917462. The audio webcast can be accessed at www.micromet-inc.com.

A replay of the call will be available from 9:00 am U.S. Eastern Time on September 22, 2009 (3:00 pm Central European Time) through, September 29, 2009. The replay number is 1-888-286-8010 (U.S.) or 1-617-801-6888 (international), passcode: 74744916.

[SLGramann]

BETHESDA, Md., Sept 21, 2009 /PRNewswire-FirstCall via COMTEX/ -- Micromet, Inc. /quotes/comstock/15*!miti/quotes/nls/miti (MITI 8.29, -0.01, -0.06%) , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented first interim data from a phase 1 dose-escalation clinical study for BiTE antibody MT110, the first T-cell engaging antibody for the treatment of solid tumors. The interim data(1) were presented at the Multidisciplinary Congress of the European Cancer Organisation (ECCO) and 34th meeting of the European Society for Medical Oncology (ESMO) in Berlin, Germany. MT110 is designed to direct the patients' own T cells against cancer cells that express the epithelial cell adhesion molecule (EpCAM).

To date, 20 patients with late-stage lung or gastrointestinal cancers have been treated with MT110. The starting dose in this phase 1 dose escalation trial was 1 g per patient per day. Results from doses up to 12 g per patient per day were reported. MT110 is administered by continuous intravenous infusion for a minimum of four weeks with the option of additional treatment cycles until disease progression. No maximum tolerated dose has been reached and dose escalation is ongoing. MT110 is well tolerated with no grade 3 or 4 clinical events related to MT110 therapy observed so far. The most frequent adverse events related to MT110 treatment were mild pyrexia and fatigue. Laboratory analysis of all patients revealed an early clinically asymptomatic increase of liver enzymes that normalized after several days under continued treatment. Other laboratory abnormalities included transient lymphopenia. No cytokine release syndrome, pancreatitis or immune response to MT110 was observed. At the dose levels tested to date, disease stabilization was seen in 7 of 18 evaluable patients after the first cycle of treatment, and dose escalation continues.

"We are very encouraged by the tolerability of MT110 observed in this heavily pre-treated population of cancer patients and look forward to updating our results as we continue to increase the dose," commented Prof. Walter Fiedler from the University Hospital of Hamburg-Eppendorf, Germany, and principal investigator of the study.

"The interim phase 1 results and activity of MT110 at the current dose level are what we expected based on our preclinical data," commented Christian Itin, CEO of Micromet. "We are now looking forward to exploring the clinical activity of MT110 at higher dose levels."

MT110 is the second BiTE antibody undergoing clinical investigation. Micromet also has ongoing trials for blinatumomab (MT103), including a phase 2 trial for acute lymphoblastic leukemia (ALL) and a phase 1 trial for non-Hodgkin's lymphoma.

[SLGramann]

Antwort auf Beitrag Nr.: 38.023.058 von SLGramann am 21.09.09 15:34:06

Ich denke, das ist in etwa das, was positiv erwartet werden konnte. Es wurde bisher keine Maximaldosis erreicht und die Eskalation kann fortgesetzt werden. Dennoch gibt es bei immerhin 7 Patienten erste Hinweise auf Wirksamkeit. Man muss bedenken, dass die ersten Dosisgruppen eine Dosis erhielten, die medizinisch wohl nicht wirksam sein kann.

Insgesamt dürfte MT110 auf dem richtigen Weg sein, auch wenn die Ergebnisse zunächst mal nicht total überwältigend wirken.

Mal sehen, wie das alles von Fachleuten kommentiert werden wird.

[SLGramann]

Antwort auf Beitrag Nr.: 38.023.058 von SLGramann am 21.09.09 15:34:06

BETHESDA, Md., Sept 21, 2009 /PRNewswire-FirstCall via COMTEX/ -- In the news release, Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors, issued 21-Sep-2009 by Micromet, Inc. over PR Newswire, we are advised by the company that in the second sentence, second paragraph, "1 g" should read "1 microgram" and in the third sentence, second paragraph, "12 g" should read "12 micrograms" as originally issued inadvertently.

[mitleser3108]

Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer

BETHESDA, Md., Sept. 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the appointment of Jan Fagerberg, M.D., Ph.D., as Senior Vice President and Chief Medical Officer effective November 1, 2009.

Dr. Fagerberg is a board-certified clinical oncologist and has more than 20 years of experience in clinical research and development of oncology drugs. His experience includes several years at F. Hoffmann-La Roche in positions of increasing responsibility both in the US and in Switzerland, ultimately serving as the Therapeutic Area Expert Oncology in Global Drug Development of Hoffmann-La Roche in Basel, Switzerland. During his tenure at Roche, he was responsible for the global clinical development of Xeloda, and for the clinical development programs of Avastin outside the US. He was also advising Roche's clinical development teams globally on the development of all compounds for the treatment of gastrointestinal cancers. Dr. Fagerberg has extensive US and European regulatory experience, and was successful in obtaining 11 FDA and EMEA approvals for Xeloda and Avastin. Dr. Fagerberg joins Micromet from TopoTarget where he was Medical Director responsible for the pivotal clinical development program for belinostat for the treatment of peripheral T-cell lymphoma.

"We are very pleased to have Jan Fagerberg join us as our new Chief Medical Officer," said Christian Itin, Micromet's Chief Executive Officer. "Jan's extensive clinical and regulatory experience will be a tremendous asset as we are preparing pivotal stage clinical trials for blinatumomab."

"I am excited about the opportunity to advance the development of blinatumomab for the treatment of patients with hematologic malignancies and of MT110 for the treatment of patients with solid tumors," commented Dr. Jan Fagerberg, "and I am looking forward to translating the highly differentiated properties of BiTE antibodies into new therapies that benefit the lives of cancer patients."

Dr. Fagerberg received his MD degree at the Karolinska Institute in Stockholm Sweden in 1988. He then received his Ph.D. for work in clinically applied passive and active immunotherapy targeting EpCAM in colorectal carcinomas in 1995. From 1995 to 1999 Jan held various clinical positions including Associate Head Section of Radiotherapy and Chief Physician at the Karolinska Hospital in Stockholm. Dr. Fagerberg joined Roche in 1999 and over the following seven years assumed positions of increasing responsibility. Since 2006 he has been Medical Director at TopoTarget in Copenhagen, Denmark.

[SLGramann]

Hammer hat eine Leserfrage zu den MT110-Daten so beantwortet:


Results are in line with what most people expected. The good safety profile implies that they might be able to dose escalate MT110 to the clinically active doses, but it’s too early to tell.

[mitleser3108]

http://www.transkript.de/wirtschaft/wirtschaftsartikel/?tx_t…

70 Mio. US-$ – Micromets Bite-Antikörper überzeugen den Kapitalmarkt
27.09.09 Kreditklemme, Finanzierungsschwierigkeiten, Wirtschaftskrise – die deutsch-amerikanische Micromet Inc. ist dagegen immun. Jetzt nahm das an der Nasdaq börsennotierte Unternehmen 70 Mio. US-$ am Kapitalmarkt mit dem Verkauf von 14 Millionen frischen Aktien ein. Hinzu kommen könnten weitere 10 Mio. US-$, sollte eine Mehrzuteilungsreserve von 2,2 Millionen Aktien vollständig gezeichnet werden. Die Investoren erhielten die frischen Aktien mit einem rund 10%igen Nachlass für 5 US-$ pro Stück. Der Kauf hat sich gelohnt, denn allein die Nachricht der geglückten Kapitalerhöhung gab der Aktie noch einmal einen gehörigen Schub: Die unter dem Kürzel MITI gehandelten Papiere stiegen in New York um 13% auf 6,34 US-$ – trotz einer Verwässerung um rund 30%, die mit der Kapitalerhöhung einhergeht. Zum Ende des zweiten Quartals hatte Micromet 49,2 Mio. US-$ auf dem Konto. Damit dürften die liquiden Mittel der Firma auf mehr als 100 Mio. US-$ steigen. Zur Not könnte Micromet auch noch auf eine Finanzierungszusage in Höhe von 75 Mio. US-$ zurückgreifen, von der erst rund 5 Mio. US-$ „verbraucht“ sind. Das Biotech-Unternehmen kann das Kapital gegen Ausgabe junger Aktien in Tranchen jederzeit abrufen. Das finanzielle Polster von Micromet dürfte damit groß genug sein, um die Entwicklung des Leitproduktes MT103 allein vorantreiben zu können. Der modifizierte Antikörper soll gegen eine spezielle Form der Leukämie (ALL) sowie Non-Hodgkin-Lymphome eingesetzt werden. Nachdem eine Phase II-Studie vielversprechende Daten bei Leukämie-Patienten erbracht hat, sind im kommenden Jahr bereits zulassungsrelevante Tests in diesem Einsatzgebiet geplant. MT103 (Blinatumumab) zielt auf das CD19-Antigen und dient als Schalter zwischen der Tumorzelle und T-Zellen. Deren Aktivierung führt dazu, dass sich das patienteneigene Immunsystem gegen die malignen Zellen richtet und diese vernichtet. Im Gegensatz zu herkömmlichen Antikörpern – den passiven Immuntherapien – löst der sogenannte Bite-Antikörper eine aktive Reaktion des Immunsystems aus, die den neuen Therapieansatz attraktiv macht. Die Micromet Inc. ist ein im Kern deutsches Biotech-Unternehmen, das sämtliche Forschungsaktivitäten am Standort München ausführt. Über eine Fusion mit der börsennotierten CancerVax Inc. und einer anschließenden Umbenennung gelangten die Münchener Anfang 2006 an die Nasdaq und verlegten den juristischen Sitz der Firma in die USA.

[mitleser3108]

ein bisschen Eigenwerbung von MITI:

http://www.dddmag.com/article-Next-Generation-Antibody-Appro…

Next-Generation Antibody Approaches to Cancer TreatmentMark Reisenauer, SVP and Chief Commercial Officer, Micromet Inc., Bethesda, Md.
Drug Discovery & Development - October 08, 2009
Over the past decade, therapeutic antibodies such as Rituxan (rituximab) from Genentech/Biogen Idec,and Genentech’s Avastin (bevacizumab) have played a significant role in cancer treatment. Combined with chemotherapy, they are becoming standard treatment for certain cancers. Despite these advances, however, there remains significant unmet need in cancer treatment. This unmet need, coupled with the commercial attractiveness of the oncology market, has led to pharma investing a significant portion of its R&D budget in the development of new approaches to antibodies for cancer. As biosimilar approaches to Ritxuan, Herceptin (trastuzumab) from Genentech, and Erbitux (cetuximab), from Bristol-Meyers Squibb, ImClone and Merck Serono are likely to become available in the next few years, new drugs will need to show more dramatic improvements in safety and efficacy if they are to become successful.

Companies are pursuing three types of enhancements to antibodies in search of improved product profiles. These enhancements include tuned, conjugated and bi-specifics.

Tuned antibodies are engineered to better engage the immune system’s natural killer cells to target and attack cancer cells. A recent example of a tuned antibody in development is GA101 from Glycart and Roche. GA101 is a humanized anti-CD20 monoclonal antibody engineered to increase target cell death. Phase 1 data presented at the American Society of Hematology meeting in 2008 showed that GA101 produced a 58% overall response rate in relapsed/refractory NHL patients.1

Conjugated antibodies contain cancer-killing agents, such as chemotherapy, toxins, or radioisotopes. Conjugated antibodies, however, have experienced limited success as a result of toxicity issues and complicated methods of administration. Examples of conjugated antibodies include the radioimmunotherapies Bexxar (Tositumomab) from GlaxoSmithKline and Zevalin (ibritumomab tiuxetan) from Spectrum Pharmaceuticals; and Wyeth’s drug-conjugated antibody Mylotarg (Gemtuzumab ozogamicin). More recent approaches in development appear to largely avoid these unwanted side-effects.

Bi-specific antibodies utilize the body’s own immune system, specifically T cells, to kill cancer cells. T cells are the immune system’s most potent killing cells due to the fact that they can proliferate and can kill targeted cells serially. The most advanced bi-specific approach is called bi-specific T cell engagers, or BiTE antibodies. BiTE antibodies have two arms, one that connects to a cancer cell, and the other that connects to a T cell. Once both connections have been made, the T cell releases its deadly toxins into the cancer cell.

The most clinically advanced BiTE antibody is blinatumomab from Micromet, Inc., Bethesda, Md.. Blinatumomab is currently in a Phase 1 trial in relapsed/refractory non-Hodgkin’s Lymphoma (NHL) and a Phase 2 study as consolidation therapy in acute lymphoblastic leukemia (ALL). Data from both trials were presented at the European Hematology Association meeting in June 2009.

Data from the Phase 1 NHL trial show that 11 out of 12 patients at the highest dosing cohort experienced a complete or partial response.

The patients included in the Phase 2 ALL clinical trial were in complete hematological remission following intense chemotherapy regimens, but retained a detectable level of ALL cancer cells in their bone marrow, a condition known as minimal residual disease (MRD). Various studies have confirmed that ALL patients with MRD following chemotherapy have a significantly worse prognosis than patients without MRD. At the time of the EHA meeting, 13 of 16 (or 81%) of evaluated patients have shown an MRD response, meeting the trial’s primary endpoint before the completion of the study.

In summary, antibody enhancement represents an approach to improving the clinical performance of these agents in an environment that will demand significant advances in efficacy to be commercially successful. The promise of these agents is evidenced by the early clinical data and the intense development and licensing activity seen in this space.

References
1. Gilles Andre Salles, MD, PhD et al, “A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease” abstract 234. ASH 2008.

About the Author
Mark Reisenauer is the Chief Commercial Officer and Senior Vice President of Micromet. He holds a B.A. degree in Political Science from the University of Wisconsin.




© 2007 Advantage Business Media


http://www.dddmag.com/article-Next-Generation-Antibody-Appro…

[VaJo]

Sieht ja mit der angekündigten KE zur Zeit gar nicht gut aus.

[VaJo]

https://chart.cortalconsors.is-teledata.com/module.chart?LAN…

Wo ist da die Unterstüzung? Bei 4,50?

Hohe MK und jetzt noch die KE. Scheint so als ob ich mir morgen meinen EK weit von unten anschauen darf

[VaJo]

[SLGramann]

Antwort auf Beitrag Nr.: 38.217.347 von VaJo am 20.10.09 20:59:12

von welcher KE redest Du?

[VaJo]

Antwort auf Beitrag Nr.: 38.217.728 von SLGramann am 20.10.09 21:39:33

Von der hier vom 16.10.2009
http://www.sec.gov/Archives/edgar/data/1131907/0001144204090…

[SLGramann]

Antwort auf Beitrag Nr.: 38.218.930 von VaJo am 21.10.09 07:50:31

Okay, interessant. Aber ich hab schon gedacht, ich hätte eine aktuelle KE verpasst. Das ist ja "nur" ein shelf-File.

[VaJo]

Antwort auf Beitrag Nr.: 38.231.420 von SLGramann am 22.10.09 14:25:00

Gut es steht nicht explizit KE darüber, aber das Ergebnis ist dasselbe. 150 Millionen sind eine Hausnummer und müssen erstmal verdaut werden, vor allem bei der Bewertung.

-> auf Übernahme hofft....

[quepos]

Moin,

nun bin ich wieder dabei seit heute (zum zweiten Mal) und hoffe, dass die Korrektur erstmal vorüber ist.

Bald gibt´s Q3-Zahlen und hoffentlich damit im Zusammenhang mal wieder ein paar Neuigkeiten!

Gruß q.

[mitleser3108]

zweimal news:

1) BBBiotech hat Micromet ins Portfolio genommen 2.3 Mio Aktien

http://www.bbbiotech.ch/fileadmin/user_upload/files/bbbiotec…

2) Vertrag mit Sanofi

http://www.reuters.com/article/rbssHealthcareNews/idUSLT1890…

[quepos]

Antwort auf Beitrag Nr.: 38.276.509 von mitleser3108 am 29.10.09 08:37:17

Moin,

mein erstes Posting von vorhin ist weg...,
aber egal: Wow!

Supernews, steigt auch schon ordentlich.
Ist wie eine "kleine" Novartis-Meldung für Morphosys, dann noch Fonds- bzw. BBBio-Einstieg. Sollte erstmal wieder bergauf laufen. Aber erinnern wir uns: Auch bei MOR wurde der 30%-Sprung nach Novartis-Deal komplett wieder konsolidiert...

hay que ver

q.

[mitleser3108]

http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher…

Another 'BiTE' as Micromet Inks Potential €320M Sanofi Alliance
By Jennifer Boggs, Assistant Managing Editor

With buzz growing about Micromet Inc.'s BiTE antibody blinatumomab (MT103) ahead of the upcoming American Society of Hematology meeting, the Bethesda, Md.-based firm scored an early stage deal with Sanofi-Aventis SA to develop another BiTE compound.

The Paris-based pharma will pay €8 million (US$11.9 million) up front, and Micromet agreed to take on the discovery, research and development of an antibody targeting an undisclosed antigen found on carcinoma cells through the end of Phase I trials.

After that, Sanofi will take over, and Micromet will be eligible for up to €312 million in milestones - €162 million for development and regulatory achievements and €150 million for performance-based sales milestones - plus royalties on product sales.

Piper Jaffray analyst Edward Tenthoff called it a "huge preclinical discovery deal," even larger than its January agreement with Berlin-based Bayer Schering AG, which paid €4.5 million for a one-year option to a preclinical BiTE antibody for cancer.

Under the terms of that collaboration, Bayer has until Jan. 5, 2010, to license an antibody, at which time it will pay an option fee and put Micromet in the path of potential milestone payments of up to €290 million. (See BioWorld Today, Jan. 13, 2009.)

"We decided to do a few select early stage deals," said Christian Itin, Micromet CEO. The firm might consider one more partnership in the next year or so, but the goal is not to spread itself too thin.
When it comes to external R&D deals, "we want to stay engaged," he told BioWorld Today. "We do all of the early work and a substantial portion of the early clinical work."

Since the bulk of milestones come on the back end of the deals, the company and its investors are betting heavily on the success of BiTE technology. But there's good reason.

BiTE, which stands for Bispecific T-Cell Engager, is an approach that has continued to generate news since last year, when a paper in Science highlighted interim Phase I data showing that CD19-targeting blinatumomab achieved a 100 percent response rate as a single agent in non-Hodgkin's lymphoma. (See BioWorld Today, Aug. 15, 2008.)

Antibodies generated by BiTE are designed to work in a seek-and-destroy pattern, first by recruiting T cells and then directing them specifically to attack tumor cells. "It really turns on the T-cell compartment against cancer," Itin said, "and we've seen a very unusual level of antitumor response so far."

Blinatumomab also made a big splash at this summer's European Society of Hematology meeting, with interim Phase II showing impressive response rates in patients with acute lymphoblastic leukemia, and analysts eagerly await further data from that trial at the December ASH meeting in New Orleans. (See BioWorld Today, June 9, 2009.)

"We hope to give full view on that trial, as well as an additional NHL trial," Itin said. "That's the key focus for us."

Micromet currently holds all rights to blinatumomab. Former collaborator Gaithersburg, Md.-based MedImmune Inc. handed back rights earlier this year, a move analysts said likely resulted from a portfolio review by MedImmune acquirer AstraZeneca plc, though MedImmune was granted a one-time option to regain North American rights under predefined terms.

But Itin said the company is in no hurry to partner, looking ahead to ASH and planning for a pivotal trial in ALL.

"So partnering is really not at the forefront at this time," he added.

Elsewhere in its pipeline, Micromet is developing MT201, a recombinant human monoclonal antibody designed to bind to epithelial cell adhesion molecules, which is in Phase II testing in colorectal cancer and partnered with Merck Serono, a division of Darmstadt, Germany-based Merck KGaA.

It also has MT203, an antibody targeted to granulocyte macrophage colony-stimulating factor, in Phase I testing under a $161 million inflammation deal with Roskilde, Denmark-based Nycomed A/S.

The company ended the second quarter with about $49.2 million in the bank, though it added net proceeds of $75 million in a public offering closed in early August. (See BioWorld Today, July 31, 2009.)

Shares of Micromet (NASDAQ:MITI) jumped 12.8 percent, or 63 cents, to close Thursday at $5.55.



Published October 30, 2009

[VaJo]

Was jemand etwas über die finanzielle Vereinbarung?

Micromet Buys Out MedImmune's Remaining Rights to Blinatumomab
Globe Newswire
November 05, 2009: 06:30 AM ET

BETHESDA, Md., Nov. 5, 2009 (GLOBE NEWSWIRE) -- Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has signed an agreement with MedImmune, LLC to buy out MedImmune's rights to blinatumomab in North America, and to terminate the collaboration agreement signed in 2003 under which MedImmune had been granted the right to develop and commercialize blinatumomab in North America. As a result of this transaction, Micromet now controls global rights to develop and commercialize blinatumomab.

In March 2009, MedImmune returned the North American rights to develop and commercialize blinatumumab to Micromet, but retained an option to reacquire the right to commercialize blinatumomab in North America. Under the terms of the termination agreement, Micromet has now regained MedImmune's remaining rights relating to blinatumomab as well as any other BiTE antibodies binding to antigens relevant for hematological cancers that had been reserved for MedImmune under the terminated agreement. Micromet will make upfront, milestone, and royalty payments to MedImmune related to the development and North American net sales of blinatumomab.

"The advancement of blinatumomab in the clinic is the top priority for Micromet," said Micromet CEO Christian Itin. "With complete control over global development and commercialization of blinatumomab, Micromet can develop an integrated clinical and regulatory strategy across multiple commercial territories, starting with the first pivotal study that we expect to initiate in 2010."

Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out and destroy lymphoma and leukemia cells. At the recent meeting of the European Hematological Association (EHA), Micromet announced that blinatumomab had achieved its primary endpoint in an ongoing phase 2 clinical trial in ALL patients. Micromet intends to initiate a pivotal trial of blinatumomab in ALL patients next year.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include sanofi-aventis, Bayer Schering Pharma, Nycomed, Merck Serono, and MedImmune.

[SLGramann]

Antwort auf Beitrag Nr.: 38.326.101 von VaJo am 05.11.09 12:59:42

Nein, noch nicht. Da wird aber sicher bald was konkreteres durchsickern.

Jedenfalls ist es grundsätzlich sehr positiv, dass MITI bei Blinatumomab wieder frei ist!

[VaJo]

Antwort auf Beitrag Nr.: 38.326.224 von SLGramann am 05.11.09 13:15:41

Ja das ist richtig. Es kommt aber drauf an wie hoch der Preis ist. Das kann uns nochmal die Stimmung verhageln.

[VaJo]

Antwort auf Beitrag Nr.: 38.326.224 von SLGramann am 05.11.09 13:15:41

Da ergibt die $150M KE Sinn. Das ganze Geld werden sie wohl nicht brauchen (Hoffe ich mal )

[mitleser3108]

http://www.fiercebiotech.com/special-reports/radar-novembers…

Micromet (MITI) Rated buy

Micromet's platform technology has recently been validated with blinatumomab in two hematologic oncology treatment settings, including advanced non-Hodgkin's lymphoma and as means of clearing minimal residual disease in adult acute lymphoblastic leukemia patients following front-line therapy. Data from a Phase 2 trial investigating blinatumomab in the latter setting is most encouraging, in our view, with important response duration data from this trial expected at ASH in early December. After recently regaining 100% of worldwide rights to blinatumomab from Medimmune, MITI intends to moves this agent into Phase 3 registration trials next year. - George Farmer
Momenta Pharmaceuticals (MNTA) Rated buy

We expect that M-Enoxaparin, Momenta and partner Sandoz's generic version of Lovenox, will be approved and launched around the beginning of 2010. We think that all regulatory safety and supply quality control concerns have been addressed, and that the drug will see rapid adoption by hospital and cardiac care centers. We think MNTA will receive meaningful royalties from M-Enoxaparin sales over 2010 into 2011 as sales and supply ramps.

Momenta and Sandoz are also developing M356, a generic version of the multiple sclerosis drug Copaxone, and have filed the first complete Paragraph IV ANDA thereby securing 180 generic exclusivity and engendering a patent infringement lawsuit from TEVA. We think that the upcoming Markman claims construction hearing (likely in December) that is part of this suit will underscore Sandoz's/MNTA strong arguments regarding the lack of validity of the TEVA Copaxone patent estate. We believe there is good chance that this hearing may provide positive clarity on M356's legal position. We also believe that MNTA's novel Phase 2 anticoagulant M118 could be a promising anticoagulant with broad use across almost the entire ACS treatment algorithm. M118 has been engineered to have to strong Xa/IIa mediated anticoagulation, monitorability and reversability as heparin, with the high bioavailability and improved safety of Lovenox. New Phase 2 data from the EMINENCE trial showed statistical non-inferiority to heparin and very good safety. As a result the company may strike a rich M118 partnership in 2010 that could be a key catalyst for the shares. - Ritu Baral

[MasaRatti]

[VaJo]

Kann jemand was zu dem Deal schreiben? Umfasst ja fast 500 Mio Dollar

[VaJo]

Antwort auf Beitrag Nr.: 38.485.313 von VaJo am 01.12.09 12:26:49

Hmm Phase1,
wie lange dürfte die Enwicklung dauern?
Kurs über 6 EUR? Oder jetzt rausgehen ?

[VaJo]

Antwort auf Beitrag Nr.: 38.485.332 von VaJo am 01.12.09 12:29:14

Ist bald Weihnachten

[Ville7]

Micromet Announces Exercise Of Option By Bayer Schering Pharma To Develop Solid Tumor BiTE Antibody - Quick Facts

(RTTNews) - Micromet, Inc. (MITI) announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors.

As per the agreement, Bayer Schering Pharma had an option until January 5, 2010 to license a specific BiTE antibody targeting an undisclosed target. The option exercise triggers a formal collaboration between Micromet and Bayer Schering Pharma on the development of the BiTE antibody. Micromet will be primarily responsible for the preclinical development of the BiTE antibody, and will collaborate with Bayer through the completion of phase 1 clinical trials, at which point Bayer Schering Pharma will assume full control of the further development and commercialization of the BiTE antibody.

Micromet would receive an option exercise fee of EUR 5 million, and is eligible for further milestone payments of up to EUR 285 million in total and up to double digit royalties on net sales of the BiTE antibody.

[VaJo]

Antwort auf Beitrag Nr.: 38.486.145 von Ville7 am 01.12.09 14:16:28

Ich bin heute nach dem Anstieg erstmal mit dem Größtenteil raus.
So ganz schlau werde ich aus der Meldung nicht, den erstmal ändert sich bei MITI finanziell ja nichts. Allerdings wird sie für eine Übernahme immer interessanter.

[Ville7]

Antwort auf Beitrag Nr.: 38.486.165 von VaJo am 01.12.09 14:19:07

Sicher nicht dumm. Kurz nach ASH ist meist die Luft raus. Aber es kann auch anders kommen...

[VaJo]

Antwort auf Beitrag Nr.: 38.486.211 von Ville7 am 01.12.09 14:23:28

Wenn meine Steuerfrei gewesen wären wäre ich vermutlich nicht raus.

[SLGramann]

Antwort auf Beitrag Nr.: 38.486.145 von Ville7 am 01.12.09 14:16:28

Ich stell mal noch die "long facts" Version rein.

(Ich finde es beeindruckend, dass für ein Programm, das noch nicht mal P I ist, double-digit-royalties ausgehandelt wurden. Micromet bekommt deutlich bessere Konditionen als andere AK-Entwickler. Mal sehen, ob all die Hoffnungen auf lange Sicht gerechtfertigt sind.)



BETHESDA, Md., Dec. 1 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors.

Under the terms of the agreement, Bayer Schering Pharma had an option until January 5, 2010 to license a specific BiTE antibody targeting an undisclosed target. The option exercise triggers a formal collaboration between Micromet and Bayer Schering Pharma on the development of the BiTE antibody. Micromet will be primarily responsible for the preclinical development of the BiTE antibody, and will collaborate with Bayer through the completion of phase 1 clinical trials, at which point Bayer Schering Pharma will assume full control of the further development and commercialization of the BiTE antibody. Micromet will receive an option exercise fee of Euro 5 million (approx. $7.5 million), and is eligible for further milestone payments of up to Euro 285 million (approx. $426 million) in total and up to double digit royalties on net sales of the BiTE antibody. In addition, Micromet will be reimbursed for its R&D expenses.

"BiTE antibodies represent a promising approach to cancer therapy," said Dr. Karl Ziegelbauer, Head Therapeutic Research Oncology of Bayer Schering Pharma AG. "We are pleased with the progress of the program since the signing of the agreement in January of this year. We are looking forward to developing a new treatment for patients with solid tumors and to further advance novel therapeutic options in our oncology portfolio."

Jens Hennecke, Micromet's Senior Vice President for Business Development added: "Our research and preclinical development teams have done an excellent job in advancing the program since January of this year. Bayer Schering Pharma's early option exercise is a recognition of Micromet's development capabilities and confirms the promise of our BiTE antibody platform."

[Barneby]

Hallo,

ich suche noch einen interessanten und natürlich aussichtsreichen Bio-Tech-Wert.

Ihr seit ja mit Micromet schon länger befaßt und ich lese , daß auch teilweise schon ausgestiegen wird.

Trotzdem meine Fragen:

Meint Ihr , daß sich ein Einstieg zu den momentanen Kursen noch lohnt ?

Könnt Ihr was zur Umsatzentwicklung und Verschuldung sagen ?

Vielen Dank schon mal vorab für eventuelle Bemühungen !!!!

[SLGramann]

NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of a poster(1) with new data from its ongoing phase 1 clinical trial of its product candidate blinatumomab in patients with non-Hodgkin's lymphoma (NHL) at the 51ST Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana. Blinatumomab is a CD19-specific, T cell-engaging BiTE® antibody designed to direct a patient's own T cells against cancer cells inducing a self-destruction process in cancer cells.

The new data presented at ASH show that 100 percent of evaluable patients (12 of 12 patients) with relapsed/refractory NHL, who were treated with blinatumomab at a dose level of 60 microgram/squaremeter per day, had an objective partial or complete response after their first 4-8 weeks of treatment. The responses were measured based on Cheson/IWG criteria and were confirmed by independent review. One patient at the 60-microgram dose level was not evaluable because of an adverse event that resulted in the discontinuation of treatment after two days. The longest duration of a response without re-treatment is currently 20 months. The response in 6 of the 12 evaluable patients is ongoing. The 60-microgram dose level has been selected for further clinical studies in patients with B-cell lymphoma.

At the 60-microgram dose level, the most common adverse events of any grade and irrespective of drug relationship were pyrexia (100%), lymphopenia (77%), leukopenia (69%), C-reactive protein increase (62%), and headache (69%) Most adverse events occurred early during treatment and improved or resolved during treatment. The most common grade 3 and 4 adverse event was lymphopenia (77%).

At active dose levels tested in this phase 1 clinical trial, permanent treatment discontinuation due to adverse events resulted mainly from fully reversible and transient neurological events during the first few days of treatment. A low ratio of B to T cells in peripheral blood was identified as a predictive biomarker for neurological events in patients with NHL. Based on these findings, and the possibility of adaptation of T cells by gradually increasing doses of blinatumomab, Micromet has developed a biomarker-guided dosing schedule designed to decrease the early neurological events and to provide all patients with the opportunity to reach the dose of 60 micrograms/squaremeter per day.

"We are very excited about the high response rate seen in patients with NHL treated at the 60-microgram dose level and are now planning larger studies to confirm these encouraging results," commented Dr. Jan Fagerberg, Micromet's Chief Medical Officer. "We expect that the biomarker-guided dosing schedule will accelerate the clinical development of blinatumomab in all relevant B-cell lymphoma indications."

(1) Nagorsen, D. et al. (2009) Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin's Lymphoma Patients Treated with 60 Microgram/Squaremeter per Day of BiTE Antibody Blinatumomab. ASH Annual Meeting, abstract no. 2723.


----------------------

Tja, klingt für mich eigentlich überragend, was die Wirksamkeit angeht. Allerdings scheinen die Nebenwirkungen problematisch zu sein.
Vielleicht kann ja jemand mit medizinischem Sachverstand hierzu eine Meinung abgeben?

[SLGramann]

Und noch einer:


NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL). The data were presented in an oral presentation(1) at the 51st Annual Meeting of the American Society of Hematology (ASH) and were selected by the Society for inclusion in its "Best of ASH" session. Blinatumomab is a CD19-specific, T cell-engaging BiTE antibody designed to direct a patient's own T cells against cancer cells inducing a self-destruction process in cancer cells.

A total of 21 patients were treated in a phase 2 clinical trial performed in collaboration with the German Multicenter Study Group on Adult Lymphoblastic Leukemia (GMALL). After having received extensive chemotherapy, all patients had ALL malignant cells persisting in their bone marrow, a disease state referred to as minimal residual disease (MRD). The primary endpoint of the clinical trial was the elimination of these cancer cells to an undetectable level in at least 22% of patients. 80% of the evaluable patients (16 of 20 patients) achieved the primary endpoint, all of them already during the first treatment cycle. The responses appear to be durable, with patients free of relapse for currently up to 15 months.

Overall, blinatumomab was well tolerated. The most common adverse events included lymphopenia, leucopenia, pyrexia and hypoimmunoglobulinemia. One patient had to discontinue treatment due to a fully reversible neurological adverse event, and was therefore not evaluable for response assessment.

"Today, patients with MRD-positive ALL after first line therapy have a very high likelihood of relapse," commented Professor D. Hoelzer, chairman of the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL). "These data suggest that blinatumomab is very active and has the potential to be an effective consolidation therapy."

"The data from this completed phase 2 study confirm the high response rate reported earlier this year from the ongoing study," commented Dr. Jan Fagerberg, Micromet's Chief Medical Officer. "We expect that the positive risk/benefit profile of blinatumomab in ALL will pave the way for a pivotal trial and a fast track to market in this indication."

(1) Topp, M. et al. (2009). Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL). ASH Annual Meeting, abstract no. 840

[SLGramann]

Antwort auf Beitrag Nr.: 38.531.154 von SLGramann am 08.12.09 20:14:25

In dem Zusammenhang eine Erinnerung an Hammers Text zu ALL:


Fast route to market

Although the NHL study represents a much larger commercial opportunity, the ALL trial will garner most of the attention. As I explained in my previous article, the ALL study evaluates blinatumomab’s effect on patients who have undergone chemotherapy but still have disease remnants in their bone marrow (minimal residual disease or MRD). These patients usually have very poor prognosis since they are destined to relapse within less than a year. The only available treatment option for some of these patients is stem cell transplant, a highly aggressive and toxic procedure which is associated with a 20-30% mortality rate. Micromet decided to enroll only patients who cannot tolerate or are unwilling to undergo stem cell transplant, as these patients have no approved treatment options.

The high medical need combined with the low prevalence of ALL make this clinical program a fast route to market, with a possible approval already in 2012. More importantly, the study could serve as the ultimate proof of concept for blinatumomab’s ability to deal with one of the central challenges in cancer, post-treatment residual disease that eventually leads to disease relapse.

Micromet’s strategy is similar to that of other biotech companies, such as Exelixis (EXEL) and Arqule (ARQL). All three have a promising compound with a very large potential market, but they decided to pursue approval for niche indications that represent the fastest and safest route to approval. Micromet’s blinatumomab targets CD19, a protein highly expressed on the majority of blood cancers, but decided to initially go after a distinct subgroup of ALL. Exelixis’ XL184 hits several targets that are relevant in most solid tumors, yet it decided to seek approval for a rare subset of thyroid cancer. Arqule’s lead compound targets c-Met, a protein believed to have a role in a plethora of solid tumors, but it decided to start with a family of rare tumors called MiT. Based on clinical data the companies have presented, their chances of obtaining an FDA approval are high.


Reasons for optimism

Data from the ALL trial could shed light on two basic questions:

1) Can blinatumomab effectively convert MRD positive patients into an MRD negative status?

2) Can the MRD conversion be translated into real clinical benefit in the form of longer remission and survival?

For the first question, the answer is a resounding “yes”. Last year, Micromet presented preliminary data on just four patients, three of which turned from MRD positive to MRD negative. A conversion rate of 75% using such a stringent parameter is impressive, but it is very hard to conclude anything from such a small sample size. Next month at EHA, the company will present results for ~17 patients, still a small number but a much more reliable one. The exact conversion rate for these patients will be announced next month, but it will probably be very high, according to a statement by one of the speakers who revealed that “almost all” of the patients responded to blinatumomab.

But response is not the ultimate parameter for these patients, who typically experience a relapse within 6 months following initial therapy. Therefore, the real issue is whether blinatumomab can keep patients in remission for a longer period of time. The majority of patients were recruited to the study only in the past six months, following the previous data at ASH, so the duration of responses will probably be available for a limited amount of patients. The company provided anecdotal evidence for blinatumomab’s effect in two patients, who were still in remission for 9 and 10 months, respectively. It is important to understand that in most cases, there is an average lag of several months between a molecular relapse (turning from MRD negative to MRD positive) and a clinical relapse, where a large amount of cancer cells is found in the bone marrow. Therefore, the two patients are looking at a time to relapse of over a year at minimum. This is highly encouraging, considering the fact that most patients in this setting experience disease relapse within 6 months.

On top of the anecdotal data, there is a good reason to believe that MRD conversion will be translated into longer remission and overall survival, perhaps even a cure. Many studies have shown that patients who are MRD positive following initial treatment have a very high risk of relapse as opposed to MRD negative patients who have a high likelihood of long term remission. MRD is not just another surrogate that can predict patient prognosis, it is the presence of the disease itself. As a bone marrow disease, ALL originates in the bone marrow and spreads to the blood and other organs as the disease progresses. Therefore, if blinatumomab manages to purge the bone marrow to the point where even the most sensitive method cannot identify cancer cells, then curing these otherwise terminal patients is not out of the question.

[Ahnung?]

Nanu ???

Was geht denn heute in dem Wert ab - fast 10 Prozent Kurszuwachs aktuell in USA ???

[SLGramann]

Antwort auf Beitrag Nr.: 38.711.789 von Ahnung? am 11.01.10 20:04:33

Vielleicht nur Zockerei...

In Bezug auf Blinatumomab stehen sicher demnächst zwei wichtige Entscheidungen an:

1.) Akzeptiert die FDA die "MRD conversion" als Kriterium für einen pivotal trial?

2.) Kann neu verpartnert werden?

Dabei könnte 2.) vielleicht von 1.) abhängen.

Vielleicht spekulieren da gerade einige auf eine positive Beantwortung dieser Fragen. Dass da vorher was durchsickert ist auch nicht auszuschließen, würde ich aber zunächst nicht annehmen wollen. Biotechs sind generell volatil.

[MasaRatti]

Micromet to Present at the 28th Annual J.P. Morgan Healthcare Conference



BETHESDA, Md., Jan. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that it will participate in the 28th Annual J.P. Morgan Healthcare Conference, to be held January 11th – 14th in San Francisco.  Christian Itin, Ph.D., Micromet's President and CEO, will present a 30 minute corporate overview on Thursday, January 14th at 12:30 PM PST.

The presentation will be webcast live and may be accessed by visiting the Micromet website at www.micromet-inc.com. A replay of the webcast will be available for 90 days.

[SLGramann]

eine neue Studie zu Micromet als pdf (mit Verkaufsempfehlung, die aber schlecht begründet ist imho):


http://www.zacks.com/ZER/zer_get_pdf.php?r=Z566702&t=MITI&id…

[quepos]

Moin,

mal wieder eine Analystenheraufstufung (Quelle: Streetinsider.com).
Immerhin etwas erfreuliches heute.

MITI vorbörslich im Plus.

Ziel 12$ klingt ja auch ganz nett!

Gruß q.

-----------------

Roth Capital Upgrades Micromet (MITI) to Buy

More News related to MITI
Micromet to Host Annual Research & Development Day on February 10, 2010
Micromet to Present at the 12th Annual BIO CEO & Investor Conference
Roth Capital Upgrades Micromet (MITI) to Buy
Needham & Co Initiates Coverage on Micromet (MITI) with a Buy
Micromet to Present at the 28th Annual J.P. Morgan Healthcare Conference
More News related to MITI
More News related to Upgrades
Morgan Stanley Upgrades Lan Airlines (LFL) to Overweight
Stifel Nicolaus Upgrades Helmerich & Payne (HP) to Buy
Piper Jaffray Upgrades Global Payments (GPN) to Overweight; Recent Pullback Creates Buying Opportunity
JPMorgan Upgrades LCC to Overweight, Downgrades DAL, CAL, ALK to Neutral
Thomas Weisel Upgrades Quest Software (QSFT) to Overweight
More News related to Upgrades
February 4, 2010 7:41 AM EST

Roth Capital upgrades Micromet (Nasdaq: MITI) from Hold to Buy. Price target increased to $12.

To see all the upgrades/downgrades on shares of MITI, visit our Analyst Ratings page.

Micromet, Inc. (Micromet) is a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases.

[mitleser3108]

bbbiotech hat von ende september 2009 auf ende dezember 2009 noch mal nachgelegt,
von 2.329.156 Stück
auf 2.983.725 Stück

[quepos]

Och nööö....


Schon wieder...


nachbörslich natürlich abgesoffen...



-----------------------
Micromet Announces Proposed Public Offering of Common Stock
Buzz up! 0 Print
Companies:Micromet, Inc. Related Quotes
Symbol Price Change
MITI 8.09 +0.16


{"s" : "miti","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Micromet, Inc. On Tuesday March 9, 2010, 4:01 pm
BETHESDA, Md., March 9 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq:MITI - News) announced today that it is offering to sell, subject to market and other conditions, 10 million shares of common stock in an underwritten public offering. In connection with the offering, the Company expects to grant the underwriters a 30-day option to purchase an additional 1.5 million shares of common stock from the Company. All of the shares in the offering are being offered by Micromet.

Goldman, Sachs & Co. is acting as sole book-running manager for this offering. Information about the offering will be available in a preliminary prospectus supplement to be filed with the Securities and Exchange Commission. Copies of the preliminary prospectus supplement and prospectus, when available, may be obtained from Goldman, Sachs & Co., Attn: Prospectus Department, 85 Broad Street, New York, New York 10004, Telephone [phone], or by email at [e-mail]

The shares will be offered and sold pursuant to a shelf registration statement filed with the Securities and Exchange Commission on October 16, 2009 and declared effective on November 2, 2009.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy the Company's common stock, nor shall there be any sale of the common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective shelf registration statement.

About Micromet

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.

Safe Harbor Statement

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, statements regarding the proposed offering of our securities, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include uncertainties regarding the market conditions and investor interest in the offering and other risks identified in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the year ended December 31, 2009. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

[quepos]

Moin,

werde nach reiflicher Überlegung wohl doch erstmal dabei bleiben. Kann zwar sein, dass MITI nun erstmal wieder 5-10% nachgibt, muss aber nicht sein.


1. MITI muss sich wie alle Bios ohne laufende Einnahmen finanzieren, diese KE von ca. 16% erfolgt immerhin zu recht guten Kursen.
2. Nach der letzten KE stieg der Kurs sogar in der Folge an, da man die Möglichkeit überhaupt Gelder locker zu machen positiv sah.
3. Ausstieg und Wiedereinstieg in die Aktie hierzulande schwierig bzw. nur mit spread von mehreren % möglich (selbst meine paar sind für den Handel hier schon viel - geht nur über MM).

Gruß q.

[SLGramann]

Antwort auf Beitrag Nr.: 39.101.996 von quepos am 10.03.10 11:14:58

Ich würde auch "nur" wegen dieser erneuten KE nicht verkaufen. Schon gar nicht hier in Deutschland, zumal man dafür noch den Bestand "umlagern" müsste, was durchaus einiges an Gebühren kosten kann.

Micromet ist allerdings wirklich sehr großzügig, wenn es um KEs geht. Es wäre schön, wenn neben den Nachrichten, wie man den Eigentümern das Geld aus der Tasche zieht, auch mal die Nachricht käme, dass sie Blinatumomab neu verpartnern konnten.

[quepos]

Hoppla!

Mit Verzögerung dann doch schlimmer als gedacht für einen Tag...
Hätten Verkauf und Rückkauf sich wohl doch gelohnt, hätte ich dem ersten Impuls diesmal doch folgen sollen, zumal langes Halten ja nun nicht mehr durch Steuerfreiheit belohnt wird.

Gab doch für viele auch Gewinne mitzunehmen.

Mal seh´n, wie der Ausgabepreis der neuen Aktien wird.

Gruß q.

[SLGramann]

Für 7 Dollar gehen die neuen Aktien über den Tisch. Ich frage mich wirklich, was das alles soll. Will (oder muss?!) man die P IIIs für Blina allein stemmen? Da reichen dann 65 Mio. aber auch nicht weit imho.
Es wäre sehr viel besser, wenn man endlich einen starken Partner ins Boot bekommen würde.


BETHESDA, Md., March 11 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) announced today the pricing of an underwritten public offering of 10 million shares of common stock at a public offering price of $7.00 per share. The Company has granted the underwriters a 30-day option to purchase an additional 1.5 million shares of common stock from the Company. All of the shares in the offering are being sold by Micromet. The closing of the offering is expected to take place on March 17, 2010, subject to the satisfaction of customary closing conditions.

The Company expects to receive net proceeds from the offering, after underwriting discount and offering expenses payable by the Company, of approximately $65.5 million (prior to any exercise of the Underwriters' option to purchase additional shares of common stock). The Company plans to use the net proceeds from the financing primarily for general corporate purposes, which may include research and development, capital expenditures, working capital and general and administrative expenses.

[mitleser3108]

http://www.transkript.de/wirtschaft/wirtschaftsartikel/?tx_t…

Meldung des Tages: Micromet holt sich erneut 70 Mio. US-$ am Kapitalmarkt

12.03.10 Es wird zur Gewohnheit. Wie schon 2009 hat sich der deutsch-amerikanische Antikörperentwickler Micromet 70 Mio. US-$ am Kapitalmarkt besorgt. 2009 mussten dafür wegen eines schlechteren Kurses noch 14 Millionen frische Aktien verkauft werden (mehr...), diesmal reichten 10 Millionen zum Stückpreis von 7 US-$ aus.
Illustre Namen stehen hinter der Anschlussfinanzierung: Unterschrieben haben Goldman Sachs, Piper Jaffray, RBC Capital Markets, Needham, Roth Capital Partners, Ladenburg Thalmann und die Maxim Group.
Micromet hatte offenbar keine Probleme, Geldgeber zu finden. Am 9. März ging die Ankündigung erst raus, am 11. März war das Volumen schon ausgeschöpft. Der Grund für die große Attraktivität von Micromet sind die hauseigenen Bite-Antikörper. Den modifizierten Antikörpern wird von vielen Beobachtern eine große Zukunft vorhergesagt. Im vergangenen Jahr hat sich der Kurs des an der amerikanischen Technologiebörse Nasdaq gelisteten Unternehmens deshalb in etwa verdreifacht.
Mit dem Kapital wird Micromet unter anderem die Entwicklung des Leitprodukts MT103 vorantreiben. Blinatumomab soll gegen eine spezielle Form der Leukämie (ALL) sowie Non-Hodgkin-Lymphome eingesetzt werden. Mitte 2010 sollen die ersten Patienten für zulassungsrelevante Tests für den Einsatz gegen ALL rekrutiert werden, sagte CEO Christian Itin gegenüber Investoren am 10. Februar 2010.
MT103 zielt auf das CD19-Antigen und dient als Schalter zwischen der Tumorzelle und T-Zellen. Deren Aktivierung führt dazu, dass sich das patienteneigene Immunsystem gegen die malignen Zellen richtet und diese vernichtet. Im Gegensatz zu herkömmlichen Antikörpern – den passiven Immuntherapien – löst der sogenannte Bite-Antikörper eine aktive Reaktion des Immunsystems aus, die den neuen Therapieansatz attraktiv macht. Die Micromet Inc. ist ein im Kern deutsches Biotech-Unternehmen, das sämtliche Forschungsaktivitäten vom Standort München ausführt. Über eine Fusion mit der börsennotierten CancerVax Inc. und eine anschließende Umbenennung gelangten die Münchener Anfang 2006 an die Nasdaq und verlegten den juristischen Sitz der Firma in die USA.

[SLGramann]

So, jetzt ist das Volumen ausgeschöpft:


Micromet Closes $80.5 Million Public Offering of Common Stock

BETHESDA, Md., March 17 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 1.5 million shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 per share.

The Company received net proceeds from the offering of approximately $75.3 million, after deducting the underwriting discount and estimated offering expenses. The Company plans to use the net proceeds from the financing primarily for general corporate purposes, which may include research and development, capital expenditures, working capital and general and administrative expenses.

[MasaRatti]

Micromet Announces Presentations on BiTE Antibody Programs at AACR Annual Meeting


BETHESDA, Md., March 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that 11 presentations will be made by the Company and its collaborators at the American Association for Cancer Research (AACR) 101st Annual Meeting to be held April 17-21, 2010 in Washington, DC.

[SLGramann]

Also, die KE hat der Markt locker geschluckt...

[mitleser3108]

http://caps.fool.com/Blogs/ViewPost.aspx?bpid=377170&t=01001…

guter Blog, hier scheint jemand wirklich Kenntnis von der Materie zu haben (gut, von biopharmazeutischer Produktion weniger, aber der Rest is grosse Klasse)

If only Micro-met a little more sense, it would help me retire
Report April 14, 2010 RELATED TICKERS: MITI

I have been a long standing fan of MITI. Frankly they have what I consider the most exciting antibody related technology at a development stage anywhere. Move over RNAi with your ambiguous activity (Can anyone say TLR activation, instead of real efficacy?) While it remains to be seen (probably not till end of this year or even 2011 with how slow they are going) whether the technology will work in solid tumours, there is still a vast potential to this stock.

Currently they are trading at a hot-technology premium versus the actual market potential of their lead compound MT103. But with good reason, as I believe they are a key take-over candidate. The one thing that drives me nuts is how slow and often clueless the company seems to be about moving the clinical program forward. For full disclosure, I own a good bit of the stock at an entry point of ~$3.50, sold to cover my entry, and am now holding out for $10 or so on the rest.

The pros to the technology... I encourage you to look on your own for the real basics of the technology. The key great aspects are a) manufacturing. These BiTEs can be produced easily, are stable at room temp, do not require fermentation or CHO cells. While they will not enjoy the generic protection inherent in mABs, they will enjoy a COGs that is a tiny fraction of their overly weighty parents. b) cross-applicability. This technology allows for the reverse engineering of virtually any antibody target. So as all the other biotech companies spend billions finding a target and optimizing a binding domain, MITI can simply mimic the domain and produce a better product for the target, as soon as any IP on the domain clears away they can move in. c) T-Cell recruitment. Essentially this apprach has all the pros of the cancer vaccines, but it actually seems to work well. d) look at the NHL data. While a small number of patients, nothing else even comes close.

The cons to the technology are certainly worth laying out as well. a) We have no idea if it will work in solid tumors. The liquid tumor data is unprecedanted, but the intra-tumor environment is very different, and whether there can be effective penetration and proliferation of BiTE activated T-Cells within this environment is yet to be convincingly shown. We won't know until MT-110 reaches doses high enough to show some CRs. If it doesn't work in solid tumors, the potential of the platform is pretty much limited to the blood cancers and possibly some autoimmune disorders. b) Seizures. Frankly the product causes signficiant CNS effects, including seizures, at high enough doses. Whether this is due to immune system activation in the brain, or just a response to the significant fevers the therapy causes, I don't know. It kills me the company won't wake up and start implementing significant titration and dexamethasone co-administration at therapy initation to counteract these fevers. I refer to my lack of sense implication in the post's title.

The Company's commercial / regulatory approach leaves even more to be desired... They refuse to admit that a continuous IV is ridiculous. This will never be more than a niche product as long as you have to carry around a fanny pack IV pump. They need to aggressively pursue a long acting injection. The failure to do so, and this tilting at windmills run after ALL (instead of NHL where MT103 belongs) is why AZ dumped the collaboration. Management is too tied up with the German regulatory authority and university culture to realize their endpoint will almost certainly be rejected by the FDA in favor of survival, leaving MITI years away from pivotal data in a tiny indication, with a bad means of administration. Furthermore, the orphan approach to pricing which they use to justify the ALL target indication is insane in light of advantage (a) I list above. Why pretend to be an antibody, when you should be proving how much better you are?

My investment thesis is that once the value is established as very high, or just a bit higher than now, (depending on solid tumor efficacy) a big pharma will step up and take over MITI. Then we can expect the technology to have the funding and hopefully common clinical and commercial sense to really shine. I predict someday BiTEs will have a major positive impact on human health, I just hope it has the same on my pocketbook while getting there.

[SLGramann]

Micromet Highlights Breadth and Potency of BiTE Antibody Platform at AACR Annual Meeting

-- Data suggest that majority of oncology indications addressable through BiTE antibody approach --

BETHESDA, Md., April 19 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that results from studies highlighting pre-clinical advances with its proprietary BiTE antibody technology were presented at the American Association for Cancer Research (AACR) Annual Meeting in Washington, DC.

The Company and its collaborators reported pre-clinical data characterizing new BiTE antibodies targeting 11 tumor-associated antigens, including CEA, EGFR, IGFR-1, cMet and FAP-alpha. The data demonstrate that BiTE antibodies can be generated to target a wide range of tumor antigens of highly different function, size and molecular composition, illustrating the wide applicability of the BiTE antibody technology for the treatment of diverse cancer indications.
"Data presented at AACR this year demonstrates the versatility of the BiTE antibody platform," said Patrick Baeuerle, Ph.D., Micromet's Senior Vice President, Chief Scientific Officer. "The breadth and potency of product candidates developed utilizing our next-generation technology give us confidence that BiTE antibodies have the potential to significantly impact the way cancer is treated."

Researchers will present additional preclinical data on programs utilizing the Company's BiTE technology during the course of the meeting.

Abstracts can be accessed through the AACR website, www.aacr.org. All posters will be accessible from Micromet's website at www.micromet-inc.com after they are presented.

[mitleser3108]

http://seekingalpha.com/article/203145-micromet-inc-q1-2010-…

besonderst interresant hier finde ich die Einzelheiten des BI Deals:

- nahezu alle Kosten von BI bezahlt, aber:
- MITI kann in US (auch) selbst verkaufen, und
- für die Verkäufe von BI in US gibts profit split (50%?)

spricht für:
1) gute Verhandlungsposition
2) Ausrichtung auf Profitabilität/Produktfirma

[SLGramann]

Blina scheint wirklich auf einem guten Weg zu sein!


Micromet's Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin's Lymphoma

- Durable responses ranging up to 30 months observed -

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL). A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing. Blinatumomab is the first in a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

The findings were presented on June 12, 2010 in an oral presentation (abstract # 0559) at the 15th Annual Congress of the European Hematology Association (EHA) in Barcelona, Spain.

"Blinatumomab continues to demonstrate a long duration of response in heavily pre-treated non-Hodgkin's lymphoma patients," said Professor Ralph Bargou, Division of Hematology and Oncology, Department of Internal Medicine II, Wuerzburg University Hospital, and the study's principal investigator. "Results of the expanded Phase 1 experience suggest that blinatumomab has the potential to alter the clinical course of disease in patients with a variety of NHL sub-types."

Phase 1 Study Design

This multi-center Phase 1 study evaluates the safety and tolerability of blinatumomab in adult patients with relapsed non-Hodgkin's lymphoma (NHL). The key objectives of the study are to assess safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-lymphoma activity. Patient response is assessed using the Cheson criteria by independent radiologic review.

Patients initially received blinatumomab at dose levels ranging from 0.5 to 90 micrograms per meter squared per day over a four or eight week cycle. Based on findings in the ongoing study, a new dosing schedule was designed to mitigate the occurrence of neurological adverse events observed at the onset of treatment. Recently enrolled patients received a "step-dose approach" including a lower starting dose (5 or 15 micrograms per meter squared per day) of blinatumomab for one week, with subsequent escalation up to the target dose of 60 micrograms per meter squared per day.

Updated Phase 1 Results

The analysis presented at EHA included 52 patients, mainly with diagnoses of follicular lymphoma (FL) (42%) and mantle cell lymphoma (MCL) (42%). The majority of enrolled patients received three or more prior lines of chemotherapy. Of eight evaluable FL and MCL patients treated with constant dosing at a dose level of 60 micrograms per meter squared per day, 100% (8 of 8) achieved an objective response. The median response duration is 21 months. Three patients currently have ongoing responses ranging from 24 up to 30 months.

Among patients treated using constant dosing, the most common clinical adverse events were pyrexia, headache and fatigue. The most common adverse events were early, transient, fully reversible and did not require discontinuation of treatment. The clinically most relevant cause of treatment discontinuation was neurologic events. These were observed in a sub-group of patients with an identified prognostic factor. All events resolved without sequelae following treatment discontinuation.

Data presented on six patients with an identified risk factor for neurologic events who were treated with blinatumomab using a "step-dose approach" indicates that the new treatment schedule appears to mitigate neurological events and maintain clinical activity. There was no occurrence of grade 3 or higher neurological events and five objective responses were achieved among the six patients treated.

"Our goal is to safely and effectively treat indolent and mantle cell lymphomas using a uniform treatment schedule irrespective of patient characteristics," said Jan Fagerberg, M.D., Ph.D., Micromet's SVP, Chief Medical Officer. "We look forward to continuing to advance enrollment in the on-going study using the adapted treatment schedule and broadening the eligible patient population to include other non-Hodgkin's lymphoma subtypes."

[SLGramann]

Micromet’s Cancer Missiles Lure Boehringer, Sanofi (Update2)
June 14, 2010, 4:25 PM EDT

By Ellen Gibson

June 14 (Bloomberg) -- Micromet Inc., a 17-year-old biotechnology company with no medicines on the market, is attracting attention from product-hungry drugmakers. The lure: a technology for fighting cancer without using toxic chemicals.

What Micromet has developed is a way to activate T-cells, the elite troops of the immune system, to attack malignancies, including a rare leukemia that strikes children. It has signed partnerships with five of Europe’s largest drug companies: Bayer AG, Sanofi-Aventis SA, AstraZeneca Plc, Merck KGaA and Boehringer Ingelheim GmbH.

For years, companies like Micromet have struggled to perfect so-called immunotherapies that mobilize the body’s natural defenses against cancer. At the European Hematology Association’s meeting in Barcelona on Saturday, Micromet announced that its leukemia treatment led to remission in almost four-fifths of patients in a trial.

“With Micromet’s technology, you can give any T-cell the ability to recognize and kill the tumor,” said Michael Morse, an associate professor of medicine and tumor immunology specialist at Duke University School of Medicine in Durham, North Carolina. Although the technology is not fully tested, “there’s every reason to believe that this could work.”

The company’s most-advanced drug, blinatumomab, is derived from a common immune-system protein called an antibody that its scientists refashioned to carry out an unnatural task. One end of the protein attracts T cells; the other is engineered to latch onto specific types of cancer cells.

Replenishing Armies

When batches of these proteins, called BiTEs, for bispecific T-cell engager, are released into the bloodstream, they not only summon the immune cells to attack the cancer, they also stimulate the body to produce more of the cells, thus replenishing its armies.

“We’re leveraging the most potent arm of the patient’s immune system and directing it onto the tumor,” said Micromet chief executive officer Christian Itin in an interview.

Micromet shares rose 16 cents, or 2.4 percent, to $6.71 in Nasdaq Stock Market composite trading at 4 p.m. The drugmaker has gained 53 percent in the 12 months through today.

Immunotherapies got a boost on April 29 when the U.S. Food and Drug Administration approved Dendreon Corp.’s first-of-its- kind cancer vaccine for prostate tumors. The day of its approval, Dendreon’s stock soared as much as 38 percent, and the Nasdaq Biotech Index had its biggest one-day rise in six months.

It was a “landmark approval” that gave “positive momentum to the whole biotech space,” said Joseph Pantginis, an analyst at Roth Capital Partners LLC in Newport Beach, CA.

Changing Mindset

Like Micromet’s drug, Provenge primes the patient’s natural immune system. To make the vaccine, doctors extract white blood cells from a prostate-cancer patient, mix them with vaccine components and inject the combination back into the bloodstream. Provenge “opens a door and changes people’s mindset” about the immunotherapy approach, said Jeffrey Crawford, chief of medical oncology at Duke.

The disease blinatumomab is designed to treat, acute lymphocytic leukemia or ALL, isn’t common, but it is a high priority for some doctors. One reason is that two-thirds of the 5,400 new cases in the U.S. each year are children, many of whom only survive with painful chemotherapy that continues for years.

In adults the disease is harder to treat than in children; only 30 percent to 40 percent are cured with conventional chemotherapy.

Complete Remission

At the Barcelona hematology meeting, Micromet showed that blinatumomab can induce complete remission in patients who still had residual leukemia cells after multiple rounds of chemotherapy. About 80 percent of patients who stayed in the study were relapse-free at a median follow-up of 11 months.

“With older patients, it’s very difficult to rout out the last bit of leukemia,” said Peter Marks, director of leukemia services at Yale-New Haven Hospital. Immunologic methods such as Micromet’s “can be very powerful,” he said. “A treatment that could specifically kill leukemia without causing toxicity would certainly be in demand,” he said.

Micromet will begin the last phase of testing required for European approval of blinatumomab this June. Edward Tenthoff, an analyst with Piper Jaffray & Co. in New York, said it could be cleared for use in the U.S. by 2012, and within five years could see $1 billion in annual sales.
“There have been no improvements in ALL treatment in three decades,” said Mark Reisenauer, Micromet’s chief commercial officer. “The only comparably underserved disease is melanoma.”

Riddled With Cancer

Libby Johns is the kind of patient who inspires cancer researchers to try harder. She was diagnosed with ALL in June 2009, a month after her second birthday. When her parents noticed bruising all over her legs, they brought her to the hospital, where doctors found that 90 percent of her bone marrow was riddled with cancer cells.

Now three years old, Libby has had blood transfusions and continuous chemotherapy at the Hospital for Sick Children in Toronto, said her mother, Megan. The girl takes pills every day, has intravenous treatments once a month, and shots in the spine once every three months. This cycle, known as the “maintenance” phase of treatment, lasts 20 months. Libby must continue the regimen until August of next year.

In the course of treatment, Libby’s hair has fallen out three times, and Megan says it’s a struggle to keep the girl’s weight up. Fevers and low blood sugar have put her in and out of the hospital, and when she’s home, the drugs can leave her lethargic.

Few Options

“Some days she doesn’t have the energy to do much,” her mother said. “We just stay home, watch movies, have picnics in the house. I try to let her lead as normal a life as possible.”

While Libby is responding well to treatment, few options are available to children who are not cured with chemotherapy. For adults, who have a high relapse rate, an ineffective procedure called stem cell transplant is the only other line of defense, according to Yale’s Marks. Proven drugs are “very much needed,” he said.

Each of Micromet’s partnerships with large drugmakers is aimed at a different, hard-to-treat cancer. The collaboration with Boehringer, announced May 5, will take aim at multiple myeloma, a deadly disease that starts in the bone marrow and often fails to respond to chemotherapy.

Micromet’s Platform

Pantginis said drugmakers’ interest in the startup goes beyond a desire to license the small company’s drugs. They’re eyeing Micromet’s platform as a way to boost the effectiveness of cancer drugs they already sell, and also to extend the patent protection on those products, he said. If the companies can retool their older drugs using BiTE technology, they can stave off competition from generics in the future.

The concept of immunotherapy took a long time to bear fruit. In the early 1970s scientists started developing lab- grown proteins called monoclonal antibodies, designed either to block tumor growth or make tumors visible to other immune-system cells. They do this by homing in on specific molecules or “targets” on the surface of cancer cells.

The first commercial success came in 1997, when Genentech Inc. and Biogen Idec Inc. launched Rituxan, a drug for non- Hodgkin’s lymphoma. This was followed by best-selling drugs led by Roche Holding AG’s colon cancer drug Avastin, with almost $6 billion in global sales last year.

Second Generation

While these drugs are a big business for companies, most have shortcomings as medicines, said Steven Rosenberg, chief of surgery at the National Cancer Institute in Bethesda, Maryland. “We need to do better than prolonging survival by months,” Rosenberg said. Most of these drugs target just one of multiple drivers of tumor growth. In just a matter of months, tumors in many patients grow resistant to the drugs.

Scientists at Micromet and other biotech companies said that second-generation antibodies of the sort they are testing will be more effective. Companies like Bothell, Washington-based Seattle Genetics Inc. and Waltham, Massachusetts-based Immunogen Inc. employ what’s known as the “payload” technique.

The idea is to link a targeted antibody to a toxic drug that is unleashed once the medicine enters the tumor. One of these experimental drugs, T-DM1 for breast cancer, joins Roche’s best-selling Herceptin to a cancer-killing toxin using Immunogen’s technology and could be approved next year.

“The industry understands the limitations of traditional antibodies,” said Micromet CEO Itin. “We’re starting to see very interesting clinical candidates to enhance the activity of antibodies. We’re seeing an evolution.”

--Editors: Neil Gross, Donna Alvarado

To contact the reporters on this story: Ellen Gibson in New York at [e-mail];

To contact the editor responsible for this story: Reg Gale at [e-mail].

[MasaRatti]

[Ahnung?]

Schon einen guten Monat alt - aber der Vollständigkeit halber:

Micromet Reports Second Quarter 2010 Financial Results

Company to Host Conference Call Today at 8:30 AM ET to Review Financial Results and Recent Corporate Progress

BETHESDA, Md., Aug 05, 2010 (BUSINESS WIRE) -- Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2010.

"Data reported during the quarter continue to reinforce blinatumomab's potential role in the treatment of patients with acute lymphoblastic leukemia (ALL) and strongly support our development plans in this disease setting," said Christian Itin, Ph.D., Micromet's President and Chief Executive Officer. "In the third quarter we will initiate two clinical studies that will serve as the foundation of a broader development program aimed at confirming blinatumomab's potential utility across the treatment continuum of patients with ALL."

Recent Events:

* In June, investigators reported updated results from a Phase 2 clinical trial of blinatumomab in adult patients with minimal residual disease (MRD) positive ALL at the 15th Annual Congress of the European Hematology Association (EHA). In this trial, a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab.
* In June, the Company announced the presentation of updated results from an on-going Phase 1 clinical trial of blinatumomab in patients with relapsed non-Hodgkin's lymphoma at EHA. A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.
* In June, investigators presented interim results from a Phase 1 clinical trial of the Company's BiTE antibody MT110 in patients with advanced solid tumors at the 2010 American Society of Clinical Oncology Annual Meeting. Enrollment and treatment of patients in this dose-finding study continues.
* In June, the Company announced the publication of pre-clinical data of new BiTE antibodies in the Proceedings of the National Academy of Sciences.
* In May, the Company entered into a collaboration agreement with Boehringer Ingelheim for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma.
* At the April 2010 American Association for Cancer Research Annual Meeting, the Company and its collaborators reported pre-clinical data characterizing new BiTE antibodies targeting 11 tumor-associated antigens, including CEA, EGFR, IGFR-1, cMet and FAP-alpha.
* In April, the Company announced that it had achieved a milestone under its collaboration agreement with Bayer Schering Pharma AG. The milestone was triggered by Micromet's achievement of pre-clinical proof of concept for a BiTE antibody for the treatment of patients with solid tumors.
* In August, the Company informed investigators participating in a Phase 2 trial of adecatumumab (MT201) in patients with resected liver metastases from colorectal cancer that enrollment in the study has been discontinued due to a change in the standard of care in this disease setting.

Financial Resultsfor the Three and Six Months Ended June 30, 2010

Three Months Ended June 30, 2010

For the three months ended June 30, 2010, Micromet recognized total revenues of $6.5 million, compared to $4.9 million for the same period in 2009. Total operating expenses were $17.4 million for the three months ended June 30, 2010, compared to $12.6 million for the same period in 2009.

Loss from operations for the three months ended June 30, 2010 was $10.9 million, compared to a loss from operations of $7.6 million for the same period in 2009.

For the three months ended June 30, 2010, Micromet reported a net loss of $3.1 million, or a loss of $0.04 per basic and diluted common share, compared to a net loss of $13.9 million, or a loss of $0.27 per basic and diluted common share, for the same period in 2009.

Six Months Ended June 30, 2010

For the six months ended June 30, 2010, Micromet recognized total revenues of $12.9 million, compared to $12.4 million for the same period in 2009. Total operating expenses were $34.8 million for the six months ended June 30, 2010, compared to $25.0 million for the same period in 2009.

Loss from operations for the six months ended June 30, 2010 was $22.0 million, compared to a loss from operations of $12.6 million for the same period in 2009.

For the six months ended June 30, 2010, Micromet reported a net loss of $19.4 million, or a loss of $0.26 per basic and diluted common share, compared to a net loss of $14.3 million, or $0.28 per basic and diluted common share, for the same period in 2009.

Micromet's cash, cash equivalents and investments were $170.0 million as of June 30, 2010.

Webcast and Conference Call

Micromet management will host a conference call today at 8:30 AM ET to review the Company's second quarter 2010 results and recent corporate progress. To participate in the conference call, please dial 866-730-5763 (domestic) or 857-350-1587 (international) and reference the access code 46379708. The presentation will be available via webcast at: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetail…

A replay of the call will be available from 11:30 AM ET on August 5, 2010 until midnight ET on September 5, 2010. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 58638627. The archived webcast will be available for 30 days in the Investor Relations section of the Micromet website at http://www.micromet.com.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at http://www.micromet.com.

Safe Harbor Statement

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the development and commercialization of blinatumomab and other BiTE antibodies, including the development of BiTE antibodies for the treatment of hematological cancers and the conduct and timing of ongoing and future clinical trials involving these product candidates, as well as plans regarding our regulatory strategy and announcements and publication of clinical data. You are urged to consider statements that include the words "continues," "will," "believes," "potential," "plans," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that blinatumomab or our other product candidates do not demonstrate safety and/or efficacy in future clinical trials, delays in development and testing, including the risk that we will not obtain approval to market blinatumomab or our other BiTE antibodies, and the risks associated with reliance on outside financing to meet capital requirements. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2009, filed with the SEC on March 5, 2010, and Micromet's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010, filed with the SEC on May 5, 2010, as well as other filings by the Company with the SEC.
Micromet, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except par value)
June 30, December 31,
2010 2009
(unaudited)

Assets
Current assets:
Cash and cash equivalents $ 112,734 $ 113,434
Short-term investments 38,244 4,169
Accounts receivable 3,132 464
Prepaid expenses and other current assets 1,005 2,156
Total current assets 155,115 120,223
Property and equipment, net 3,695 3,959
Goodwill 6,462 6,462
Patents, net 525 1,016
Other long-term assets 10 -
Long-term investments 19,056 -
Restricted cash 3,039 3,153
Total assets $ 187,902 $ 134,813

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 4,573 $ 6,053
Accrued expenses 9,924 16,360
Common stock warrants liability 17,973 20,244
Current portion of deferred revenue 10,162 9,838
Total current liabilities 42,632 52,495
Deferred revenue, net of current portion 20,579 13,281
Other non-current liabilities 1,805 2,196
Stockholders' equity:
Preferred stock, $0.00004 par value; 10,000 shares authorized; no shares issued and outstanding - -
Common stock, $0.00004 par value; 150,000 shares authorized; 80,991 shares issued and outstanding at June 30, 2010 and 69,178 shares issued and outstanding December 31, 2009 3 3
Additional paid-in capital 394,573 314,627
Accumulated other comprehensive income 3,558 8,062
Accumulated deficit (275,248 ) (255,851 )
Total stockholders' equity 122,886 66,841
Total liabilities and stockholders' equity $ 187,902 $ 134,813

Micromet, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
2010 2009 2010 2009
Revenues
Collaboration agreements $ 6,523 $ 4,594 $ 12,563 $ 11,900
License fees and other 26 336 296 493
Total revenues 6,549 4,930 12,859 12,393
Operating expenses
Research and development 12,013 8,803 24,216 17,280
General and administrative 5,388 3,776 10,608 7,675
Total operating expenses 17,401 12,579 34,824 24,955
Loss from operations (10,852 ) (7,649 ) (21,965 ) (12,562 )
Other income (expense)
Interest expense (61 ) (94 ) (148 ) (170 )
Interest income 115 141 230 280
Change in fair value of warrants 7,878 (6,261 ) 2,271 (1,829 )
Other income (expense) (224 ) (82 ) 215 4
Net loss $ (3,144 ) $ (13,945 ) $ (19,397 ) $ (14,277 )
Basic and diluted net loss per common share $ (0.04 ) $ (0.27 ) $ (0.26 ) $ (0.28 )
Weighted average shares used to compute basic and diluted net loss per share 80,857 51,480 75,954 51,198


SOURCE: Micromet, Inc.

Micromet, Inc.
Jennifer Neiman
Director, Corporate Communications
240-235-0246
[e-mail]

[SLGramann]

Na endlich!


Press Release Source: Micromet, Inc. On Monday September 20, 2010, 7:00 am EDT

BETHESDA, Md.--(BUSINESS WIRE)--Micromet, Inc. (NASDAQ: MITI - News) today announced the initiation of a pivotal, multi-center study of the Company’s lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body’s T cells to kill cancer cells.

"This trial is an important element of a broader clinical development plan aimed at establishing blinatumomab as an essential component of ALL therapy," said Christian Itin, Ph.D., Micromet’s President and Chief Executive Officer. “We view the initiation of this study to be a key milestone in the development of blinatumomab and a potentially important future value driver for the company.”

This Phase 2 multi-center, single-arm study, also known as BLAST (Blinatumomab Adult ALL MRD Study of T cell engagement), is intended to evaluate the efficacy, safety and tolerability of blinatumomab in up to 130 evaluable adult patients with B-precursor ALL with MRD after treatment with front-line chemotherapy. Patients will receive 15 micrograms per meter squared per day of blinatumomab for 28 days followed by two weeks off therapy over a six week treatment cycle, for up to four treatment cycles. The primary endpoint of the study is MRD response. Secondary endpoints include 18 month relapse-free survival rate (for non-transplanted patients) and mortality rate within 100 days after stem cell transplantation. The Company currently expects that enrollment at up to 70 leading cancer centers in Europe and the U.S. will take approximately two years to complete.

“Historical experience suggests that the majority of ALL patients with MRD following front-line chemotherapy who do not receive a transplant will relapse within one year,” said Nicola Goekbuget, M.D., Goethe University Hospital Frankfurt and the international study chair. “Results reported to date suggest that blinatumomab has the potential to fundamentally change the long-term clinical outcome for this difficult to treat disease.”

[SLGramann]

Antwort auf Beitrag Nr.: 40.180.686 von SLGramann am 20.09.10 20:13:44

Press Release Source: Micromet, Inc. On Monday September 20, 2010, 7:01 am EDT

BETHESDA, Md.--(BUSINESS WIRE)--Micromet, Inc. (NASDAQ: MITI - News) today announced the initiation of a phase 2 trial of the Company’s lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body’s T cells to kill cancer cells.

This phase 2, single-arm study is intended to evaluate the efficacy, safety and tolerability of blinatumomab in 20 adult patients with B-precursor ALL who are resistant or intolerant to standard chemotherapy. Patients will receive blinatumomab daily for 28 days followed by two weeks off therapy over a six week treatment cycle, for up to five treatment cycles. Patients will receive starting doses of blinatumomab of 15 micrograms per meter squared, with dose escalation in subsequent cohorts based on tolerability. The primary endpoint of the study is objective response rate. Secondary endpoints include duration of response and overall survival.

“Existing treatment options for relapsed/refractory ALL fail to produce durable remissions in the majority of patients,” said Christian Itin, Ph.D., Micromet’s President and Chief Executive Officer. “This trial will enable us to validate blinatumomab's potential utility in patients with ALL with more advanced disease, and, if successful, would be the basis for potential pivotal studies in relapsed/refractory ALL.”

[SLGramann]

Micromet bedient sich erneut großzügig an ihrem shelf filing:


November 11, 2010 09:15 AM Eastern Time

Micromet Announces Pricing of Public Offering of 9.9 Million Shares of Common Stock

BETHESDA, Md.--(BUSINESS WIRE)--Micromet, Inc. (NASDAQ: MITI) announced today the pricing of an underwritten public offering of 9,900,000 shares of its common stock at a public offering price of $7.30 per share. The Company has granted the underwriter a 30-day option to purchase an additional 1,485,000 shares of common stock from the Company to cover over-allotments, if any. The closing of the offering is expected to take place on or about November 16, 2010, subject to the satisfaction of customary closing conditions.

The Company plans to use the net proceeds from the financing primarily for general corporate purposes, which may include research and development, capital expenditures, working capital and general and administrative expenses.

The shares will be offered and sold pursuant to a shelf registration statement filed with the Securities and Exchange Commission on October 16, 2009 and declared effective on November 2, 2009 and a registration statement filed with the Securities and Exchange Commission pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission.

[quepos]

Antwort auf Beitrag Nr.: 40.502.851 von SLGramann am 11.11.10 15:47:47

Moim,

leider kommt dies fast regelmäßig bei kleinen Biotechs, brauchen immer mal Geld...

oder auch

Was solls, Kurs wurde immerhin vorher ganz nett raufgezogen, wenn mal wieder gute News kommen, ist die Sache auch schnell vergessen.

Gruß q.

[SLGramann]

Antwort auf Beitrag Nr.: 40.504.981 von quepos am 11.11.10 18:51:14

In Hammers Blog wurde das so kommentiert:

heymang Says:

November 15th, 2010 at 1:03 pm

What do you think of MITI secondary. Horrible timing by Itin. 3 offerings in 18 months is crazy..what you think is going on???


Ohad Hammer Says:

November 16th, 2010 at 8:20 am

MITI’s offering probably implies they are going all the way to registration alone. They raise money because this is the only way to make sure completion of the ongoing pivotal ALL trial, which is not crazy at all imo.

--------------

Es ist eben schon etwas krass, dass Blina nicht neu verpartnert werden konnte (sollte?). Auf der anderen Seite könnte das vielleicht doch die richtige Strategie sein, wenn man von dem Projekt voll überzeugt ist. Nische ist es sowieso, aber dafür mit höchster medizinischer Dringlichkeit. Wäre im Erfolgsfall fast das optimale Produkt, um eine kleine Vertriebsstruktur aufzubauen.

[SLGramann]

Long-Term Follow-Up Data from Phase 2 Study Show Micromet’s Blinatumomab Produces Durable Remissions in Patients with Acute Lymphoblastic Leukemia

– European pivotal trial now enrolling at leading cancer centers –

BETHESDA, Md.--(BUSINESS WIRE)--Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months. Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

The data were reported in an oral presentation (abstract # 174) today at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL.

"Blinatumomab continues to produce durable remissions in patients with ALL, with no relapses seen since the ASH 2009 Annual Meeting," said Christian Itin, Ph.D, President and CEO. "The experience to date supports our belief in blinatumomab's potential to change the long-term outlook for patients with ALL. We look forward to further expanding our ALL development program in 2011."

Phase 2 Design and Results

This multi-center Phase 2 study evaluated the efficacy and safety of blinatumomab in adult patients with B precursor acute lymphoblastic leukemia. Enrolled patients had evidence of leukemic cells in the bone marrow following treatment with front-line chemotherapy, so called minimal residual disease (MRD). The primary endpoint of the study was molecular complete response. Key secondary endpoints included time to hematological relapse, time to molecular relapse and overall incidence and severity of adverse events. Patients received 15 micrograms per meter squared per day of blinatumomab for 28 days followed by two weeks off therapy over a six week treatment cycle. Patients received up to seven treatment cycles.

21 patients were treated in the study. Of 20 evaluable patients, 80% (16 out of 20) achieved a complete molecular response, all within the first cycle of treatment. Nine of the patients in the study received an allogeneic stem cell transplant, a toxic procedure that typically carries a high short-term risk of mortality. Notably, all nine transplanted patients were alive 100-days following the transplant.

Overall, blinatumomab was well-tolerated. Most adverse events occurred early, were transient and reversible. The most common clinical adverse events (any grade) were fever, headache and chills. Two patients discontinued treatment due to fully reversible adverse events; a seizure and a syncope (temporary loss of consciousness), respectively.

[quepos]

Antwort auf Beitrag Nr.: 40.657.322 von SLGramann am 06.12.10 20:43:38

Hallo,

läuft ja gut im Moment für MITI, die Kapitalerhöhung ist (fast) schon wieder vergessen, die jüngsten Daten sind auch sehr gut. Man darf aber bei kleinen Bios nie vergessen, dass es immer wieder lange nachrichtenarme Zeiten gibt, dazu kommt dann plötzlich ein schlechtes Marktumfeld, dazu noch plötzlich Downgrades, weil´s sowieso gerade so fällt - und schon hat sich der Kurs halbiert.

Ich erwäge daher ein "sell on good news", im Moment habe ich wieder sehr gute Gewinne in MITI. Andererseits das Potenzial...


hay que ver

Gruß q.

[quepos]

Antwort auf Beitrag Nr.: 40.658.037 von quepos am 06.12.10 21:59:11

Moin,

Neues Jahr, neues Glück...
bin noch dabei.
Hier mal wieder ein Fund vom Yahoo-Message-Board.
Artikel aus der Zeitschrift "Phase Biotech"

Gruß von q.


----------------------------

Phase Biotech
The Future Of Medicine

Friday, January 14, 2011
Micromet and AstraZeneca’s MedImmune Begin their Phase I Trial of MEDI-565 in Patients with Advanced Gastrointestinal Cancer

MedImmune, formerly MEDI and now the global biologics division of AstraZeneca PLC (NYSE: AZN), and Micromet, Inc. (NASDAQ: MITI) announced the initiation of a joint phase I trial of MEDI-565 (“MT111”) in patients with advanced gastrointestinal cancer. MEDI-565 (“MT111”) is a BiTE antibody designed to direct T cells, the body's most capable cancer defense cells, against cancer cells that have carcinoembryonic antigen (“CEA”). CEA is a protein often located on the surface of a gastrointestinal cancer sites, including those located in the colorectal, pancreatic, esophageal and gastric areas.



Preclinical studies demonstrated potent activity of CEA BiTE antibody against human cancer cell lines, and inhibition of tumor growth in animal models. "The initiation of this trial represents an important step forward in our commitment to advancing our oncologic biologics pipeline, addressing different mechanisms to treat cancer," stated Gerald McMahon, MedImmune's senior vice president of R&D and Head of the Oncology Innovative Medicines unit. "We are very eager to understand the potential of this investigational agent."

This phase 1 dose-escalation study will primarily evaluate the safety and comfort of the candidate in adult patients with advanced gastrointestinal cancers, with a secondary focus on its anti-tumor activity. After a maximum tolerated dose is identified, a larger group of patients with refractory colorectal or pancreatic cancer will be enrolled to further assess safety and anti-tumor activity.

"We are very pleased to see the third BiTE antibody enter the clinic," said Christian Itin, PhD, Micromet's president and chief executive officer. "Pre-clinical results reported to date suggest that MT111 may represent a new approach to treating gastrointestinal cancers, and may also have potential applications in other solid tumors."

[quepos]

Moin,

still geworden hier...
Ich hoffe nicht aus Mangel an Investoren?

Hier mal wieder something encouraging, eine neue "Wunderstory" dank Blinatumomab.

Gruß q.

Link:


http://www.theaustralian.com.au/news/health-science/recovery…

[nokaempf]

Ich ergänze den letzten Beitrag von quepos mit folgendem Videolink aus März 2011
The power of love, part 1 and part 2 (jeweils im Archiv anklicken) und den Werbetrailer als Vorspann ablaufen lassen.
http://au.tv.yahoo.com/sunday-night/video/-/watch/24427328/p…

Wer die Geschichte der mit Blinatumomab geheilten Natalie auf Dauer weiter verfolgen will, wird unter Facebook fündig:
http://www.facebook.com/pages/Help-Save-Natalie/151714068206…


Nur schade, daß die Versuchreihe gemäß micromet.de erst Ende 2012 abgeschlossen werden soll. Siehe auskopierten Absatz.

Blinatumomab in MRD-positive Adult Acute Lymphoblastic Leukemia

* In June and December 2010, investigators reported positive results from a multi-center Phase 2 trial of blinatumomab in patients with minimal residual disease (MRD)-positive ALL. 80% of patients (16 of 20) achieved a molecular complete response, the primary endpoint of the trial, all within the first cycle of treatment. As of November 2010, 60% of patients were alive without clinical evidence that their disease had come back, with a follow-up period of up to 27.5 months
* In September 2010, the Company initiated a European pivotal Phase 2 multi-center, single-arm study, also known as BLAST (Blinatumomab Adult ALL MRD Study of T cell engagement) that will look to enroll 130 adult patients with B-precursor ALL with MRD after treatment with front-line chemotherapy. Data from the trial, if positive, is intended to support a market authorization in Europe. The Company currently expects to complete patient enrollment by the end of 2012.


Man ist genötigt, bei fallenden Kursen wie in den letzten Monaten passiert, immer wieder zuzukaufen - es ist halt ein Langfrist-Investment, das sich hoffentlich irgend wann auszahlt.

[quepos]

Antwort auf Beitrag Nr.: 41.217.521 von nokaempf am 16.03.11 15:50:10

Hallo nokaempf,

danke für den Link, habe mir das ganze (lange) Video angesehen, war für meinen Geschmack als Wissenschaftler etwas zu rührend gemacht (mir kamen fast die Tränen), aber doch auch informativ. Es bleibt natürlich abzuwarten, wie die Geschichte weitergeht, aber es ist doch zunächst ein excellenter Erfolg, der wohl auch nicht unter "Spontanremission" oder so durchgehen kann.

Schön so eine Story zu sehen, müsste eigentlichauch gut für das Investment sein...
Habe bereits einmal nachgekauft, werde es noch ein weiteres Mal tun (wohl jetzt bald).

Ja, bei den Bios ist Geduld gefragt, aber bei gutem timing und etwas Glück auch viel drin, drum bin ich schon so lange (mit Erfolg) dabei.


Gruß q.

[quepos]

Moin,

obwohl die AACR-Präsentation ziemlich positiv daherkommt, ist der Kurs nicht angesprungen sondern hat die Talfahrt der letzten Zeit fortgesetzt.
Habe weiter zugekauft, ist für mich kein Grund ersichtlich, an der grundsätzlichen Qualität von Micromet zu zweifeln.


Wait and see.

Gruß q.

-------------------
BiTE Antibody MT112/BAY 2010112 Demonstrates Potent Activity against Human Prostate Cancer Cells
Companies:Micromet, Inc. Related Quotes
Symbol Price Change
MITI 5.28 -0.18


{"s" : "miti","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: Micromet, Inc. On Tuesday April 5, 2011, 1:00 pm EDT

BETHESDA, Md.--#BUSINESS WIRE#-- Micromet, Inc. #NASDAQ:MITI - News#, a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced the presentation of pre-clinical data on its BiTE antibody MT112/BAY 2010112, discovered and developed in collaboration with Bayer HealthCare Pharmaceuticals, at the 102nd Annual Meeting of the American Association for Cancer Research #AACR# in Orlando, Florida. MT112/ BAY 2010112 is designed to direct a patient's T cells, the body's most potent killer cells, against cancer cells that express prostate specific membrane antigen #PSMA#. PSMA is a target protein that is highly and specifically expressed in the majority of human prostate cancer patients1.



Data presented at AACR #poster # 4561# demonstrate the potent activity of the BiTE antibody against human cancer cell lines and inhibition of tumor growth in animal models. MT112/ BAY 2010112 directed human and non-human primate T cells against PSMA-positive human prostate can

[VoIPer]

Antwort auf Beitrag Nr.: 41.325.001 von quepos am 06.04.11 07:43:23

Nach den aktuellen Infos habe ich mir jetzt auch ein paar Aktien ins Depot gelegt.
Die Untersuchungen mit verschiedenen Patienten laufen bisher sehr positiv und die Welt hat doch eigentlich nur darauf gewartet ein Krebsmedikament zu erforschen das auch schnell und bei vielen wirkt ;-)

[quepos]

Moin,
schon wieder was...

Leitet hoffentlich die Wende ein...
q.

-----------------

RBC Capital Upgrades Micromet (MITI) to Outperform

RBC Capital upgraded Micromet (NASDAQ: MITI) from Sector Perform to ...



This article: 49 words
Date Published: Apr 6, 2011 07:57AM
Why is this preview so short?
StreetInsider.com provides up-to-the-minute active trading news and information. Only the most relevant news makes it through to our members, and only what you need to hear. Our articles are concise and packed with information, so we are only able to provide you with short previews. Join StreetInsider.com today to see the full version of this article and many more like it.

[SLGramann]

Das scheint gut anzukommen. Denke, dass der Kurs auf den MT112 reagiert. Mal sehen, wann da ein IND ansteht.

BiTE Antibody MT112/BAY 2010112 Demonstrates Potent Activity against Human Prostate Cancer Cells

BETHESDA, Md., Apr 05, 2011 (BUSINESS WIRE) --

Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced the presentation of pre-clinical data on its BiTE antibody MT112/BAY 2010112, discovered and developed in collaboration with Bayer HealthCare Pharmaceuticals, at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida. MT112/ BAY 2010112 is designed to direct a patient's T cells, the body's most potent killer cells, against cancer cells that express prostate specific membrane antigen (PSMA). PSMA is a target protein that is highly and specifically expressed in the majority of human prostate cancer patients1.


Data presented at AACR (poster # 4561) demonstrate the potent activity of the BiTE antibody against human cancer cell lines and inhibition of tumor growth in animal models. MT112/ BAY 2010112 directed human and non-human primate T cells against PSMA-positive human prostate cancer cells, resulting in highly efficient cancer cell destruction. In mice, daily doses of MT112/BAY 2010112 as low as 0.05 milligram/kilogram were sufficient to inhibit growth of tumors from human prostate cancer cells.

"PSMA is a well established prostate cancer target for antibody-based therapeutic approaches," said Patrick Baeuerle, Ph.D., Micromet's Chief Scientific Officer. "Data presented at the AACR Annual Meeting suggest a high therapeutic potential for MT112/ BAY 2010112 for the treatment of prostate cancer."

Micromet is advancing the development of MT112/BAY 2010112 under a collaboration and license agreement signed with Bayer Schering Pharma AG, Germany, in January 2009. Under the terms of the agreement, Micromet is primarily responsible for the preclinical development of this BiTE antibody, and will collaborate with Bayer through completion of Phase 1 clinical trials. Beginning in Phase 2, Bayer will assume full control of clinical development and commercialization of MT112/BAY 2010112. Micromet is eligible to receive progress-dependent milestone payments and royalties on future potential tiered net sales of this product candidate.

During the course of the meeting, the Company also presented preclinical data on MT110, its BiTE antibody targeting epithelial cell adhesion molecule (EpCAM). Results reported (poster # 1790) provide further validation of EpCAM as a cancer stem cell target, and show utility of MT110 to eradicate cancer stem cells derived from breast and hepatocellular carcinoma.

Both abstracts can be accessed through the AACR website, www.aacr.org. Posters will be accessible from Micromet's website at www.micromet.com after they are presented.

[quepos]

Moin,

hier wieder ein neuer Patientenbericht, Ausgang noch unklar

Gruß q.

------------------



News
Pioneer drug offers battling cancer sufferer hope
Chris Jones

May 13, 2011

Share Article| Submit Comments | Comments (13) | Printable Version Previous | Next
Close Map
Kevin in hospital in Germany Kevin in hospital in Germany 1/3 Play Slideshow

A cancer sufferer who was given weeks to live is hoping an experimental drug will hand him a lifeline.

Kevin Grimshaw, 25 has flown to Germany to take part in the pioneering trial, which has an 80 per cent success rate so far.

His brother Warren, 28, said: "Last month, we were planning Kevin’s funeral but since he has gone to Germany we’ve felt like he’s been given a second a chance. We are grasping on to the hope it is giving us."

Kevin, from High Hillgate in Stockport, was diagnosed with acute lymphobaliastic leukaemia in 2007.

He has already had months of painful chemotherapy, as well as a bone-marrow transplant.

He fell seriously ill again in March as he was moving into his first home with fiancée Jen Bayley – who he met in hospital where she was being treated for the same leukaemia.

Kevin, who grew up in Blackley, was rushed to the The Christie where doctors said the cancer had returned. They told him he had just weeks to live.

But Kevin’s friends refused to give up – and when they heard about the trial in Germany they arranged for him to take part.

Jen said she first read about the German trials after a friend gave them an internet article. Ms Bayley said: "I kept looking and looking, trying to find a reason why this wasn’t for Kevin because we had gone through so much hope and then despair. But the more I looked at it I realised it was exactly the same type of cancer Kevin had."

Stockport primary care trust will pick up the £90,000 hospital bill.

Only 35 other people have taken part in the German trial, which uses a drug called Blinatumomab. It works by latching on to the leukaemia cells then activating the body’s immune system to destroy them.

Four in five of the people who have been on the trial so far have gone into remission.

Kevin is set to start his second round of treatment later this month, which his family hope will finally rid him of the disease that has blighted him for the last three years.

Speaking from the University Clinic Wurzburg in Germany, he said: "The treatment is my last chance. I am trying to stay as positive as I can. I have my up and down days, but it is less intensive than the chemotherapy and we’re hoping the trial is successful for me."

The drug trial could take up to six months and Kevin was on the plane with his mum Pat and dad Keith less than a week after finding out he was taking part.

Leukaemia specialist Dr Adrian Bloor, Kevin’s doctor at The Christie, said: "We wanted to support his wish to pursue all available treatment options, including overseas, so we were pleased that we were able to arrange for him to travel to Germany to participate in study. We appreciate the help from NHS Stockport who agreed to fund the treatment and all hope for a successful outcome."

Kevin’s family are raising money to help pay for travel and hotel costs while he is in Germany.

A benefit night will be held at the Ducie Bridge on Corporation Street, Manchester, from 7.30pm tomorrow.

[SLGramann]

Jason Chew über bispezifische AK im Allgemeinen, MITI und die Konkurrenz:



Micromet Leads In Bispecific Antibodies, Watch For DARTs
By Jason Chew | May 10, 2011 | Filed under: Drug Development, Recent Posts

Bis­pe­cific an­ti­bod­ies are an­other front in the race to mod­ify ther­a­peu­tic an­ti­bod­ies for in­creased ef­fi­cacy. Un­like nor­mal an­ti­bod­ies, bis­pecifics are able to rec­og­nize and bind two or even three dif­fer­ent anti­gens. The mod­i­fied an­ti­bod­ies have new at­trib­utes al­low­ing them to per­form func­tions in­con­ceiv­able for stan­dard an­ti­bod­ies.

The pur­suit of bis­pe­cific an­ti­bod­ies be­gan at least two decades ago but was ham­pered by the dif­fi­culty in pro­duc­ing the novel agents, es­pe­cially in high quan­tity and pu­rity. Sci­en­tists at­tempted to cre­ate bis­pecifics us­ing mul­ti­ple strate­gies, from us­ing dif­fer­ent Fab arms on the same an­ti­body, to chem­i­cal crosslink­ing of dif­fer­ent an­ti­bod­ies or frag­ments, to min­i­mally sized mol­e­cules.

Mi­cromet was one of the first to solve the prob­lems vex­ing de­vel­op­ers of bis­pe­cific an­ti­bod­ies. It de­vel­oped a plat­form tech­nol­ogy termed BiTE (bis­pe­cific T-cell en­gagers), po­tent sin­gle-chain an­ti­bod­ies with bis­pe­cific ca­pa­bil­i­ties.

The BiTE re­cruit T-cells through CD3 and are ac­tive at 10-100pg/ml con­cen­tra­tions. A sin­gle T-cell is ca­pa­ble of killing mul­ti­ple can­cer cells dec­o­rated with small num­ber of BiTE. They are ca­pa­ble of di­rect­ing T-cell killing with­out the need to pre- or co-stim­u­late the cells. It is thought this is be­cause BiTE in­duce cy­toytic im­muno­log­i­cal synapses be­tween cy­to­toxic T-cells and tar­get cells that are sim­i­lar to nor­mal T-cell synapses.

There are now sev­eral bis­pe­cific an­ti­bod­ies from Mi­cromet in clin­i­cal tri­als, both wholly owned and in col­lab­o­ra­tion with pharma part­ners. Its most ad­vanced can­di­date is bli­na­tu­momab, de­signed to redi­rect T-cells to­ward CD19 pos­i­tive B-cells. Bli­na­tu­momab is in piv­otal tri­als for min­i­mal resid­ual dis­ease (MRD) pos­i­tive lym­phoblas­tic leukemia; MRD re­sults when front-line chemother­apy fails to clear all the leukemia cells from a pa­tients bone mar­row. The drug is also be­ing tested in non-Hodgkin’s lym­phoma (NHL) pa­tients.

Data for bli­na­tu­momab was most re­cently pre­sented at ASH in De­cem­ber last year; it was quite im­pres­sive. Of 20 evalu­able pa­tients for MRD Acute Lym­phoblstic Leukemia (ALL), 80% achieved MRD neg­a­tiv­ity, and 60% reg­is­tered hema­to­logic dis­ease free at 27.5 months of fol­low-up.

The piv­otal bli­na­tu­momab trial is a sin­gle armed, open la­bel trial set to ac­crue 130 MRD pos­i­tive pa­tients with ALL. The pri­mary end­point is MRD re­sponse rate at 6 weeks. Sec­ondary out­come mea­sures in­clude hema­to­log­i­cal re­lapse-free sur­vival, over­all sur­vival, and over­all ad­verse ef­fects. It was ini­ti­ated in Q3 2010.

Early NHL re­sults were also quite good. At 60 mi­cro­gram/square me­ter, 18 of 22 (82%) pa­tients with re­lapsed non-Hodgkin’s lym­phoma achieved an ob­jec­tive re­sponse. There was one con­cern­ing is­sue of CNS events, but they ap­pear to be re­versible; it ap­peared to be linked to B-cell to T-cell ra­tio, pa­tients with a higher B:T ra­tio had a low in­ci­dence of dis­con­tin­u­a­tion due to CNS events. The com­pany be­lieves the ef­fect can be de­tected early and man­aged with steroids.

Mi­cromet has turned its suc­cess into lu­cra­tive col­lab­o­ra­tions with Phar­mas in­clud­ing Med­Im­mune, Sanofi-Aven­tis, and Boehringer. Its al­liances have net­ted the com­pany $131 mil­lion be­tween 2006 to 2010 alone.

There is a surge in in­ter­est in bis­pe­cific an­ti­bod­ies. Mi­cromet is clos­est to mar­ket in the US, but there is one al­ready ap­proved in the EU. Trion, in col­lab­o­ra­tion with Fre­se­nius had de­vel­oped the bis­pe­cific an­ti­body catu­max­omab, which was ap­proved in 2009. The drug con­sists of half a mouse anti-CD3 an­ti­body to­gether with half a rat anti-Ep­CAM an­ti­body. It is con­sid­ered a tri-func­tional an­ti­body; Catu­max­omab binds CD3 pos­i­tive T-cells, Ep­CAM pos­i­tive tu­mor cells, as well as other im­mune cells via its Fc chain.

Other con­tenders in­clude Macro­gen­ics and the start-up f-star. Both made splashy head­lines in re­cent days with big tech­nol­ogy li­cens­ing deals. Macro­gen­ics has its Dual-Affin­ity Re-Tar­get­ing (DART) tech­nol­ogy. Their mol­e­cules are still in pre-clin­i­cal de­vel­op­ment but have al­ready gen­er­ated sig­nif­i­cant in­ter­est. An in­de­pen­dent pa­per com­par­ing DART and BiTE an­ti­bod­ies showed DARTs may be more po­tent in vivo.

Prod­ucts from f-star are at a very early stage; its key dif­fer­en­tia­tor is a Mod­u­lar An­ti­body Tech­nol­ogy for­mat from which it can en­gi­neer sin­gle chain an­ti­bod­ies, di­a­bod­ies, as well as full an­ti­bod­ies. A ma­jor at­trac­tion of their tech­nol­ogy is its ease of pro­duc­tion.

An­ti­body tech­nol­ogy is chang­ing at a rapid clip due to ad­vances in ge­netic en­gi­neer­ing. It has taken the in­dus­try some 25 years, but the goal is near. Bis­pe­cific an­ti­bod­ies will soon take their place along­side “reg­u­lar” ther­a­peu­tic an­ti­bod­ies; BiTEs from Mi­cromet will lead the charge.

http://nexparadigm.com/2011/05/micromet-leads-in-bispecific-…

[VaJo]

*Ganz frisch* :-)

Press Release Source: Micromet, Inc. On Tuesday May 17, 2011, 7:15 am EDT

ROCKVILLE, Md.--(BUSINESS WIRE)-- Micromet, Inc. (Nasdaq:MITI - News) today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive (MRD) acute lymphoblastic leukemia (ALL) were published in the May 16th on-line edition of the Journal of Clinical Oncology (JCO). Results of the study demonstrated that blinatumomab produced durable remissions in front-line adult ALL patients at high risk of relapse. Blinatumomab is the most advanced of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

“ALL patients with residual leukemic cells in the bone marrow following treatment with front-line chemotherapy have a 90% risk of relapse and a resulting poor long-term prognosis," said Professor Max Topp, Department of Internal Medicine II, University of Wuerzburg, and lead author of the publication. "Results from this study show that blinatumomab has the potential to fundamentally change the long-term outcome for this difficult-to-treat disease."

[VoIPer]

In der nächsten Zeit, sollen neue Studien bekanntgegeben werden die sehr erfolgsversprechend sind.
Das neuerforschte Krebsmittel reagiert sensationell auf die meisten Patienten. Alle werden nicht geheilt werden, aber für micromet dürfte das Mittel Goldwert sein, da es noch kein effizientes Krebsmittel bisher gibt oder jetzt gegeben hat.

[SLGramann]

MITI mal schön im Überblick:
(hat der Markt heute Angst vor dem 09.06.?)


(RTTNews) - * Interim results from a mid-stage trial of Micromet's BiTE antibody scheduled to be reported in June.

BiTE or Bispecific T cell Engager antibodies are proprietary compounds of biopharmaceutical company Micromet Inc. (MITI: News ). These antibodies represent a novel way of harnessing the body's immune system to treat cancer by mobilizing T cells, the body's most potent killer cells, enabling them to detect and destroy cancer cells that are not normally recognized by the immune system.

Three of Micromet's BiTE antibodies are currently in clinical development. The most-advanced BiTE antibody in the company's pipeline is Blinatumomab (MT103).

Blinatumomab is currently the subject of three clinical trials, namely

- Pivotal trial for adult patients with MRD(minimal residual disease)-positive acute lymphoblastic leukemia. - Phase II trial for adult patients with relapsed/refractory acute lymphoblastic leukemia. - Phase I trial for adult patients with relapsed non-Hodgkin's lymphoma.

For investors who are new to Micromet, here's what to expect in the coming months. Next month ( June, 2011), the company will be reporting interim data from a phase II clinical trial of Blinatumomab in adult patients with relapsed/refractory acute lymphoblastic leukemia.

Acute Lymphocytic Leukemia is an aggressive cancer of the blood and bone marrow and according to the American Cancer Society, this disease afflicts about 5,760 patients in the U.S. annually. The subtypes of ALL include precursor B acute lymphoblastic leukemia, precursor T acute lymphoblastic leukemia, Burkitt's leukemia, and acute biphenotypic leukemia.

The standard treatments of ALL involve chemotherapy and radiation. However, the existing treatment options for relapsed/refractory ALL fail to produce durable remissions in the majority of patients, according to Christian Itin, Micromet's President and CEO. The average five-year survival rate for adult ALL patients after first relapse is 7%.

Micromet initiated the phase II trial of Blinatumomab in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia last September.

The phase II trial, which is a single-arm study, designed to enroll 20 adult patients with B-precursor ALL who are resistant or intolerant to standard chemotherapy. Patients will be treated with Blinatumomab daily for 28 days followed by two weeks off therapy over a six week treatment cycle, for up to five treatment cycles. The primary endpoint of the study is objective response rate while duration of response and overall survival are the secondary endpoints. Enrollment in this trial is expected to be complete in the second half of 2011 and updated results can be anticipated before year end, according to Micromet.

And now about the other clinical trials of Blinatumomab...

The results from an on-going phase 1 trial of Blinatumomab in patients with relapsed NHL (non-Hodgkin's lymphoma) reported last December showed that the BiTE antibody continues to produce a high response rate and duration of response in a number of different NHL subtypes. The company plans to initiate a phase II trial of Blinatumomab in mantle cell lymphoma this year. Mantle cell lymphoma is a very rare form of non-hodgkin's lymphoma.

The long-term follow-up data from a phase II trial of Blinatumomab in adult patients with MRD (minimal residual disease) positive acute lymphoblastic leukemia were reported last December. The trial results demonstrated that Blinatumomab produced prolonged remissions (the state of absence of disease activity) in patients with ALL.

In September 2010, Micromet initiated a phase II multi-center, single-arm study, also known as BLAST (Blinatumomab Adult ALL MRD Study of T cell engagement), intended to evaluate the efficacy, safety and tolerability of Blinatumomab in up to 130 evaluable adult patients with B-precursor ALL with MRD after treatment with front-line chemotherapy. This European pivotal trial in MRD-positive adult ALL patients is currently recruiting patients and enrollment is expected to be completed in 2012.

Micromet has received orphan drug designation from the European Medicines Agency for Blinatumomab for the treatment of acute lymphoblastic leukemia, mantle cell lymphoma and chronic lymphatic leukemia and from the FDA for the treatment of acute lymphoblastic leukemia, chronic lymphocytic leukemia and indolent B cell lymphoma.

The other two BiTE investigational antibodies of Micromet under clinical development include MT110 in phase 1 clinical trial in patients with advanced solid tumors and MT111, which is also in phase 1 trial in patients with advanced gastrointestinal cancers. Micromet has partnered with MedImmune, LLC , the global biologics unit of AstraZeneca, for developing MT111 for advanced solid tumors.

The BiTE antibodies under pre-clinical development are MT112 for advanced prostate cancer, solid tumor BiTE for carcinoma and a new BiTE antibody for multiple myeloma.

Micromet also has collaboration agreements with Bayer Schering Pharma AG, Germany for the development of MT112 and with sanofi-aventis and Boehringer Ingelheim for the development of solid tumor BiTE and a new BiTE antibody for the treatment of multiple myeloma, respectively.

Micromet signed the collaboration and license agreement with Bayer Schering Pharma in January 2009. Under the terms of the agreement, Micromet is primarily responsible for the preclinical development of MT112 , and will collaborate with Bayer through completion of phase 1 clinical trials. Beginning in phase II, Bayer will assume full control of clinical development and commercialization of MT112. Micromet is eligible to receive progress-dependent milestone payments and royalties on future potential tiered net sales of this product candidate.

Last month, the company presented pre-clinical data on MT112, which demonstrated potent activity against human prostate cancer cells.

The conventional antibodies in the company's pipeline include

- MT203, which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis, is under development in a phase 1 clinical trial being conducted by its collaboration partner Nycomed.

- MT201, which is the subject of a collaboration with Merck Serono

- MT228, which is licensed to Morphotek, Inc. and is the subject of an ongoing phase 1 clinical trial in patients with advanced melanoma and

- MT293, which has completed a phase 1 clinical trial for the treatment of patients with cancer.

The company has no marketed products and has no current sources of material ongoing revenue, other than upfront license fees, the reimbursement of development expenses and potential future milestone payments from its collaborators or licensees.

As on March 31, 2011, the company's accumulated deficit totaled $312.5 million while cash, cash equivalents and investments were $207.8 million.

Shares of Micromet have thus far hit a 52-week low of $4.75 and a 52-week high of $8.63. The stock is currently down 0.98 percent trading at $6.08 on a volume of 16,696 shares.

[SLGramann]

Background: Relapsed/refractory B-precursor ALL is an aggressive malignant disease with a dismal prognosis and therapy is an unmet medical need. 80-90% of adults with relapsed ALL die from their disease or adverse effects of therapy. CD19 is the most frequently expressed B-cell differentiation antigen and can be targeted by blinatumomab, a member of a novel class of T-cell engaging, bispecific single-chain antibodies called BiTE antibodies. We initiated an open-label multi-centre exploratory Phase 2 study in collaboration with the German Multicenter Study Group for Adult Lymphoblastic Leukemia (GMALL) in order to determine the efficacy and safety of blinatumomab in adult patients with relapsed/refractory B-precursor ALL.

Methods: The primary endpoint is complete remission (CR) rate with hematological recovery. Secondary end-points are minimal residual disease (MRD) response rate (defined by an MRD level below the quantitative detection limit of 10e-4), time to hematological relapse and overall survival. Eligible patients must have B-precursor ALL relapsed after at least induction and consolidation or primary refractory disease. Prior allogeneic HSCT is permitted. Patients with Ph-positive ALL have to be ineligible for tyrosine kinase inhibitors. Blinatumomab is administered as a 4-week continuous intravenous infusion followed by a 2-week treatment-free period. Responders may receive up to 3 additional cycles. The first cohort of five evaluable patients received a dose of 15 μg/m²/d. A second cohort receives 5 μg/m²/d for the first 7 days of the first cycle followed by 15 μg/m²/d for the remaining 3 weeks of the cycle and the following cycles. A risk-benefit assessment will determine which of the dose levels will be evaluated in the second stage enrolling 10 additional patients.

Results: Seven patients have been treated in the first cohort. Their age ranged from 18 to 77 years. Four of the five evaluable patients had a reduction of bone marrow blasts < 5% within the first cycle two with CR and two with a complete remission with only partial hematologic recovery (CRh*). To date, three also have an elimination of MRD below quantitative detection limit within the first 2 cycles. One responder had an extra-medullary relapse during the third cycle of treatment. The most common adverse events were fever and chills. Two patients were not evaluable for response assessment as they had to permanently discontinue treatment without completion of the first cycle due to adverse events. One non evaluable patient with high leukemic burden had a completely reversible SAE of cytokine release syndrome (CRS). Subsequent patients with high leukemia burden were managed by pre-treatment with dexamethasone and/or cyclophosphamide, and no further treatment discontinuations due to CRS were observed. The second non evaluable patient had treatment discontinued due to a completely reversible CNS event of encephalopathy and disorientation. Despite a limited course of treatment, this patient showed an elimination of MRD below quantitative detection limit. Recruitment of the second cohort receiving a low initial dose of blinatumumab is ongoing,

Conclusion: These initial data show that blinatumomab elicits pronounced anti-leukemic activity in patients with relapsed/refractory ALL and support further evaluation in this patient population.

[Ville7]

Antwort auf Beitrag Nr.: 41.583.256 von SLGramann am 31.05.11 17:18:24

was sollte gestern gewesen sein? die jefferies conference? oder das update zu den phase II daten?

[SLGramann]

Antwort auf Beitrag Nr.: 41.630.236 von Ville7 am 10.06.11 07:21:25

War zeitlich etwas desorientiert. Es ging mir um das Update P II in ALL. Die Daten sehen mal wieder heiß aus.
War so aus dem abstract auch nicht wirklich erkennbar.


Study Demonstrates Micromet’s Blinatumomab Produces High Single-Agent Activity In Patients With Relapsed Acute Lymphoblastic Leukemia
Business Wire

06/10/11 - 04:30 AM EDT

Data to be presented tomorrow at the 16th Annual Meeting of the European Hematology Association (EHA) in London, UK, show that Micromet’s blinatumomab produced a high complete remission rate in adult patients with acute lymphoblastic leukemia (ALL) who had relapsed following treatment with standard therapy. 1 Blinatumomab is the most advanced of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

Interim results from this phase 2 single-arm trial showed that 75% of patients (9 of 12) achieved a complete remission (CR) or CR with partial recovery of blood counts (CRh*) following treatment with blinatumomab. All nine responding patients achieved a complete molecular response, or had no evidence of leukemic cells in their bone marrow, a key prognostic factor for patient survival. Notably, four patients with genetic abnormalities typically associated with poorer outcomes all achieved a CR or CRh*.

“Relapsed/refractory acute lymphoblastic leukemia is a difficult to treat disease that has seen no meaningful improvement in decades,” said Professor Max Topp, Department of Internal Medicine II, University of Wuerzburg and the chair of the study. “To date blinatumomab has shown an impressive and unprecedented level of efficacy in a patient population with limited therapeutic options."

The most common clinical adverse events were fever, peripheral edema and fatigue. Treatment of two of the twelve patients was interrupted due to fully reversible and manageable CNS events. In one patient, cytokine release syndrome was observed, which was mitigated in subsequent patients through dose modification and pre-treatment with concomitant medication. No additional cytokine release syndrome was observed.

“These results are particularly striking relative to the fact that the majority of enrolled patients had characteristics typically associated with a dismal outlook,” said Professor Topp.

Current treatment for Philadelphia negative relapsed/refractory ALL consists of combinations of toxic chemotherapy drugs that in the majority of cases fail to drive the disease into remission. In more than 30 years, no new drug has been approved for use in this setting, leaving physicians with few options to improve long-term patient outcomes other than variations in the dose and schedule of old drugs with limited efficacy. With current approaches, complete remission rates range from 17-45%. 2-6 Standard chemotherapy is associated with a mortality rate of up to 23%. 7 The average five-year survival rate for adult ALL patients after first relapse is 7%. 5

Study design

This study is designed to evaluate the efficacy, safety and tolerability of blinatumomab in up to 25 adult patients with B-precursor ALL who relapsed after at least induction and consolidation treatment or who have refractory disease. Patients receive blinatumomab as a continuous infusion for 28 days followed by a treatment free interval of two weeks. Patients who achieve a CR/CRh* within the first two treatment cycles can receive consolidation with either three additional cycles of blinatumomab or allogeneic HSCT. The primary endpoint of the study is the rate of CR/CRh*. Secondary endpoints include molecular response rate, duration of response and overall survival. Enrollment in this study is currently on-going.

[SLGramann]

Hammer mit einer aktuellen Einschätzung:


Micromet (MITI), who is developing antibodies for cancer, definitely has a potential game changer in its hands. The company’s lead agent, blinatumomab (Bmab), belongs to a new class of antibodies called BiTE (Bispecific T cell Engagers). These antibodies can harness the patient’s immune system to attack tumors by redirecting T cells (the most potent immune cells in the body) against cancer cells. BiTE antibodies achieve this by simultaneously binding a cancer cell on one side and an immune cell on the other. This unleashes a potent anti-tumor immune response.

Bmab is Micromet’s lead BiTE antibody, currently in pivotal phase II in acute lymphoblastic leukemia (ALL). Due to the unique properties of Bmab, Micromet decided to evaluate this antibody in a setting where the disease is cleared from the blood but there is still a small amount of leukemia cells in the bone marrow (minimal residual disease or MRD). This setting is perhaps the most crucial setting in the natural history of ALL, as MRD cells ultimately lead to disease relapse and death. Therefore, eliminating them as part of front line therapy could have a real impact on patient outcome, as shown in several studies.

Earlier this year, the company published final results from a 21 patient trial evaluating blinatumomab in MRD+ ALL. The antibody converted 16 of the 21 patients to MRD negative status, an impressive achievement given the fact most of these patients could not reach this status with prolonged regimens of aggressive chemotherapy. Most importantly, all 16 patients enjoyed durable hematologic remissions (no disease in the blood), with a relapse free survival rate 76% after over a year. This represents a dramatic improvement compared to historical data, even though this was a small single arm trial.

The ongoing pivotal trial, which is taking place mainly in Europe, is very similar to the phase II trial. It is also a single arm trial with MRD conversion as the primary endpoint in 130 patients. The fact that the European regulators agreed for this design validates the clinical relevance of MRD conversion as an endpoint. The similarity with the first phase II trial also bodes well for eventual approval (at least in Europe) based the ongoing pivotal trial.

Last month, Micromet presented an even more impressive data set, this time in relapsed/refractory ALL patients. Unlike MRD+ patients, who have only disease remnants in the bone marrow, these patients have full blown disease and have a very dismal prognosis. Of 12 evaluable patients, 9 (75%!!!) achieved a complete response, which included disappearance of leukemic cells from the blood and more importantly from the bone marrow (conversion to MRD negative). Despite the low number of patients, this degree of responses in heavily pretreated patients is very unusual and cannot be reached with the most aggressive chemo regimens.

Although Bmab appears much safer than alternative approaches for these patients, the antibody led to a notable amount of toxicity in some patients. It appears that investigators found a way to mitigate most of the side effects using an alternative treatment regimen and pretreatment but this has to be validated in future trials. In December, the company is expected to present an update which will include more patients as well as durability of responses.

It is hard to stay unmoved by the ALL data from the two studies, which position Bmab as a phenomenal drug for patients who have very few treatment options. More importantly, Bmab is one of the few drugs that actually have the potential to change the entire treatment landscape of ALL and induce durable remissions and even cures in some patients. This again exemplifies the unique profile of cancer immunotherapy, which could have a dramatic impact for certain patients and not just extend survival by a few months.

Micromet is enrolling patients in a pivotal trial in MRD+ ALL, which is expected to have data in 2013. This could support registration in Europe and potentially in the US. Next year the company intends to start another pivotal trial in relapsed/refractory ALL. Although no details were released, it is easy to assume that given the unmet medical need and the impressive activity, a fairly small and short trial could be the basis for accelerated approval in the US and Europe.

The direct market opportunity for MRD+ ALL is limited (~1500 patients per year in US+EU). Even assuming the premium pricing for orphan disease drugs, the commercial opportunity is in the $150M-$250M range. Label expansion to relapsed/refractory ALL could double sales (depending on the amount of cannibalism between the two indications). Migration to first line ALL, where there is still no data or to pediatric ALL (very good anecdotal data), which is more prevalent than adult ALL, could easily bring the market opportunity to $1-1.5B, depending on label and penetration.

Blinatumomab has also generated excellent data in NHL, which is a multi-billion $ indication. However, the heterogeneous patient population and multiplicity of treatment options make this indication very difficult to navigate. Unlike ALL, where there are very few promising agents in development, Micromet’s blinatumomab will have to compete with highly effective oral agents from Pharmacyclics (PCYC) and Calistoga (recently acquired by Gilead). One option for Micromet to differentiate itself in NHL is pursuing blinatumomab for NHL patients with MRD, similarly to the ALL program. The importance of MRD is becoming widely accepted as an important factor for evaluating benefit and prognosis (see this 2010 paper as an example).

Although the company has not guided for any partnership deals around Bmab, Micromet could license Asian rights for the program or do a lucrative co-development deal. At the moment there is no pressure on the company to bring additional funds as it has the resources to pursue approval in ALL. In order to accelerate development in NHL, which requires a lot of resources and a large footprint, a licensing deal is inevitable, the only question is when.

Micromet and its partners are developing several other BiTE antibodies. MT110, wholly owned by Micromet, is currently in phase I in solid tumors. In contrast to blood cancers, where the BiTE platform is considered validated, it is unclear whether it is suitable for solid tumors. The main obstacle is the need to administer higher doses, which might lead to severe side effects. The market still awaits initial proof concept and it is hard to predict if and when this will happen, as each target will probably result in a unique clinical profile.


http://www.hammerstockblog.com/top-10-oncology-drugs-availab…


Bin sehr froh, hier dabei sein zu dürfen! Es ist einfach ein faszinierender Ansatz!

[SLGramann]

Es wäre so sehr zu wünschen, dass man mit bispezifischen AK auch bei soliden Tumoren Erfolg hat!

Zumindest wird es nun ein Mal mehr versucht werden.


ROCKVILLE, Md., Jul 11, 2011 (BUSINESS WIRE) -- --- Upfront payment of EUR10 million upon deal execution

--- Maximum deal value of EUR695 million plus royalties and development cost reimbursement

Micromet, Inc. /quotes/zigman/100922/quotes/nls/miti MITI +6.08% announced today that it has entered into a collaboration agreement with Amgen Inc. for the research of BiTE antibodies against three undisclosed solid tumor targets. Amgen will have the right to pursue development and commercialization of BiTE antibodies against up to two of these targets, to be selected by Amgen.

"The BiTE antibody provides an innovative approach to cancer therapy," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "Amgen is pleased to collaborate with the Micromet scientific team to deploy this technology against targets for the treatment of solid tumors."

Under the terms of the agreement, Amgen is expected to pay EUR10 million upon deal execution. If milestones in multiple indications and tumor types are achieved, Micromet is eligible to receive up to EUR342 million in clinical and commercial milestone payments. Micromet is also eligible to receive up to double-digit royalties on worldwide net sales.

For the second BiTE program, Micromet is eligible to receive an additional cash payment upon initiation of the program, milestones, royalties and development funding comparable to the first program. The combined potential payments to Micromet from both programs, excluding reimbursement of research and development costs, are approximately EUR695 million. The initial development plan contemplates EUR25 million in funding of Micromet R&D activities if two BiTE antibodies are advanced to IND. All expected costs associated with the research, development and commercialization of the BiTE antibodies will be borne by Amgen.

Micromet will be primarily responsible for the discovery and pre-clinical development of the BiTE antibodies. Amgen will lead the clinical development, manufacturing, and commercialization of any products resulting from the collaboration.

"We are very pleased to collaborate with Amgen, an industry leader with a proven track record of success in oncology and biologics," said Christian Itin, Ph.D., Micromet's President and Chief Executive Officer. "This collaboration aligns well with our strategy to expand development of BiTE antibodies into solid tumor indications with support from a partner and brings important non-dilutive capital into the company."

[MasaRatti]

Hi,
hier die Kooperation mit Amgen in Deutsch


http://www.bionity.com/de/news/133551/micromet-und-amgen-ent…

[MasaRatti]

Press Release Source: Micromet, Inc. On Thursday August 4, 2011, 7:30 am EDT

ROCKVILLE, Md.--(BUSINESS WIRE)-- Micromet, Inc. (Nasdaq:MITI - News), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2011.

“Over the past three months, we presented initial data demonstrating blinatumomab’s high complete response rate in patients with relapsed acute lymphoblastic leukemia (ALL) and announced a new, multi-target BiTE collaboration with Amgen,” said Christian Itin, Ph.D., Micromet's President and Chief Executive Officer. “We look forward to expanding our clinical trials in ALL and expect to release additional blinatumomab data at ASH.”

Recent Events:

* In July, the Company entered into a collaboration agreement with Amgen for the research of BiTE antibodies against three solid tumor targets. Amgen has the right to pursue development and commercialization of BiTE antibodies against up to two of these targets, to be selected by Amgen. Per the terms of the agreement, in July Amgen paid an upfront fee of €10 million, of which €4 million was an advanced payment for research and development expenses to be incurred. Micromet is eligible to receive up to €342 million in clinical and commercial milestone payments and up to double-digit royalties on worldwide net sales. If Amgen choses a second BiTE program, Micromet will be eligible to receive an additional cash payment upon initiation of the program, as well as milestones, royalties and development funding comparable to the first program.
* In June, the Company announced the appointment of Ulrich Grau, Ph.D., as Executive Vice President and Chief Operating Officer. Dr. Grau brings to Micromet extensive operations and research and development leadership experience in global pharmaceutical and biotechnology companies.
* In June, at the 15th Annual Congress of the European Hematology Association, investigators reported interim results from a Phase 2 clinical trial of blinatumomab in adult patients with ALL who had relapsed following treatment with standard therapy. 75% of patients (9 of 12) achieved a complete remission (CR) or CR with partial recovery of blood counts (CRh*) following treatment with blinatumomab. All nine responding patients also achieved a complete molecular response, meaning they had no evidence of leukemic cells in their bone marrow, a key prognostic factor for patient survival.
* In June, at the 11th Annual International Conference on Malignant Lymphoma, investigators reported updated results from a Phase 1 clinical trial of blinatumomab in adult patients with relapsed non-Hodgkin’s lymphoma (NHL). At the therapeutic dose level of 60 micrograms per meter squared per day, 71% (20 of 28) achieved an objective response. As of March 2011, the median duration of response for all patients was 508 days with responses of 11 patients on-going.
* In May, the Company announced the publication of data from a Phase 2 clinical trial of blinatumomab in patients with minimal residual disease positive (MRD) ALL in the Journal of Clinical Oncology. Results of the study demonstrated that blinatumomab produced durable remissions in front-line adult ALL patients at high risk of relapse.

Financial Results for the Three and Six Months Ended June 30, 2011

Three Months Ended June 30, 2011

For the three months ended June 30, 2011, Micromet recognized total revenues of $7.1 million, compared to $6.5 million for the same period in 2010. Total operating expenses were $27.1 million for the three months ended June 30, 2011, compared to $17.4 million for the same period in 2010.

Loss from operations for the three months ended June 30, 2011 was $20.0 million, compared to a loss from operations of $10.9 million for the same period in 2010.

For the three months ended June 30, 2011, Micromet reported a net loss of $17.3 million, or a loss of $0.19 per basic and diluted common share, compared to a net loss of $4.1 million, or a loss of $0.05 per basic and diluted common share, for the same period in 2010.

Six Months Ended June 30, 2011

For the six months ended June 30, 2011, Micromet recognized total revenues of $12.6 million, compared to $12.9 million for the same period in 2010. Total operating expenses were $52.4 million for the six months ended June 30, 2011, compared to $34.8 million for the same period in 2010.

Loss from operations for the six months ended June 30, 2011 was $39.8 million, compared to a loss from operations of $22.0 million for the same period in 2010.

For the six months ended June 30, 2011, Micromet reported a net loss of $25.5 million, or a loss of $0.28 per basic and diluted common share, compared to a net loss of $22.4 million, or $0.29 per basic and diluted common share, for the same period in 2010.

Micromet's cash, cash equivalents and investments were $188.3 million as of June 30, 2011.

[MasaRatti]

Neues von der "Szene"

http://www.wallstreet-online.de/nachricht/3468112-report-pre…

[schnappi]

http://phx.corporate-ir.net/phoenix.zhtml?c=197259&p=irol-ne…

[VaJo]

WOW, das Ding explodiert gerade!
Könnten da nächstes Jahr schon Ergebnisse kommen?

[SLGramann]

Also, ich weiß wirklich nicht, ob ich das richtig einschätze, deshalb mit großem Vorbehalt folgendes: Ich halte es für denkbar, dass sie für Blinatumomab in der Indikation B-precursor relapsed/refractory ALL für die USA eine vorläufige Zulassung bekommen könnten, falls der P II-Trial, den sie jetzt im Q4 beginnen wollen, sehr gute Daten produziert. Wenn ich damit richtig liege, wäre eine vorläufige Zulassung schon 2013 vorstellbar.

Wir bekommen bestimmt demnächst kompetentere Einschätzungen der Situation.

[VaJo]

Wie groß sind die Chancen für MITI das es ein Erfolg wird und wohin könnte der Kurs laufen? Jemand eine Idee?

[SLGramann]

Antwort auf Beitrag Nr.: 42.210.303 von SLGramann am 13.10.11 21:14:49

Ohad Hammer hat wie erhofft/erwartet sehr schnell die kompetente Einschätzung der Situation geliefert:


Micromet unveils another fast route to market, marks Pfizer as lead competitor

Developing oncology drugs is getting harder and harder. The rising regulatory hurdles, the constant flow of new agents and competition for trial participants all make getting a drug to market a formidable challenge. This is particularly true in drugs for blood cancers, a field that saw tremendous progress in the past decade and is becoming very crowded. As a result, even highly effective drugs require long and expensive studies with active regimens in the control arm and survival as an endpoint.

These challenges can be coped with, to some extent, by identifying settings where it is possible to get a drug to market quickly and cost-effectively. These settings should include a small, well defined patient population with limited therapeutic options and an agent with robust activity that could persuade regulators to grant accelerated approval based on a small single arm trial. Micromet’s (MITI) lead agent, blinatumomab (Bmab), is a perfect example of how creative clinical planning can differentiate a product by facilitating quick approval.

Although Bmab has potential across many types of blood cancers, the company focused on specific patient populations and treatment settings that enabled it to avoid the classic development route. Bmab is about to be in two small pivotal phase II trials in ALL (Acute lymphoblastic leukemia), both could generate data in the 1st half of 2013 and potentially support filing. The indications Micromet is going after are certainly not the largest opportunity for Bmab, but they are probably the safest and quickest way to market. Following approval, Micromet will be able to generate cash via commercial sales as well as a licensing deal, which could support expansion into larger indications such as NHL.

New route

Last week Micromet announced that based on feedback from the FDA, a small single arm phase II study could be enough to get accelerated approval in relapse/refractory ALL. Of course, there is no obligation from the regulator’s end, but the fact Micromet is pursuing this path implies the FDA is willing to consider approval, providing results are compelling. Micromet is already recruiting patients in another pivotal phase II trial in ALL where Bmab is given to patients who still have disease remnants in their bone marrow (minimal residual disease or MRD) after conventional therapy.

The new pivotal phase II trial will include 65 ALL patients from the US and Europe, all of whom will receive Bmab. The primary endpoint is complete remission (CR), with response duration and survival as secondary endpoints. This design is extremely favorable for Micromet based on recent results in a similar patient population which included a CR rate of 75%. Although the data set included only 12 patients, this level of activity in such an advanced population is unprecedented.

New competitors

Bmab is an anti-CD19 antibody that can redirect the immune system to attack cancer cells very efficiently. Originally, Bmab’s main competitors were other antibodies targeting CD19. The most advanced of these is Sanofi-Aventis’ (SNY) SAR3419, an antibody drug conjugate (ADC) based on Immunogen’s (IMGN) technology. Initial data from this program was presented last year with clear activity in other blood cancers but it did not include ALL patients. Sanofi just started a phase II in ALL with SAR3419, which should trigger a $4M milestone to Immunogen (expected to be announced shortly).

Since Micromet shifted its focus to ALL, with two ongoing registration-enabling phase II trials, Micromet’s main competitor is now Pfizer (PFE). Following the Wyeth acquisition, Pfizer got inotuzumab ozogamicin, an antibody drug conjugate targeting CD22 that has strong activity in ALL. Data at ASCO 2011 included a 56% response rate in 40 patients. Investigators concluded the data stating that inotuzumab is “likely the single most active single agent tested so far in relapsed/refractory ALL”.

It is too early to pick a winner between Bmab and inotuzumab due to the limited available data. One clear advantage inotuzumab has is its convenient administration (one injection every 3 weeks) in contrast to Micromet’s Bmab which is given as continuous infusion over 4 weeks. Although Pfizer’s inotuzumab is clearly active and has a more extensive data set, the responses it induces are not necessarily as deep (the criteria to reach bone marrow response in the Micromet study was more stringent) and prolonged as those observed with Bmab to date. In the long run the two drugs could be combined or used in tandem, as each agent binds a different target.

Another potential competitor is Genentech, who also has a CD22 ADC, powered by Seattle Genetics’ (SGEN) technology. It is currently in phase I alone and in combination with Rituxan. The phase I does not include ALL patients but focuses on NHL, however, expanding into ALL is an obvious step based on data with Pfizer’s anti-CD22 ADC. Based on the superiority of Seattle Genetics’ technology compared to Wyeth’s older technology, Genentech’s ADC might be an even stronger contender.

Data flow during 2012

The pivotal trial in relapsed/refractory ALL will join another pivotal study Micromet is running in MRD-positive ALL. The latter could support registration in Europe but probably not in the US. Although the company has not provided specific timelines, both studies should complete enrollment towards the end of 2012. As the primary endpoints in both trials require short follow up (CR rate and MRD conversion rate, respectively), top line results could be available in the 1st half of 2013. It remains to be seen whether regulators demand more matured data from both studies for submission. Since both trials are single arm open label studies, Micromet will have a constant flow of data it may or may not choose to share with investors during 2012.

Micromet’s strategy of targeting ALL as a lead indication enables it to pursue regulatory approval in two treatment lines with minimal time and cost. The two pivotal trials cost several tens of millions of dollars and could open up a market of ~$400M for Micromet in ALL, assuming a certain degree of off label use. Eventually, Bmab will surely face competition but thanks to Micromet’s strategy, it will be the first to get approval for ALL.


Portfolio updates

3 years after inception, the biotech portfolio managed by Ran Nussbaum and myself is up 90%, which compares favorably to general and healthcare related indices and ETFs (see tables below). We feel comfortable with the three positions in Micromet (account for 10% of portfolio) going into ASH this December.


http://www.hammerstockblog.com/micromet-unveils-another-fast…

[MasaRatti]

Micromet Reports Third Quarter 2011 Financial Results

http://www.finanznachrichten.de/nachrichten-2011-11/21873958…

[MasaRatti]

Needham & Company, LLC stuft MICROMET INC auf buy
Autor: Aktiencheck Analysen

New York (aktiencheck.de AG) - Die Analysten von Needham & Co stufen die Aktie von Micromet (ISIN US59509C1053/ WKN A0JMQD) in einer Ersteinschätzung mit "buy" ein. Das Kursziel sehe man bei 10 USD. (Analyse vom 11.11.2011) (11.11.2011/ac/a/a)

[MasaRatti]

Micromet Initiates Global Phase 2 Trial of Blinatumomab in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Micromet, Inc. (NASDAQ: MITI) today announced that it has initiated a phase 2 trial of its lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

"Relapsed/refractory acute lymphoblastic leukemia is a difficult to treat disease that has seen no meaningful improvement in decades," said Professor Max Topp, Department of Internal Medicine II, University of Wuerzburg and the study's coordinating investigator for Europe. "To date blinatumomab has demonstrated an unprecedented level of efficacy and adequate safety in a patient population with limited therapeutic options."

This phase 2, single-arm study will evaluate the efficacy and safety of blinatumomab in approximately 65 patients with relapsed/refractory Philadelphia-negative B-precursor ALL. Patients will receive blinatumomab daily for 28 days followed by two weeks off blinatumomab over a six week treatment cycle. Patients who achieve a complete remission (CR) or complete response without full recovery of platelets (CRh*) within two cycles of treatment will receive up to three additional cycles of consolidation treatment. The primary endpoint of the study is CR/CRh*. Secondary endpoints include duration of response and overall survival. The study will be conducted at approximately 40 leading cancer centers in the U.S. and EU. The Company currently expects to complete enrollment in this trial by year end 2012.

"In the event that initial data generated from this trial are compelling, we plan to discuss with the FDA potential avenues to accelerate blinatumomab's path to market," said Jan Fagerberg, MD, Ph.D., Micromet's Senior Vice President and Chief Medical Officer.

Additional information regarding this Phase 2 study is available at the U.S. government's clinical trials database at http://www.clinicaltrials.gov.

Blinatumomab Clinical Experience in Adult R/R ALL

Interim results from a Phase 2 trial presented at the 2011 Meeting of the European Hematology Association show that blinatumomab produced a high CR rate in adult patients with ALL who had relapsed following treatment with standard therapy. 75% of patients (9 of 12) achieved a CR or CRh* following treatment with blinatumomab1. All nine responding patients achieved a complete molecular response, or had no evidence of leukemic cells in their bone marrow, a key prognostic factor for patient survival. Notably, four patients with genetic abnormalities typically associated with poorer outcomes all achieved a CR or CRh*. The most common clinical adverse events were fever, peripheral edema and fatigue. Treatment of two of the twelve patients was interrupted due to fully reversible and manageable central nervous system (CNS) events.

[MasaRatti]

Micromet Inc. (MITI - Analyst Report) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute lymphoblastic leukemia (ALL).

The trial was advised to be conducted by the US Food & Drug Administration (FDA) to support accelerated approval of blinatumomab. The trial is a single-arm study which will evaluate 65 patients with the primary endpoint of complete remission (CR) or CR with partial recovery of blood counts (CRh). Micromet expects to complete enrollment for the trial by year-end 2012. The mid-stage study will be followed by a late-stage trial (with a time dependent endpoint) to evaluate the safety and efficacy of blinatumomab versus chemotherapy in adult patients with relapsed refractory B precursor ALL. Design details of the late-stage trial will be provided in 2012.

Blinatumomub is one of the leading BiTE antibodies that Micromet is developing. BiTE antibodies represent a new class of antibodies that activate the T-cells of a patient’s immune system to eliminate cancer cells. The company is developing the candidate on its own.

Currently, Micromet is conducting another mid-stage study (n=20) of blinatumomab in adults suffering from relapsed or refractory B-precursor ALL. This study is evaluating the efficacy, safety and tolerability of blinatumomab in patients who do not respond to standard chemotherapy. Updated data from the trial is expected at the American Society of Hematology (ASH) meeting in December 2011. We believe this data presentation is a major near-term catalyst for the company as it will provide further visibility on the clinical potential of blinatumomab.

Relapsed/refractory ALL is an aggressive cancer of the blood and bone marrow. This disease is difficult to treat and has limited treatment options. No new drug has been approved for the treatment of this disease in the last 30 years. The disease affects 5,330 patients in the US annually.

Our Recommendation

Currently, we have a Neutral stance on Micromet. The stock carries a Zacks #3 Rank (short-term Hold recommendation).

We believe blinatumomab holds tremendous potential in the treatment of ALL. Besides, Micromet’s partnerships with large pharma and biotech companies could generate substantial future royalty revenues for the company. Micromet has entered into contracts with pharma giants like Bayer (BAYRY - Analyst Report), AstraZeneca (AZN - Analyst Report), Sanofi-Aventis (SNY - Analyst Report), Amgen, Inc. (AMGN - Analyst Report), which are focused on developing BiTE antibodies against disclosed/undisclosed solid tumor targets.

However, we believe that Micromet requires the strength of a large established player to accelerate blinatumomab’s development in order to gain a head-start over potential competitors on approval. We are also concerned about its early stage pipeline. Accordingly, we prefer to remain on the sidelines.

Am Ende des Börsentags nochmal dicke Umsätze

[MasaRatti]

http://seekingalpha.com/article/312130-biotech-focused-baker…

[MasaRatti]

Micromet's Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma Patients

55% of evaluable patients achieved an objective response
Median duration of response not reached, with a median follow-up of 7.1 months

New findings from a phase 1 trial presented yesterday at the 53rd Annual American Society of Hematology (ASH) Annual Meeting demonstrate Micromet's blinatumomab induces durable responses in patients with extensively pre-treated diffuse large B cell lymphoma (DLBCL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

Data presented at the meeting focused on a cohort of 13 patients with DLBCL, of which 11 received the target dose and were evaluable for response. Of these 11 patients, 6 (55%) achieved an objective response following treatment with blinatumomab. 4 of 11 patients (38%) achieved a complete response. Patients were treated with a single course of blinatumomab induction therapy for up to eight weeks. As of October 2011, 5 of 6 patients had ongoing responses for up to 16.6 months. The median duration of response had not been reached with a median observation time of 7.1 months.

All patients enrolled in this study had received prior rituximab-containing regimens. Most had received three or more prior lines of therapy, including 8 of 13 patients with prior autologous stem cell transplant.

"The level of activity observed with a single agent in this heavily pre-treated patient population is unusual," said Andreas Viardot, M.D., Department of Medicine III, University of Ulm. "We look forward to further exploring blinatumomab's activity in patients with relapsed diffuse large B cell lymphoma."

The most common clinical adverse events were grade 1 or 2 and included flu-like symptoms, pyrexia, headache, and fatigue. These were most frequently seen at the onset of treatment. The clinically most relevant adverse events were fully reversible central nervous system (CNS) events. A key objective of this study was to optimize the type and timing of steroid administration to mitigate the risk of developing CNS adverse events. Notably, no discontinuations due to CNS events were observed in the five patients who received an optimized steroid schedule including dexamethasone administration starting 12 hours before the start of blinatumomab infusion.

"With an improved steroid pre-medication schedule, we have successfully treated patients with relapsed diffuse large B cell lymphoma at the blinatumomab target dose," said Jan Fagerberg, M.D., Ph.D., Micromet's Senior Vice President and Chief Medical Officer. "We plan to initiate in 2012 a phase 2 trial in patients with diffuse large B cell lymphoma."

Study design

This open-label, single-arm phase 1 study was designed to assess the safety and efficacy of blinatumomab in 76 patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) whose disease progressed despite prior treatment. Endpoints included safety, objective response rate, progression-free survival, time to disease progression, and overall survival.

Blinatumomab Experience in Indolent Lymphoma and Mantle Cell Lymphoma

Results from this study were reported at the 2011 Annual International Conference on Malignant Lymphoma. At the therapeutic dose level of 60 micrograms per meter squared per day, 71% of NHL patients (20 of 28) achieved an objective response, including 10 out of 12 follicular lymphoma patients and 4 out of 5 mantle cell lymphoma patients. The most common adverse events were early, transient, fully reversible and did not require discontinuation of treatment. The clinically most relevant adverse events were fully reversible and manageable CNS events.

Phase 2 Trial in Patients with Relapsed Diffuse Large B-Cell Lymphoma

Based on the results reported at ASH, in 2012 the Company plans to initiate a phase 2 study intended to further evaluate the efficacy and safety of blinatumomab in patients with relapsed/refractory DLBCL. The primary endpoint of the study will be objective response rate according to Cheson criteria. Secondary endpoints will include duration of response, time to progression, overall survival, and incidence and severity of adverse events. Results from this trial will inform the Company's registration strategy in this patient population.

Conference Call and Webcast

Micromet management will host a meeting for the investment community on Monday, December 12 beginning at 12 PM PT to review the data presented at ASH. To participate in the event, please dial 888-567-1602 (domestic) or 201-604-5049 (international) and reference the Micromet ASH analyst event. The presentation will be available via webcast in the Investors and Media section of the Micromet website at: www.micromet.com. The archived webcast will be available for 30 days at www.micromet.com.

[SLGramann]

Antwort auf Beitrag Nr.: 42.466.383 von MasaRatti am 12.12.11 06:49:17

Micromet – Unprecedented activity, as usual

Micromet has been dazzling ASH attendees with impressive results for blinatumomab for the past 4 years. This time it was an updated phase II trial in relapsed refractory ALL (acute lymphocytic leukemia) as well as a phase II in DLBCL (diffuse large B cell lymphoma), two aggressive forms of blood cancer.

In the ALL trial, Bmab led to a complete response in ~70% of patients in a small single arm trial. These patients are very hard to treat, as their disease is highly refractory and their active disease precludes them from receiving the only potentially curative treatment - stem cell transplant.

The trial was small but results were dramatic both in terms of the percentage of patients achieving them, their depth (as evidenced by wiping out of disease remnants in the bone marrow, or MRD) and their duration. The only drug that comes close to this is Pfizer’s inotuzumab, which is now Bmab’s main competitor as I discussed here.

Based on the results, Micromet is about to start a potentially pivotal trial in relapsed/refractory ALL. At the company’s analyst event, the study’s principle investigator, Hagop Kantarjian from MD Anderson, sounded very excited with Bmab, suggesting it might be the “Gleevec of ALL”. Kantarjian, one of top Leukemia experts in the world, also noted he has patients for whom there are no good alternatives waiting for the trial to start to get on the drug.

Micromet also presented new data in DLBCL, probably the most attractive blood cancer in terms of size and unmet need. Of 11 evaluable patients, 6 (55%) achieved an objective response, including 4 complete responders. Strikingly, 5 of the 6 responses were still ongoing, two of which for over a year.

Albeit small, this trial leaves no doubt that the drug has ample activity in these heavily pretreated patients. Other targeted agents such as Afinitor and inotuzumab had a response rate of ~30% in small studies, but the duration of responses appear to be lower. The high response rate and more importantly the long response duration could provide Micromet with yet another route to registration, although results with more patients are needed.

http://www.hammerstockblog.com/5-winners-of-ash-2011/

[SLGramann]

ROCKVILLE, Md.--(BUSINESS WIRE)-- Micromet (Nasdaq: MITI - News) announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to expand development of the Company’s lead product candidate blinatumomab in patients with acute lymphoblastic leukemia (ALL) and various sub-types of lymphoma. Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

Under the terms of the agreement, the NCI and Micromet will collaborate on a series of clinical trials to evaluate the safety and efficacy of blinatumomab in patients with B-cell derived hematologic malignancies. The initial NCI-sponsored studies will explore blinatumomab’s utility as a first-line treatment for patients newly diagnosed with ALL, older patients with ALL, and patients with Waldenstrom’s macroglobulinemia. Additional studies will be designed based on the agreement of both parties.
“We are very pleased that the NCI has chosen to support the clinical development of blinatumomab,” said Jan Fagerberg, M.D., Ph.D., Micromet’s Senior Vice President and Chief Medical Officer. “This partnership will enable us to further explore blinatumomab’s clinical potential across a wide range of blood cancers and will expand leading U.S. investigators’ experience with the drug."


-----------

Sehr schön!

[VaJo]

Wieviel dürfte Micromet wert sein? Soviel wie Inhibitex? 2,5 Milliarden ;-)

[SLGramann]

Antwort auf Beitrag Nr.: 42.570.547 von VaJo am 09.01.12 20:37:58

2,5 Mrd. wäre derzeit wohl noch überzogen. Mit Börsenschluss gestern sind zumindest die Hochpunkte aus 2010 wieder erreicht, nachdem das Jahr 2011 ja ziemlich müde war.

Mein Szenario geht so, dass spätestens 2014 Zulassungen in ALL erfolgen und dass allein damit mittel und langfristig ein Umsatzvolumen zwischen 300 Millionen und einer Milliarde Dollar erschlossen werden kann.
Dabei ist Blina keineswegs auf ALL beschränkt.

Weiterhin sehr gute Daten vorausgesetzt, kann der Kurs in einem Jahr gut und gerne bei 15 Dollar stehen.

Meiner Meinung nach überwiegen hier die Chancen deutlich die Risiken.

[VaJo]

Antwort auf Beitrag Nr.: 42.577.073 von SLGramann am 11.01.12 09:01:53

Danke Dir. Klingt sehr gut.

[VaJo]

Laut dem BBBiotech Hochglanz Monatsblättchen haben die ihr Depot Beteilligung an Micromet auf 9,4% erhöht. Damit ist Micromet dort die 3 größte Position.

[quepos]

Hallo, ich glaubs ja nicht...



hab kürzlich alle verkauft.
grrrrrrrrrrrrrrrr

Glückwunsch allen investierten. Übernahmepreis recht moderat.






January 26, 2012, 9:21 amMergers & Acquisitions
Amgen to Buy Micromet for $1.16 Billion
By EVELYN M. RUSLI
Amgen has agreed to buy Micromet, a biotechnology company that develops cancer drugs, for $1.16 billion.

The offer of $11 a share represents a premium of 33 percent from Micromet’s closing stock price on Wednesday.

Micromet, which currently has no drugs on the market, designs cancer treatments that target blood and solid tumor cancers, including leukemia and non-Hodgkin’s lymphomas. The company has research facilities in Munich, Germany and offices in Rockville, Maryland.

Among Micromet’s drugs in development is blinatumomab, which treats acute lymphoblastic leukemia, that is now in Phase 2 trials.

Article Tools E-mailPrintRecommendShare
Close
Tumblr
Digg
Linkedin
Reddit
Permalink

.Twitter ..Related Links•The press release
.“The acquisition of Micromet is an opportunity to acquire an innovative oncology asset with global rights and a validated technology platform with broad potential clinical applications,” Kevin Sharer, Amgen’s chief executive, said in a statement on Thursday. “Blinatumomab will serve as an important complement to our oncology pipeline.”

Amgen, which is set to reporting earnings after Thursday’s close, plans to acquire Micromet’s shares in two phases. A subsidiary of Amgen will buy at least a majority of Microment’s outstanding shares at $11 a piece. The parent company will then buy any remaining shares, at the same price. The deal will likely close in the first quarter, the company said in a statement.

Amgen, is one of the world’s largest drug makers, with more than $15 billion in annual sales, however, the company has struggled to fill its pipeline with new blockbuster drugs. Last year, the company slashed 6 percent of its research and development staff and issued a $5 billion share buy back in December.

This would be the biggest acquisition by Amgen since it had agreed to acquire Abgenix for $2.2 billion in cash in 2005, according to Capital IQ data.

Amgen was advised by Moelis & Company and the law firm of Sullivan & Cromwell. Goldman Sachs and the law firm of Cooley advised Micromet.

[SLGramann]

Na ja, bin heute eher traurig. Micromet hatte sehr, sehr große Aussichten. Eine Zulassung von Blina in 2013/2014 ist sehr wahrscheinlich. Der Übernahmepreis spiegelt das definitiv nicht wieder.

Man freut sich ein bissel, weil da +30% steht und weiß rei rational genau, dass man beschissen wird.

Ähnlich wie damals bei Medarex.

Tja, die Story MITI ist damit zu Ende.

[hacho18]

tja tja tja - 30% aufschlag hört sich viel an ist aber ein witz bei dem phänomenalen klinischen erfolgen - blintoumab ist ja geradezu durchgereicht worden in den bisherigen schritten im zulassungsverfahren; ich versteh nicht warum die sich so billig verkaufen - vielleicht gabs ja einen goldenen handschlag fürs management...

[VaJo]

Tolle Verarsche! Dank ans Management. *Grrrr.
Scheint mittlerweile üblich zu sein aussichtsreiche Bios zu verramschen.

[MasaRatti]

Hallo meine lieben Mitleser und Mitwirkende, wie man sieht, hatte Micromet genau das Potential was wir alle vermutet haben und wie sooft, landet es in den großen Mäulern der Biotech-Playern - aber mal ehrlich,
wir haben doch alle gut verdient ... auf zum nächsten aussichtsreichen Investment ...

Grüße
MasaRatti

[VaJo]

Hallo Masa,
du hast recht. Nur fehlt mir im Moment die Inspiration wo ich anlegen könnte.

Wie wäre es wenn die Micromet'r hier ihre Tips diskutieren wo wir unser Biotechgeld aussichtsreich versenken könnten?

[Ville7]

Jammert nicht. Das war insgesamt ein super Investment.
Mehr als +200% in knapp drei Jahren bei mir.
Was will man mehr?

[Ben2005]

wie geht´s denn jetzt eigentlich weiter muss mann die Aktien jetzt verkaufen oder wie ?
ist meine erste übernahme

gruß ben2005

[quepos]

Hi,

kannst du dir aussuchen, ob du verkaufst (kannst du ja immer) oder nicht.
Wahrscheinlich bekommst du nicht mehr als die 11$, vielleicht aber doch.
1. Jetzt schon gibt es eine Klage gegen MITI, die Belange der Aktionäre nicht genügend berücksichtigt zu haben (Chance auf Erfolg m.E. gering).
2. Es könnte der "weiße Ritter" kommen und mehr bieten.

Ein squeeze-out wird´s nicht geben, da die meisten Aktionäre zustimmen werden.
Im Moment steigt der Euro tendenziell etwas, d.h. der $ sinkt, wäre also ein Verkauf besser.
Kannst aber auch warten, deine Bank meldet sich dann bei dir und zahlt dir letztlich die 11.

Gruß q.

P.S.: Grrrrrrrrr (s.o.)

[quepos]

Nachtrag...

3. Theoretisch könnte es auch sein, dass auch in USA die dort üblichen (ich glaube nur 50) Prozente der Aktien angeboten werden. In dem Falle müsste das Angebot erhöht werden, oder die Übernahme abgeblasen.
Letzteres ist auch schon vorgekommen auf dieser Welt, dann sinkt der Kurs natürlich wieder!

Halte ich aber für sehr unwahrscheinlich.

q.

[VaJo]

Ich mach erstmal gar nichts und werde das Angebot auch nicht annehmen. Mal schauen was passiert.

[Ville7]

Die Chance für USA Aktien, wie MITI eine ist, ist gering da noch etwas rauszuholen, siehe Medarex Übernahme. In D (z.B. Morphosys) würde ich bei so etwas an meinem Aktien kleben bleiben - da sind 95% Mehrheit für ein Squeeze Out dieser Art nötig, in USA reichen Amgen 50%+1. Ich bin daher gestern zu 10.93 rausgegangen.

[schnappi]

ich hab gestern auch meine gegeben mal sehn wo ich nu einsteige

[VaJo]

Zitat von schnappi: ich hab gestern auch meine gegeben mal sehn wo ich nu einsteige

Ja das wüßte ich auch gerne... Ideen?

[gunar_s]

Ersatzinvestment: Schaut auch mal "Immunogen" an, da bin ich schon investiert. (keine Anlageempfehlung, nur ein Tipp) Dort sollen Ergebnisse der Phase 3 Studie (in Kooperation mit Genentech/Roche wohl im Laufe des ersten Halbjahres herauskommen, Medikament TDM-1, Behandlung von Brustkrebs)

Könnte interessant werden, und die Ergenisse sollen ja recht "zeitnah" herauskommen.

Eigentlich wäre mein Ersatzinvestment von Immunogen dann Micromet geworden, da dort ja Ergenisse für Mitte 2013 angestanden hätten. Naja, dumm gelaufen für mich, aber so ist es halt mit den Biotechs.

Für Immunogen ist das US-Forum bei yahoo ganz informativ. (hier im deutschen Forum ist ziemlich wenig los)

Glückwunsch noch an alle wo hier bei Micromet investiert waren. (ihr hattet ein besseres Timing als ich)

Gruß
gunar_s

[Ville7]

Antwort auf Beitrag Nr.: 42.670.085 von gunar_s am 30.01.12 19:26:45

Jo Immunogen ist auch heiß, allerdings würde ich da jetzt nicht mehr rein. Seit meinem Einstieg vor 1,5 Jahren hat das Ding schon mehr als 100% Plus gemacht.

[VoIPer]

So, jetzt ist mit micromet gar nichts mehr los...
Jetzt stellt sich mir die Frage, was passiert mit den Aktien?
Verschwinden die irgendwann mal und man bekommt das Ausbezahlt, was der aktuelle Börsenwert ist?
Würde die noch gerne länger im Depot liegen lassen bis das eine Jahr vorüber ist und die Steuer entfällt.

[SLGramann]

Antwort auf Beitrag Nr.: 42.975.673 von VoIPer am 29.03.12 19:42:14

bis das eine Jahr vorüber ist und die Steuer entfällt.

?

Das gibts seit Jahren nicht mehr, dass Aktien steuerfrei verkauft werden können...

Wenn Du nichts machst, sollte es eines Tages automatisch zu einer Ausbuchung der Stücke aus Deinem Depot gegen Barabfindung kommen.